{
  "questions": [
    {
      "id": "63f73f1b33942b094c000008",
      "type": "yesno",
      "body": "Is erenumab effective for trigeminal neuralgia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484889",
          "text": "tion, which adversely affects the lives of patients. Current treatments are only mildly effective. Anti-calcitonin gene-related peptide (CGRP) monoclo",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3971692",
          "text": "Carbamazepine is considered the drug of choice and is initially very effective in treating trigeminal neuralgia.",
          "offsetInBeginSection": 912,
          "offsetInEndSection": 1024,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3716698",
          "text": "cupuncture in patients with trigeminal neuralgia should be used differentially. It is effective only in patients with peripheral trigeminal neuralgia.",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 509,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6937112",
          "text": "Trigeminal thermocoagulation is safe and effective in relieving recurrent trigeminal neuralgia in patients who have had a previous intra-cranial operation for their symptoms.",
          "offsetInBeginSection": 356,
          "offsetInEndSection": 530,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24889155",
          "text": "Compression of the trigeminal nerve by an aberrant vascular loop has been proposed as the causative factor in the majority of cases leading to the development of a highly effective surgical treatment approach termed \"microvascular decompression\".",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 390,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829200",
          "text": "rd drugs for treating patients with trigeminal neuralgia. They are effective in most patients. The undesired effects however cause withdrawal from tre",
          "offsetInBeginSection": 803,
          "offsetInEndSection": 953,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6487105",
          "text": "Drugs that are effective in the treatment of trigeminal neuralgia facilitate segmental inhibition in the trigeminal nucleus, as well as depressing excitatory transmission.",
          "offsetInBeginSection": 193,
          "offsetInEndSection": 364,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28905370",
          "text": "Surgery can have comorbidity (such as anesthesia dolorosa, or painful differentiation of the affected nerve distribution) and also is not always effective.",
          "offsetInBeginSection": 521,
          "offsetInEndSection": 676,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29626679",
          "text": "GKS is a simple and effective option even in cases with severe cranial deformity.",
          "offsetInBeginSection": 1446,
          "offsetInEndSection": 1527,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33428801",
          "text": "BACKGROUND\nIt is widely agreed that carbamazepine and oxcarbazepine are highly effective in the long-term treatment of trigeminal neuralgia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27743594",
        "http://www.ncbi.nlm.nih.gov/pubmed/26130986",
        "http://www.ncbi.nlm.nih.gov/pubmed/26000688",
        "http://www.ncbi.nlm.nih.gov/pubmed/26722633",
        "http://www.ncbi.nlm.nih.gov/pubmed/3716698",
        "http://www.ncbi.nlm.nih.gov/pubmed/8232946",
        "http://www.ncbi.nlm.nih.gov/pubmed/15096027",
        "http://www.ncbi.nlm.nih.gov/pubmed/6937112",
        "http://www.ncbi.nlm.nih.gov/pubmed/3971692",
        "http://www.ncbi.nlm.nih.gov/pubmed/34484889"
      ]
    },
    {
      "id": "643d41e757b1c7a315000037",
      "type": "list",
      "body": "What is the first indication for lurasidone?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002828",
          "text": "RESULTS\nLurasidone is demonstrated to be cost-saving as a first-line treatment within the adolescent and adult populations when compared to second-line and third-line respectively.",
          "offsetInBeginSection": 1385,
          "offsetInEndSection": 1565,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29075309",
          "text": "CONCLUSIONS\nLurasidone was associated with a reduction in weight at 1\u00a0year following its initiation in patients with schizophrenia or bipolar disorder.",
          "offsetInBeginSection": 1850,
          "offsetInEndSection": 2001,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26771990",
          "text": "antipsychotic drug that was initially developed for the treatment of schizophrenia. Since no previous atypical antipsychotic development program had p",
          "offsetInBeginSection": 426,
          "offsetInEndSection": 576,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28098496",
          "text": "Patients were 18-64 years, had insurance coverage 12 months pre- and 6 months post-index, and no pre-index use of the index drug.",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 642,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33588674",
          "text": "e of the first claim for lurasidone or cariprazine was defined as the index date. A difference-in-difference (DID) analysis, which mitigated bias by u",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 591,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31636356",
          "text": "This is the first study to show a significant association between functional HTR1A polymorphisms and treatment response to lurasidone.",
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1681,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34534629",
          "text": "Lurasidone is an important antipsychotic drug indicated for the treatment of schizophrenia and bipolar disorder, with an oral bioavailability of 9-19% owing to its poor aqueous solubility.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675261",
          "text": "Of the antipsychotic drugs, lurasidone has the highest affinity for the 5-hydroxytryptamine (5-HT)(7) receptor.",
          "offsetInBeginSection": 93,
          "offsetInEndSection": 204,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29075309",
          "text": "CONCLUSIONS\nLurasidone was associated with a reduction in weight at 1\u00a0year following its initiation in patients with schizophrenia or bipolar disorder.",
          "offsetInBeginSection": 1850,
          "offsetInEndSection": 2001,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31590422",
          "text": "Lurasidone is an atypical mood-stabilizing antipsychotic agent with unique receptor-binding profile, including 5-HT7 receptor (5-HT7R) antagonism.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21753886",
        "http://www.ncbi.nlm.nih.gov/pubmed/34534629",
        "http://www.ncbi.nlm.nih.gov/pubmed/25765597",
        "http://www.ncbi.nlm.nih.gov/pubmed/29075309",
        "http://www.ncbi.nlm.nih.gov/pubmed/26603973",
        "http://www.ncbi.nlm.nih.gov/pubmed/36002828",
        "http://www.ncbi.nlm.nih.gov/pubmed/29730043",
        "http://www.ncbi.nlm.nih.gov/pubmed/21889878",
        "http://www.ncbi.nlm.nih.gov/pubmed/31636356",
        "http://www.ncbi.nlm.nih.gov/pubmed/21177242"
      ]
    },
    {
      "id": "643c88a257b1c7a315000030",
      "type": "yesno",
      "body": "Can other vaccines be given with COVID-19 vaccine?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36439898",
          "text": "ly learning about this novel disease, although multiple vaccines have been shown to be effective against COVID-19. However, we report a case of unique",
          "offsetInBeginSection": 1729,
          "offsetInEndSection": 1879,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35136470",
          "text": "ieties about blood donation after COVID-19 vaccination, all types of COVID-19 vaccines included. We also present some experiences of blood transfusion",
          "offsetInBeginSection": 1162,
          "offsetInEndSection": 1312,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35751566",
          "text": "As currently approved COVID-19 vaccines that utilize virus-related genetic material are less than ideal, other vaccine types have been also widely investigated.",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 403,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32703743",
          "text": "There was agreement that programs to deliver existing influenza, pneumococcal, herpes zoster vaccines, and future COVID-19 vaccines to over a billion older adults who are at substantially higher risk of death and disability due to vaccine-preventable diseases are more urgent than ever before.",
          "offsetInBeginSection": 1700,
          "offsetInEndSection": 1993,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34919597",
          "text": "Although COVID-19 vaccination priority is given for high-risk individuals including healthcare workers (HCWs), the success of the immunization efforts hinges on peoples' willingness to embrace these vaccines.",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 371,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35848521",
          "text": "CONCLUSION\nEven in a high-risk population, most patients can be vaccinated with available COVID-19 vaccines.",
          "offsetInBeginSection": 1682,
          "offsetInEndSection": 1790,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34304240",
          "text": "The Centers for Disease Control and Prevention (CDC) has shifted their recommendations recently, allowing for the co-administration of the currently available COVID-19 vaccines with other vaccines.",
          "offsetInBeginSection": 146,
          "offsetInEndSection": 343,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36066031",
          "text": "Generally, the vaccine should be given before starting the chemotherapy if possible or in between chemotherapy cycles and away from nadir phase.",
          "offsetInBeginSection": 733,
          "offsetInEndSection": 877,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34455440",
          "text": "Presently, the US Centers for Disease Control and Prevention, British Society for Immunology, and various other governmental and professional societies and organizations endorse COVID-19 vaccination in the immunocompromised population.",
          "offsetInBeginSection": 1301,
          "offsetInEndSection": 1536,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33577086",
          "text": "Remarkably safe and highly effective mRNA COVID-19 vaccines are now available for widespread use and should be given to all adult patients with CLD and LT recipients.",
          "offsetInBeginSection": 1375,
          "offsetInEndSection": 1541,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33760673",
        "http://www.ncbi.nlm.nih.gov/pubmed/34455440",
        "http://www.ncbi.nlm.nih.gov/pubmed/36452995",
        "http://www.ncbi.nlm.nih.gov/pubmed/35751566",
        "http://www.ncbi.nlm.nih.gov/pubmed/34894000",
        "http://www.ncbi.nlm.nih.gov/pubmed/35848521",
        "http://www.ncbi.nlm.nih.gov/pubmed/36066031",
        "http://www.ncbi.nlm.nih.gov/pubmed/34863620",
        "http://www.ncbi.nlm.nih.gov/pubmed/34919597",
        "http://www.ncbi.nlm.nih.gov/pubmed/33543649"
      ]
    },
    {
      "id": "64403c4257b1c7a31500004f",
      "type": "summary",
      "body": "What is Sublocade?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35999975",
          "text": "Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade\u00ae), subdermal implant (Probuphine\u00ae), and sublingual tablets (Subutex\u00ae).",
          "offsetInBeginSection": 487,
          "offsetInEndSection": 660,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724686",
          "text": "Sublingual buprenorphine is one option, but subcutaneous extended-release buprenorphine (Sublocade\u00ae) is an alternate form administered in monthly injections.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34631459",
          "text": "Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade\u2122) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine\u2122].",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 421,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31399813",
          "text": "ns may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade\u2122) and a\u00a06-month buprenorphine depot implant (Probuphine\u2122). ",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 469,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33212514",
          "text": " depot formulations CAM 2038 (Buvidal\u00ae), the monthly depot formulation RBP-6000 (Sublocade\u2122), and a 6-month buprenorphine implant (Probuphine\u2122). Clini",
          "offsetInBeginSection": 276,
          "offsetInEndSection": 426,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34238190",
          "text": "OBJECTIVE\nCurrent in-situ injectable implants of buprenorphine (BP) such as Sublocade\u00ae consist of N-methyl-2-pyrrolidone (NMP)-dissolved PLGA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15734663",
          "text": "Secondary bilateral calcification is also reported in a variety of genetic, developmental, metabolic, infectious and other conditions.",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 616,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15734663",
        "http://www.ncbi.nlm.nih.gov/pubmed/33212514",
        "http://www.ncbi.nlm.nih.gov/pubmed/35999975",
        "http://www.ncbi.nlm.nih.gov/pubmed/34238190",
        "http://www.ncbi.nlm.nih.gov/pubmed/34631459",
        "http://www.ncbi.nlm.nih.gov/pubmed/31399813",
        "http://www.ncbi.nlm.nih.gov/pubmed/32724686"
      ]
    },
    {
      "id": "6441302d57b1c7a315000056",
      "type": "yesno",
      "body": "Is music therapy effective for pain management in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508181",
          "text": "The current best available evidence fails to support the benefits of music therapy as an effective non-pharmacological option in reducing pain and anxiety following open-heart surgery.",
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28398914",
          "text": "FINDINGS\nMusic therapy was shown to positively affect physiologic indicators, feeding, length of stay, and pain outcomes for PTIs.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1089,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30508181",
          "text": "The current best available evidence fails to support the benefits of music therapy as an effective non-pharmacological option in reducing pain and anxiety following open-heart surgery.",
          "offsetInBeginSection": 1139,
          "offsetInEndSection": 1323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31104642",
          "text": "OBJECTIVES\nMusic therapy has been shown to be effective for reducing anxiety and pain in people with a serious illness.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16597777",
          "text": "Results show that music therapy is an effective intervention for patients with chronic pain, children with migraine, and patients suffering from chronic tinnitus.",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 566,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426604",
          "text": "CONCLUSION\nMassage therapy was an effective method for reducing and relieving labor pain compared with music therapy and can be clinically recommended as an alternative, safe and affordable method of pain relief where using either pharmacological or nonpharmacological methods are optional.",
          "offsetInBeginSection": 1240,
          "offsetInEndSection": 1530,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22913761",
          "text": "Analysis of studies shows that non-pharmacological methods used to control pain in neonates are much more effective when used in combination with other non-pharmacological methods, such as music therapy, swaddling, facilitated tucking, multiple-stimulation, kangaroo care and non-nutritive suction.",
          "offsetInBeginSection": 587,
          "offsetInEndSection": 885,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30845807",
          "text": "OBJECTIVES\nRecent evidence suggests that music therapy, a holistic method of care, potentially is beneficial for symptom management.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18355741",
          "text": "CONCLUSIONS\nMusic is effective in reducing anxiety and pain in children undergoing medical and dental procedures.",
          "offsetInBeginSection": 1429,
          "offsetInEndSection": 1542,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20426604",
          "text": "Painkillers have previously been used for childbearing women, but nowadays, owing to some well-known limitations and serious side effects, nonpharmacologic methods such as massage and music therapies are being broadly recommended.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 377,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11227684",
        "http://www.ncbi.nlm.nih.gov/pubmed/31987233",
        "http://www.ncbi.nlm.nih.gov/pubmed/31104642",
        "http://www.ncbi.nlm.nih.gov/pubmed/8364698",
        "http://www.ncbi.nlm.nih.gov/pubmed/26697822",
        "http://www.ncbi.nlm.nih.gov/pubmed/29428919",
        "http://www.ncbi.nlm.nih.gov/pubmed/16219608",
        "http://www.ncbi.nlm.nih.gov/pubmed/29144240",
        "http://www.ncbi.nlm.nih.gov/pubmed/16580851",
        "http://www.ncbi.nlm.nih.gov/pubmed/21704068"
      ]
    },
    {
      "id": "63f042e2f36125a426000022",
      "type": "summary",
      "body": "What is the mechanisms of action of Gilteritinib?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32378574",
          "text": "Gilteritinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor that has shown efficacy in patients with refractory or recurrent adult acute myeloid leukemia (AML) with FLT3 mutations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35149666",
          "text": "BACKGROUND\nGilteritinib, a novel oral tyrosine kinase inhibitor, is used to treat acute myeloid leukemia (AML) with FMS-like tyrosine kinase-3 (FLT3) mutations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
          "text": "Here, we investigated the effect of FL on the efficacy of gilteritinib, a FLT3 inhibitor, in AML-derived cells in vitro and in mice.",
          "offsetInBeginSection": 561,
          "offsetInEndSection": 693,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33175659",
          "text": "Gilteritinib is primarily metabolized by the liver through the CYP3A4 enzyme and is eliminated in both the feces and urine.",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 534,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088841",
          "text": "Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33179270",
          "text": "Gilteritinib, an oral inhibitor of FMS-like tyrosine kinase 3 (FLT3), is a standard treatment for FLT3-mutated acute myeloid leukemia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34686212",
          "text": "BACKGROUND\nGilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33214069",
          "text": "Gilteritinib is a second-generation FLT3 inhibitor with activity against ITD and high affinity toward the FLT3 receptor, thereby showing therapeutic potential for relapsed/refractory FLT3-mutated AML.",
          "offsetInBeginSection": 164,
          "offsetInEndSection": 364,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322291",
          "text": "tion have a low response rate to salvage therapy. Gilteritinib has activity against FLT3, ALK and AXL. This article shall present two cases, for which",
          "offsetInBeginSection": 360,
          "offsetInEndSection": 510,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32850078",
          "text": "INTRODUCTION\nGilteritinib is a FLT3 kinase inhibitor approved for FLT3-mutated acute myeloid leukemia (AML).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34518298",
        "http://www.ncbi.nlm.nih.gov/pubmed/35198371",
        "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
        "http://www.ncbi.nlm.nih.gov/pubmed/36296409",
        "http://www.ncbi.nlm.nih.gov/pubmed/33340276",
        "http://www.ncbi.nlm.nih.gov/pubmed/34322291",
        "http://www.ncbi.nlm.nih.gov/pubmed/35857899",
        "http://www.ncbi.nlm.nih.gov/pubmed/34048999",
        "http://www.ncbi.nlm.nih.gov/pubmed/33214069",
        "http://www.ncbi.nlm.nih.gov/pubmed/32546970"
      ]
    },
    {
      "id": "64184483690f196b51000038",
      "type": "summary",
      "body": "What is the reason for N-acetylgalactosamine (GalNAc) conjugation of siRNAs?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35867041",
          "text": "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33861634",
          "text": "conjugated to the N-acetylgalactosamine (GalNAc) ligand bind to proteins present in circulation. However, it is not known if these protein interaction",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 611,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
          "text": "e (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR). Here we have evaluated the potential of GalNAc",
          "offsetInBeginSection": 354,
          "offsetInEndSection": 504,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413198",
          "text": "Conjugation of small interfering RNA (siRNA) to tris N-acetylgalactosamine [(GalNAc)3] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30820542",
          "text": "conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Exposure to 2'-F-monomer metabolites was low and transien",
          "offsetInBeginSection": 422,
          "offsetInEndSection": 572,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32170309",
          "text": "d to a trivalent N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Sense and antisense strands of the parent duplex were syn",
          "offsetInBeginSection": 344,
          "offsetInEndSection": 494,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35505960",
          "text": " to N-acetylgalactosamine (GalNAc) providing durable gene knockdown in hepatocytes following subcutaneous injection. GalNAc binds the asialoglycoprote",
          "offsetInBeginSection": 262,
          "offsetInEndSection": 412,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434769",
          "text": "from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc ar",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 244,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792572",
          "text": "development of N-acetylgalactosamine (GalNAc) siRNA conjugates for delivery to liver. Tris-GalNAc binds to the Asialoglycoprotein receptor that is hig",
          "offsetInBeginSection": 507,
          "offsetInEndSection": 657,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786782",
          "text": "We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
        "http://www.ncbi.nlm.nih.gov/pubmed/30417171",
        "http://www.ncbi.nlm.nih.gov/pubmed/34154993",
        "http://www.ncbi.nlm.nih.gov/pubmed/28129130",
        "http://www.ncbi.nlm.nih.gov/pubmed/31393218",
        "http://www.ncbi.nlm.nih.gov/pubmed/35505960",
        "http://www.ncbi.nlm.nih.gov/pubmed/25786782",
        "http://www.ncbi.nlm.nih.gov/pubmed/29792572",
        "http://www.ncbi.nlm.nih.gov/pubmed/32808038",
        "http://www.ncbi.nlm.nih.gov/pubmed/35867041"
      ]
    },
    {
      "id": "643de76757b1c7a315000039",
      "type": "summary",
      "body": "What is synthetic lethality?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107871",
          "text": "Exploiting a phenomenon known as synthetic lethality, in which simultaneous loss of two interacting genes leads to loss of viability, aids in the investigation of these interactions.",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 366,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189863",
          "text": "One such genetic interaction is synthetic lethality, in which the combination of two non-lethal mutations leads to loss of organism viability.",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 265,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30125975",
          "text": "Synthetic lethality is the synthesis of mutations leading to cell death. Tumor-specific synthetic lethality has been targeted in research to improve c",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26211783",
          "text": "ment of novel anticancer therapies. SL can be described as lethality (cell death) resulting from the combination of the two mutations, wherein the mut",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 349,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26630128",
          "text": "Synthetic lethality occurs when inhibition or mutation in two or more separate genes leads to cell death while inhibition or mutations of either gene alone has no lethal effect on the cell.",
          "offsetInBeginSection": 282,
          "offsetInEndSection": 471,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22864477",
          "text": "Synthetic lethality is a promising strategy for specific targeting of cancer cells that carry mutations that are absent in normal cells.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23888686",
          "text": "Inhibition of PARP in DNA repair-defective tumors (like those with BRAC1/2 mutations) can lead to cell death and genomic instability, what is so called \"synthetic lethality\".",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 358,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34163025",
          "text": "Synthetic lethality exploits cancer cell dependency on a protein or pathway, which arises when the function of a tumor suppressor is defective.",
          "offsetInBeginSection": 470,
          "offsetInEndSection": 613,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18789146",
          "text": "BACKGROUND\nSynthetic lethality defines a genetic interaction where the combination of mutations in two or more genes leads to cell death.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737609",
          "text": "Synthetic lethality is based on the incompatibility of cell survival with the loss of function of two or more genes, not with loss of function of a single gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22864477",
        "http://www.ncbi.nlm.nih.gov/pubmed/32070778",
        "http://www.ncbi.nlm.nih.gov/pubmed/18789146",
        "http://www.ncbi.nlm.nih.gov/pubmed/35170959",
        "http://www.ncbi.nlm.nih.gov/pubmed/8722765",
        "http://www.ncbi.nlm.nih.gov/pubmed/30059974",
        "http://www.ncbi.nlm.nih.gov/pubmed/34050264",
        "http://www.ncbi.nlm.nih.gov/pubmed/21094158",
        "http://www.ncbi.nlm.nih.gov/pubmed/22010575",
        "http://www.ncbi.nlm.nih.gov/pubmed/24893124"
      ]
    },
    {
      "id": "64403ab057b1c7a31500004d",
      "type": "factoid",
      "body": "How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33547034",
          "text": "METHODS\nTreatment consisted of two suprachoroidal injections of CLS-TA 4\u2009mg, 12 weeks apart.",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 420,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30588631",
          "text": " patients did not have clear characterization of their tremor. A total of 49 injections were reviewed (25 thyroarytenoid [TA], 24 thyroarytenoid and s",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 862,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31479196",
          "text": "METHODS\nIn this split-face controlled trial, 17 patients were randomized to receive eight weekly transdermal injections of TA or VC via Myjet either on the right or the left side of their face.",
          "offsetInBeginSection": 552,
          "offsetInEndSection": 745,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322164",
          "text": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.",
          "offsetInBeginSection": 711,
          "offsetInEndSection": 1109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25748280",
          "text": "RESULTS\nThirty-nine patients received TA and 35 patients received DEX injections.",
          "offsetInBeginSection": 683,
          "offsetInEndSection": 764,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29027510",
          "text": "MATERIALS AND METHODS\nIn this split-face controlled trial, 37 patients were randomized to receive three monthly sessions of TA intradermal injections either on the right or the left side of their face and topical HQ once a night for three months on the other side.",
          "offsetInBeginSection": 386,
          "offsetInEndSection": 650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36138388",
          "text": "While the participating students administered 62 (51.7%) injections, the experienced dentist administered 58 (48.3%) injections.",
          "offsetInBeginSection": 985,
          "offsetInEndSection": 1113,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36399237",
          "text": "Patients received SCS-TA 4.0\u00a0mg (0.1\u00a0ml of 40\u00a0mg/ml) or control at baseline and week 12.",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 800,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30113933",
          "text": "The primary endpoint was met in subjects who received suprachoroidal injection of CLS-TA 4.0 mg, mean central subfield thickness significantly decreased from baseline by 135 \u00b5m and 164 \u00b5m at Month 1 (P = 0.0056) and Month 2 (P = 0.0017), respectively.",
          "offsetInBeginSection": 575,
          "offsetInEndSection": 826,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30113933",
          "text": "corticosteroid-related increases in intraocular pressure.\n\n\nCONCLUSION\nA single suprachoroidal injection of CLS-TA (4.0 mg; 0.1 mL) in subjects with m",
          "offsetInBeginSection": 1166,
          "offsetInEndSection": 1316,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34740628",
        "http://www.ncbi.nlm.nih.gov/pubmed/36399237",
        "http://www.ncbi.nlm.nih.gov/pubmed/25748280",
        "http://www.ncbi.nlm.nih.gov/pubmed/29199012",
        "http://www.ncbi.nlm.nih.gov/pubmed/30588631",
        "http://www.ncbi.nlm.nih.gov/pubmed/33547034",
        "http://www.ncbi.nlm.nih.gov/pubmed/36138388",
        "http://www.ncbi.nlm.nih.gov/pubmed/30113933",
        "http://www.ncbi.nlm.nih.gov/pubmed/29027510",
        "http://www.ncbi.nlm.nih.gov/pubmed/16584436"
      ]
    },
    {
      "id": "64179139690f196b5100002f",
      "type": "list",
      "body": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29991987",
          "text": "The most common types of muscular dystrophy were found to be Duchenne dystrophy (131 cases, 38.9%), limb-girdle dystrophy (91 cases, 27%), Becker dystrophy (58 cases, 17.2%), FSHD dystrophy (31 cases, 9.2%), and SMA (26 cases, 7.7%), respectively.",
          "offsetInBeginSection": 1399,
          "offsetInEndSection": 1646,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35943031",
          "text": "Duchenne muscular dystrophy is the most common form of muscular dystrophy diagnosed in childhood but is not routinely screened for prenatally or at birth in the United States.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29991987",
          "text": "The most common types of muscular dystrophy were found to be Duchenne dystrophy (131 cases, 38.9%), limb-girdle dystrophy (91 cases, 27%), Becker dystrophy (58 cases, 17.2%), FSHD dystrophy (31 cases, 9.2%), and SMA (26 cases, 7.7%), respectively.",
          "offsetInBeginSection": 1399,
          "offsetInEndSection": 1646,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357214",
          "text": "Lower urinary tract symptoms were the most common urological diagnosis (32% of patients).",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 681,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29991987",
          "text": "The results also showed that genetic tests, para-clinical tests, pathology analysis, and EMG-NCV tests can serve as good diagnostic tools for different varieties of dystrophy.",
          "offsetInBeginSection": 2236,
          "offsetInEndSection": 2411,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12398835",
          "text": "s in these 30% of Duchenne muscular dystrophy patients. Denaturing gradient gel electrophoresis showed a high mutation detection rate (100%) for Duche",
          "offsetInBeginSection": 973,
          "offsetInEndSection": 1123,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357214",
          "text": "Lower urinary tract symptoms were the most common urological diagnosis (32% of patients).",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 681,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33057110",
          "text": "The muscular dystrophy X-linked mouse (mdx) is the most commonly used preclinical model for Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35862363",
          "text": "ating Scale. The Motor Function Measure (general instrument), Duchenne Muscular Dystrophy Upper-limb Patient-reported Outcome Measure, North Star Ambu",
          "offsetInBeginSection": 1581,
          "offsetInEndSection": 1731,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669113",
          "text": "Diagnostic use of Xp21 probes is now as necessary as EMG, muscle biopsy and serum CK assay for the definition of Duchenne muscular dystrophy.",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 713,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23357214",
        "http://www.ncbi.nlm.nih.gov/pubmed/35862363",
        "http://www.ncbi.nlm.nih.gov/pubmed/26136844",
        "http://www.ncbi.nlm.nih.gov/pubmed/8745379",
        "http://www.ncbi.nlm.nih.gov/pubmed/12398835",
        "http://www.ncbi.nlm.nih.gov/pubmed/468274",
        "http://www.ncbi.nlm.nih.gov/pubmed/2669113",
        "http://www.ncbi.nlm.nih.gov/pubmed/22583668",
        "http://www.ncbi.nlm.nih.gov/pubmed/7056028",
        "http://www.ncbi.nlm.nih.gov/pubmed/28393671"
      ]
    },
    {
      "id": "63f02b50f36125a426000014",
      "type": "yesno",
      "body": "Is there any association between Tripe palms and cancer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24050449",
          "text": "Acanthosis nigricans, tripe palms and acquired hypertrichosis lanuginosa can develop in association with both neuroendocrine and endometrial carcinoma.",
          "offsetInBeginSection": 669,
          "offsetInEndSection": 820,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33074559",
          "text": "TP and malignant acanthosis nigricans (MAN) occur together and may precede even years before the index cancer.",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2651581",
          "text": "In cancer patients with tripe palms alone, the most common underlying neoplasm was pulmonary carcinoma (53% of cases), whereas patients with both tripe palms and acanthosis nigricans frequently had gastric (35% of cases) or pulmonary (11% of cases) carcinomas.",
          "offsetInBeginSection": 572,
          "offsetInEndSection": 832,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9190991",
          "text": "CONCLUSIONS\nIn clinical practice the association of malignant acanthosis nigricans and tripe palms with endometrial adenocarcinoma is found extremely rarely.",
          "offsetInBeginSection": 1218,
          "offsetInEndSection": 1375,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11812096",
          "text": "CONCLUSION\nTripe palms can be associated with endometrial carcinoma and may be the first sign of malignancy.",
          "offsetInBeginSection": 1341,
          "offsetInEndSection": 1449,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21978503",
          "text": "A diagnosis of paraneoplastic tripe palms was made, prompting repetition of the biopsy which ultimately revealed a neuroendocrine carcinoma.",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 652,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31334069",
          "text": "Any patient with tripe palms must have a complete cancer workup, as in many of the cases it often precedes the malignancy by many months.",
          "offsetInBeginSection": 359,
          "offsetInEndSection": 496,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10640836",
          "text": "cutaneous paraneoplastic keratoderma. Tripe palms are frequently associated with gastric and pulmonary carcinoma. The pathogenetic mechanism remains u",
          "offsetInBeginSection": 51,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8638207",
          "text": "Approximately 90% of patients with tripe palms have an associated cancer, most commonly involving the lung or the stomach.",
          "offsetInBeginSection": 138,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21738980",
          "text": "The association of these three paraneoplastic dermatoses (florid cutaneous papillomatosis, acanthosis nigricans maligna and tripe palms) in the same patient, apparently with a common pathogenic mechanism, is noteworthy.",
          "offsetInBeginSection": 469,
          "offsetInEndSection": 688,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9640384",
        "http://www.ncbi.nlm.nih.gov/pubmed/26185340",
        "http://www.ncbi.nlm.nih.gov/pubmed/31334069",
        "http://www.ncbi.nlm.nih.gov/pubmed/21978503",
        "http://www.ncbi.nlm.nih.gov/pubmed/9190991",
        "http://www.ncbi.nlm.nih.gov/pubmed/21738980",
        "http://www.ncbi.nlm.nih.gov/pubmed/33603399",
        "http://www.ncbi.nlm.nih.gov/pubmed/11812096",
        "http://www.ncbi.nlm.nih.gov/pubmed/1421630",
        "http://www.ncbi.nlm.nih.gov/pubmed/10640836"
      ]
    },
    {
      "id": "6411b678201352f04a000036",
      "type": "factoid",
      "body": "is prosopagnosia inherited or  acquired?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18523592",
          "text": "BACKGROUND\nCongenital prosopagnosia is a severe face perception impairment which is not acquired by a brain lesion and is presumably present from birth.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26318239",
          "text": " objectively) in the EEG frequency-domain data. A well-studied case of acquired prosopagnosia (PS) and a group of age- and gender-matched controls com",
          "offsetInBeginSection": 928,
          "offsetInEndSection": 1078,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14757987",
          "text": " ability to recognize other persons by facial information alone has never been acquired. Due to the very low incidence of this syndrome, case reports ",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7091286",
          "text": "Three patients with prosopagnosia, and acquired inability to recognize familiar faces usually resulting from cerebrovascular insufficiency, had left-sided visual field defects and color vision abnormalities of central origin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16817175",
          "text": "The segregation pattern of this hereditary prosopagnosia (HPA) is fully compatible with autosomal dominant inheritance.",
          "offsetInBeginSection": 1042,
          "offsetInEndSection": 1161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27115682",
          "text": "A Quick guide to developmental prosopagnosia, a condition definied by problems in recognising faces that, in contrast with acquired prosopagnosia, develop in the absence of manifest brain injury.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657764",
          "text": "BACKGROUND\nProsopagnosia is a selective deficit in facial identification which can be either acquired, (e.g., after brain damage), or present from birth (congenital).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26393348",
          "text": "nother category (houses) were indistinguishable between subjects with congenital prosopagnosia and unimpaired controls. Latency and amplitude of face-",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 922,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31740940",
          "text": "ing clinically significant impairments in facial recognition. Cases of acquired prosopagnosia were identified through a systematic literature search a",
          "offsetInBeginSection": 506,
          "offsetInEndSection": 656,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389150",
          "text": "Reflecting this, acquired prosopagnosia is not a single entity but a family of disorders with different anatomic lesions and different functional deficits.",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 326,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16817175",
        "http://www.ncbi.nlm.nih.gov/pubmed/26874939",
        "http://www.ncbi.nlm.nih.gov/pubmed/19429021",
        "http://www.ncbi.nlm.nih.gov/pubmed/21366884",
        "http://www.ncbi.nlm.nih.gov/pubmed/27312747",
        "http://www.ncbi.nlm.nih.gov/pubmed/35094060",
        "http://www.ncbi.nlm.nih.gov/pubmed/19823580",
        "http://www.ncbi.nlm.nih.gov/pubmed/19334306",
        "http://www.ncbi.nlm.nih.gov/pubmed/18523592",
        "http://www.ncbi.nlm.nih.gov/pubmed/33274147"
      ]
    },
    {
      "id": "643bc8f957b1c7a31500002b",
      "type": "factoid",
      "body": "Where are promoters typically found in DNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33227813",
          "text": "NA polymerase initiates, which is typically located proximal to the transcription start site (TSS). How to correctly identify the gene TSS and the cor",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 244,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10843847",
          "text": " curved, less flexible, and less stable than DNA in coding regions and in intergenic DNA without promoters. This trend is present regardless of the ab",
          "offsetInBeginSection": 1646,
          "offsetInEndSection": 1796,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283192",
          "text": "The cell-free transcription-translation of multiple proteins typically exploits genes placed behind strong transcriptional promoters that reside on separate pieces of DNA so that protein levels can be easily controlled by changing DNA template concentration.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20161746",
          "text": "Here, we show that in contrast to yeast, DNA at human promoters, enhancers, and TFBSs generally encodes high intrinsic nucleosome occupancy.",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 330,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258451",
          "text": "These sequences are typically located in promoters, which are regions of variable length upstream of the open reading frames of genes.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 245,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21059933",
          "text": "DNA methylation of the cytosine in the CpG dinucleotide is typically associated with gene silencing.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18831794",
          "text": "l promoters lie between adjacent genes, which are transcribed from opposite strands of DNA. The functional mechanisms underlying the activation of bid",
          "offsetInBeginSection": 23,
          "offsetInEndSection": 173,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445637",
          "text": "Nicks in rDNA and the rest of the genome were typically found at the ends of combed DNA molecules, occasionally together with R-loops, comprising a major pool of vulnerable sites that are connected with transcriptional regulation.",
          "offsetInBeginSection": 1018,
          "offsetInEndSection": 1248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25448745",
          "text": "Surprisingly, the promoters are largely unmethylated in those genes whose expression has been previously found to be permanently deregulated by T in the liver, as e.g.",
          "offsetInBeginSection": 1148,
          "offsetInEndSection": 1315,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34071849",
          "text": "mponents of synthetic gene circuits. They are DNA segments where transcription initiation takes place. New constitutive and regulated promoters are co",
          "offsetInBeginSection": 28,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32567845",
        "http://www.ncbi.nlm.nih.gov/pubmed/33227813",
        "http://www.ncbi.nlm.nih.gov/pubmed/20161746",
        "http://www.ncbi.nlm.nih.gov/pubmed/36099980",
        "http://www.ncbi.nlm.nih.gov/pubmed/19258451",
        "http://www.ncbi.nlm.nih.gov/pubmed/30445637",
        "http://www.ncbi.nlm.nih.gov/pubmed/34071849",
        "http://www.ncbi.nlm.nih.gov/pubmed/19843335",
        "http://www.ncbi.nlm.nih.gov/pubmed/21679449",
        "http://www.ncbi.nlm.nih.gov/pubmed/6473101"
      ]
    },
    {
      "id": "64403be357b1c7a31500004e",
      "type": "factoid",
      "body": "What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23722119",
          "text": "The median time of follow-up was 19 months (range: 2-57), during which 31% of patients healed and 39% succumbed.",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1105,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23722119",
          "text": "The median time of follow-up was 19 months (range: 2-57), during which 31% of patients healed and 39% succumbed.",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1105,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23722119"
      ]
    },
    {
      "id": "644289c457b1c7a31500005e",
      "type": "list",
      "body": "Which are some symptoms of FSHD?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34675094",
          "text": "nal capacity may still occur as the child grows up. Pain, fatigue, and a decreased quality of life were common symptoms and need to be addressed in th",
          "offsetInBeginSection": 1713,
          "offsetInEndSection": 1863,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592052",
          "text": "t neuromuscular disorder characterized by progressive weakness of the facial, shoulder and upper arm muscles. The major gene involved has been mapped ",
          "offsetInBeginSection": 68,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1908258",
          "text": "We report an 18-year-old female with facioscapulohumeral dystrophy (FSHD), who had sensorineural deafness, retinal vessel abnormality, mental retardation, and epilepsy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12134683",
          "text": "cular dystrophy characterized by progressive weakness and wasting of the facial, shoulder-girdle and upper arm muscles. The gene locus for FSHD is map",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
          "text": "nherited myopathy clinically characterized by weakness in the facial, shoulder girdle and upper a muscles. FSHD is caused by chromatin relaxation of t",
          "offsetInBeginSection": 53,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30546343",
          "text": " carry the short allele of D4Z4 region. To date, two forms of FSHD (FSHD1 and FSHD2) are known. FSHD2 is usually observed in patients without the D4Z4",
          "offsetInBeginSection": 643,
          "offsetInEndSection": 793,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22907234",
          "text": "Presenting symptoms were monomelic lower limb (n = 3) or upper limb (n = 2) atrophy, or axial weakness (n = 2).",
          "offsetInBeginSection": 591,
          "offsetInEndSection": 702,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31025273",
          "text": "PURPOSE\nSevere manifestations of facioscapulohumeral dystrophy (FSHD) may be associated with sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and nocturnal hypoventilation (NH), but prevalence data are scarce.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35020192",
          "text": "The most common reported symptoms included pain (71%), difficulty sleeping (41%), headaches (27%), and altered mood (24%).",
          "offsetInBeginSection": 781,
          "offsetInEndSection": 903,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
          "text": "Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 374,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32008231",
        "http://www.ncbi.nlm.nih.gov/pubmed/27530735",
        "http://www.ncbi.nlm.nih.gov/pubmed/31025273",
        "http://www.ncbi.nlm.nih.gov/pubmed/28263188",
        "http://www.ncbi.nlm.nih.gov/pubmed/22551571",
        "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
        "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
        "http://www.ncbi.nlm.nih.gov/pubmed/29563141",
        "http://www.ncbi.nlm.nih.gov/pubmed/26862222",
        "http://www.ncbi.nlm.nih.gov/pubmed/23225386"
      ]
    },
    {
      "id": "63f02ec1f36125a426000017",
      "type": "summary",
      "body": "What is the mechanism of action of Adagrasib?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35167329",
          "text": "PURPOSE\nAdagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404402",
          "text": "Adagrasib (MRTX849), a potent oral small-molecule KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state.",
          "offsetInBeginSection": 119,
          "offsetInEndSection": 267,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658005",
          "text": "BACKGROUND\nAdagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
          "text": "The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35404402",
        "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
        "http://www.ncbi.nlm.nih.gov/pubmed/35167329",
        "http://www.ncbi.nlm.nih.gov/pubmed/35658005",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312"
      ]
    },
    {
      "id": "641c516d690f196b5100003f",
      "type": "yesno",
      "body": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18608106",
          "text": "Mutations in the Cu/Zn superoxide dismutase 1 (SOD1) gene have been reported to cause adult-onset autosomal dominant amyotrophic lateral sclerosis (FALS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7820674",
          "text": "Mutations of the Cu/Zn superoxide dismutase (SOD-1) gene were recently implicated in the pathogenesis of familial amyotrophic lateral sclerosis (ALS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10202988",
          "text": "We report the absence of superoxide dismutase (SOD-1) gene mutations in 30 patients with amyotrophic lateral sclerosis (ALS) including individuals with a confirmed family history of ALS (familial ALS/FALS), ALS with an unclear family history (UFALS) and sporadic ALS (SALS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283821",
          "text": "A novel mutation of the SOD-1 gene which encodes the enzyme copper-zinc superoxide dismutase was identified in a family manifesting amyotrophic lateral sclerosis (ALS) in three generations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11284995",
          "text": "Two patients (10%) with the amyotrophic lateral sclerosis (ALS) form of the disease were found to have a disease-related mutation.",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9065559",
          "text": "Mutations of the gene SOD-1, which encodes the enzyme copper-zinc superoxide dismutase, occur in patients with a familial form of amyotrophic lateral sclerosis (ALS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9065559",
          "text": "A predilection for disease onset in the lower limbs appears to be a distinguishing feature of familial ALS with SOD-1 mutations, and accords with findings in transgenic mouse models.",
          "offsetInBeginSection": 860,
          "offsetInEndSection": 1042,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15079798",
          "text": "It is a new type of SOD1 mutation which may be associated with familial amyotrophic lateral sclerosis.",
          "offsetInBeginSection": 645,
          "offsetInEndSection": 747,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681966",
          "text": "One female patient with amyotrophic lateral sclerosis (ALS) was heterozygous for G12R mutation.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19618436",
          "text": "re sporadic, 10% are familial, of which 20%-25% result from mutations in the superoxide dismutase (SOD1) gene. We describe a novel case of SOD1 (A4V)-",
          "offsetInBeginSection": 179,
          "offsetInEndSection": 329,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10869061",
        "http://www.ncbi.nlm.nih.gov/pubmed/21740381",
        "http://www.ncbi.nlm.nih.gov/pubmed/11284995",
        "http://www.ncbi.nlm.nih.gov/pubmed/9065559",
        "http://www.ncbi.nlm.nih.gov/pubmed/24283821",
        "http://www.ncbi.nlm.nih.gov/pubmed/21755517",
        "http://www.ncbi.nlm.nih.gov/pubmed/8906612",
        "http://www.ncbi.nlm.nih.gov/pubmed/22999566",
        "http://www.ncbi.nlm.nih.gov/pubmed/19618436",
        "http://www.ncbi.nlm.nih.gov/pubmed/15987780"
      ]
    },
    {
      "id": "64371c5957b1c7a31500002a",
      "type": "summary",
      "body": "What are enhancers?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35128025",
          "text": "INTRODUCTION\nCognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32804082",
          "text": "Shadow enhancers, groups of seemingly redundant enhancers, are found in a wide range of organisms and are critical for robust developmental patterning.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24119843",
          "text": "Super-enhancers are large clusters of transcriptional enhancers that drive expression of genes that define cell identity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32952117",
          "text": "Enhancers are a type of cis-acting DNA elements that enhance transcriptional activity of target genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473601",
          "text": "ecific variation in gene expression patterns, mediated by specialized cis-regulatory elements called enhancers. Recent large-scale epigenomic mapping ",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30033119",
          "text": "Enhancers are genetic elements that regulate spatiotemporal gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 76,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22083793",
          "text": "This paper, in the form of a frequently asked questions page (FAQ), addresses outstanding questions about \"shadow enhancers\", quasi-redundant cis-regulatory elements, and their proposed roles in transcriptional control.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35906072",
          "text": "Poised enhancers share many attributes of active enhancers, such as open chromatin, but are marked by repressive histone H3 lysine 27 (H3K27) trimethylation rather than H3K27 acetylation.",
          "offsetInBeginSection": 583,
          "offsetInEndSection": 770,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33037064",
          "text": "Enhancers are DNA sequences composed of transcription factor binding sites that drive complex patterns of gene expression in space and time.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28193687",
          "text": " and functions, we name the ponli and crb2b enhancers collectively rainbow enhancers. Rainbow enhancers may represent a cis-regulatory mechanism to tu",
          "offsetInBeginSection": 1032,
          "offsetInEndSection": 1182,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30033119",
        "http://www.ncbi.nlm.nih.gov/pubmed/30979870",
        "http://www.ncbi.nlm.nih.gov/pubmed/22083793",
        "http://www.ncbi.nlm.nih.gov/pubmed/34526084",
        "http://www.ncbi.nlm.nih.gov/pubmed/28760812",
        "http://www.ncbi.nlm.nih.gov/pubmed/23503198",
        "http://www.ncbi.nlm.nih.gov/pubmed/22828638",
        "http://www.ncbi.nlm.nih.gov/pubmed/30925856",
        "http://www.ncbi.nlm.nih.gov/pubmed/32197056",
        "http://www.ncbi.nlm.nih.gov/pubmed/34879086"
      ]
    },
    {
      "id": "6440396957b1c7a31500004b",
      "type": "factoid",
      "body": "What is the mode of delivery of the drug XIPERE?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35868358",
          "text": "pension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. Suprachoroidal (SC) delivery facilitate",
          "offsetInBeginSection": 158,
          "offsetInEndSection": 308,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
      ]
    },
    {
      "id": "641791ca690f196b51000031",
      "type": "list",
      "body": "What are the most common muscular dystrophies?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33669654",
          "text": "leotides to target the most common MDs such as Duchenne Muscular Dystrophy and the Myotonic Dystrophies. The challenge related to in vitro and in vivo",
          "offsetInBeginSection": 1082,
          "offsetInEndSection": 1232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794464",
          "text": "This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies.",
          "offsetInBeginSection": 558,
          "offsetInEndSection": 924,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340611",
          "text": "AREAS COVERED\nDuchenne muscular dystrophy is the most common muscular dystrophy.",
          "offsetInBeginSection": 548,
          "offsetInEndSection": 628,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29971759",
          "text": "There are several clinical forms, the most frequent being Duchenne's muscular dystrophy and Becker muscular dystrophy.",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 289,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3728255",
          "text": "Myotonic muscular dystrophy is the most common of the adult-onset muscular dystrophies.",
          "offsetInBeginSection": 333,
          "offsetInEndSection": 420,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29770119",
          "text": "Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21484336",
          "text": "Duchenne muscular dystrophy is the most common childhood form of muscular dystrophy.",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 783,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215857",
          "text": "We discuss the involvement of the immune system in the most common muscular dystrophy, Duchenne muscular dystrophy, and show that the immune system influences muscle death and fibrosis as disease progresses.",
          "offsetInBeginSection": 856,
          "offsetInEndSection": 1063,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217326",
          "text": "The most common X-linked recessive disease is Duchenne muscular dystrophy (DMD), which arises from defects in the dystrophin gene.",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 419,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427100",
          "text": "Duchenne's muscular dystrophy is the most common form of inherited muscle disease of childhood.",
          "offsetInBeginSection": 477,
          "offsetInEndSection": 572,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33200426",
        "http://www.ncbi.nlm.nih.gov/pubmed/21484336",
        "http://www.ncbi.nlm.nih.gov/pubmed/28427100",
        "http://www.ncbi.nlm.nih.gov/pubmed/25987458",
        "http://www.ncbi.nlm.nih.gov/pubmed/35393236",
        "http://www.ncbi.nlm.nih.gov/pubmed/23622361",
        "http://www.ncbi.nlm.nih.gov/pubmed/12409822",
        "http://www.ncbi.nlm.nih.gov/pubmed/17217326",
        "http://www.ncbi.nlm.nih.gov/pubmed/32418485",
        "http://www.ncbi.nlm.nih.gov/pubmed/34628793"
      ]
    },
    {
      "id": "63eef7eff36125a42600000e",
      "type": "summary",
      "body": "Which disease is targeted by Fazirsiran?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "6431708a57b1c7a315000017",
      "type": "factoid",
      "body": "Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15478621",
          "text": "Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are secreted from cardiomyocytes in response to atrial or ventricular wall stretch.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 309,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120963",
          "text": "riuretic peptide (BNP) are primarily produced by, and secreted from, heart tissue. They maintain cardiovascular homeostasis by binding to natriuretic ",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14987573",
          "text": "rom atrial tissue, BNP related peptides are produced mainly from ventricular myocytes. Ventricular (NT-pro)BNP production is strongly upregulated in c",
          "offsetInBeginSection": 744,
          "offsetInEndSection": 894,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978892",
          "text": ") and brain natriuretic peptide (BNP) are delivered predominantly by the heart. Two C-type natriuretic peptides (CNPs) are paracrine messengers, notab",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17690842",
          "text": "levated within 24 h after TBI in some patients. However, it does not originate from the brain and increased NT-proBNP concentrations are not consisten",
          "offsetInBeginSection": 1373,
          "offsetInEndSection": 1523,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11558673",
          "text": "tic and renin-angiotensin systems. Although originally isolated from porcine brain, the BNP gene is expressed in a specific manner in cardiac myocytes",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14987573",
          "text": "cid cardiac natriuretic peptide hormone originally isolated from porcine brain tissue. The human BNP gene is located on chromosome 1 and encodes the p",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1349867",
          "text": "BNP, first isolated from the porcine brain, has a marked divergence in its molecular size and sequence among species.",
          "offsetInBeginSection": 521,
          "offsetInEndSection": 638,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35741432",
          "text": "Unlike other members, i.e., atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which are cardiac hormones secreted from the atrium and ventricle of the heart, respectively, CNP is regarded as an autocrine/paracrine regulator with broad expression in the body.",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 366,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706401",
          "text": "However, there is an accumulating evidence that B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) may originate from right ventricle and their concentrations are elevated in patients with acute pulmonary embolism (APE) especially when resulting in right ventricular dysfunction (RVD).",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 418,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21296556",
        "http://www.ncbi.nlm.nih.gov/pubmed/8670204",
        "http://www.ncbi.nlm.nih.gov/pubmed/1334000",
        "http://www.ncbi.nlm.nih.gov/pubmed/22776607",
        "http://www.ncbi.nlm.nih.gov/pubmed/17690842",
        "http://www.ncbi.nlm.nih.gov/pubmed/14769750",
        "http://www.ncbi.nlm.nih.gov/pubmed/18378336",
        "http://www.ncbi.nlm.nih.gov/pubmed/16689366",
        "http://www.ncbi.nlm.nih.gov/pubmed/12084525",
        "http://www.ncbi.nlm.nih.gov/pubmed/1349867"
      ]
    },
    {
      "id": "643c396457b1c7a31500002d",
      "type": "yesno",
      "body": "Are any medications available to prevent COVID-19 following exposure?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32383430",
          "text": "Currently, there is no available treatment proven to be effective against COVID-19, but multiple medications, including hydroxychloroquine (HCQ), are used off label.",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 350,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32869015",
          "text": "on were considered exposed: chloroquine, hydroxychloroquine, losartan, azithromycin, naproxen, dexamethasone and prednisone.\n\n\nRESULTS\nFor azithromyci",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 809,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35999834",
          "text": "Despite the recent clearance of several medications, effective and safe COVID-19 vaccinations are still urgently needed, not only to prevent the disease from spreading but also to restore social and economic activity through mass vaccination.",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 429,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33160408",
          "text": "on were considered exposed: chloroquine, hydroxychloroquine, losartan, azithromycin, naproxen, dexamethasone and prednisone.\n\n\nRESULTS\nFor azithromyci",
          "offsetInBeginSection": 655,
          "offsetInEndSection": 805,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35521985",
          "text": "Although several therapeutic options have been used to control COVID-19, none of these medications have been proven to be a definitive cure.",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 284,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33542646",
          "text": "In particular, the use of hydroxychloroquine PrEP affords a safe and readily available means to avoid COVID-19 complications in pregnancy.",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 753,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33495727",
          "text": "Currently, antiviral drugs and/or vaccines are not yet available to treat or prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32612804",
          "text": "A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab.",
          "offsetInBeginSection": 448,
          "offsetInEndSection": 751,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35073629",
          "text": "Compared to currently available monoclonal antibodies and remdesivir, where parenteral administration is required, oral antivirals offer treatments in an outpatient setting with dissemination available on a larger scale.",
          "offsetInBeginSection": 559,
          "offsetInEndSection": 779,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36126225",
          "text": "No evidence is available on nirmatrelvir/ritonavir to treat hospitalized people with COVID-19 and to prevent a SARS-CoV-2 infection.",
          "offsetInBeginSection": 6827,
          "offsetInEndSection": 6959,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35079984",
        "http://www.ncbi.nlm.nih.gov/pubmed/33390800",
        "http://www.ncbi.nlm.nih.gov/pubmed/33516648",
        "http://www.ncbi.nlm.nih.gov/pubmed/34010282",
        "http://www.ncbi.nlm.nih.gov/pubmed/34799365",
        "http://www.ncbi.nlm.nih.gov/pubmed/34531332",
        "http://www.ncbi.nlm.nih.gov/pubmed/32383430",
        "http://www.ncbi.nlm.nih.gov/pubmed/36254081",
        "http://www.ncbi.nlm.nih.gov/pubmed/36430371",
        "http://www.ncbi.nlm.nih.gov/pubmed/35521985"
      ]
    },
    {
      "id": "6440092d57b1c7a315000040",
      "type": "yesno",
      "body": "Has RTA 408 received FDA approval?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26940233",
          "text": "There was agreement between ODAC recommendations and final FDA approval; FDA approval was received for all 41 drugs that ODAC recommended approval.",
          "offsetInBeginSection": 1252,
          "offsetInEndSection": 1399,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25416452",
          "text": "cute radiation syndrome (ARS) over the past six decades, no drug has been approved by the US FDA. Several biologics are currently under development as",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30479199",
          "text": "tion; 42% (60 of 144) received priority review; and 11% (16 of 144) received accelerated approval. The proportion of novel therapeutics covered by at ",
          "offsetInBeginSection": 1647,
          "offsetInEndSection": 1797,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
          "text": "ythroid 2-related factor 2 (Nrf2) signaling pathway. Moreover, RTA 402 is an FDA-approved compound for the treatment of solid tumors, lymphoid maligna",
          "offsetInBeginSection": 495,
          "offsetInEndSection": 645,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33950209",
          "text": "Of the 70 countries contributing research participants for FDA drug approvals, 7% (5 countries) received market access to drugs they helped test within 1 year of FDA approval and 31% (22 countries) did so within 5 years.",
          "offsetInBeginSection": 1847,
          "offsetInEndSection": 2067,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19288888",
          "text": "ss experimental drugs that have passed Phase I testing, but have not yet received FDA approval. Since that case was decided, patients and patients' ri",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 316,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26775045",
          "text": "A number of IGBs have appeared since that time, mostly originating in Europe or South America, but none has acquired FDA approval until recently; the ReShape Duo Integrated Dual Balloon System (ReShape Medical Inc., San Clemente, California) received FDA approval in August 2015.",
          "offsetInBeginSection": 356,
          "offsetInEndSection": 635,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33950209",
          "text": "One drug was approved for marketing in all testing countries within 1 year of FDA approval and 15% (5 of 34 drugs) were approved in all testing countries within 5 years of FDA approval.",
          "offsetInBeginSection": 1661,
          "offsetInEndSection": 1846,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26940233",
        "http://www.ncbi.nlm.nih.gov/pubmed/19288888",
        "http://www.ncbi.nlm.nih.gov/pubmed/34573098",
        "http://www.ncbi.nlm.nih.gov/pubmed/25416452",
        "http://www.ncbi.nlm.nih.gov/pubmed/30479199",
        "http://www.ncbi.nlm.nih.gov/pubmed/26775045",
        "http://www.ncbi.nlm.nih.gov/pubmed/33950209"
      ]
    },
    {
      "id": "644291fa57b1c7a31500005f",
      "type": "list",
      "body": "Which are the types of myotonic dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17885447",
          "text": "rogress in elucidating the disease mechanism in myotonic dystrophy type 1 and type 2.\n\n\nRECENT FINDINGS\nResearch on myotonic dystrophy has led to the ",
          "offsetInBeginSection": 65,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32067592",
          "text": "The 2 major genetic forms of myotonic dystrophy, type 1 and type 2, differ in genetic etiology yet share clinical features.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 326,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121518",
          "text": "RECENT FINDINGS\nAn active approach to screening and management of myotonic dystrophies type 1 and type 2 requires a multidisciplinary medical, rehabilitative and social team.",
          "offsetInBeginSection": 901,
          "offsetInEndSection": 1075,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24435591",
          "text": "onest adult muscular dystrophy. Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are often discussed jointly, and although they sha",
          "offsetInBeginSection": 30,
          "offsetInEndSection": 180,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121518",
          "text": "PURPOSE OF REVIEW\nMyotonic dystrophies type 1 and type 2 are progressive multisystem genetic disorders with clinical and genetic features in common.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625963",
          "text": "Two genetically distinct forms of DM are identified - type 1 (DM1), the classic form first described by Steinert, and type 2 (DM2), identified by Ricker.",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 302,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8337494",
          "text": "Of the eyes studied, 26 (26.6%) had butterfly-shaped macular pigmentary changes, 24 (24.5%) had reticular pigmentary retinal changes, and 43 (43.9%) had peripheral atrophic polygonal-shaped changes.",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9710180",
          "text": "Hydrocephalus and cognitive deterioration are not commonly considered part of adult-onset myotonic dystrophy.",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35243403",
          "text": "Myotonic dystrophy types 1 and 2 are a group of complex genetic disorders resulting from the expansion of (CTG)n nucleotide repeats in the DMPK gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6519603",
          "text": "Since 1940, 29 patients with myotonic dystrophy (10 adult, 17 congenital, two unclassified) have been followed at the Alfred I. duPont Institute.",
          "offsetInBeginSection": 265,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25813338",
        "http://www.ncbi.nlm.nih.gov/pubmed/24435591",
        "http://www.ncbi.nlm.nih.gov/pubmed/21496635",
        "http://www.ncbi.nlm.nih.gov/pubmed/34840883",
        "http://www.ncbi.nlm.nih.gov/pubmed/8337494",
        "http://www.ncbi.nlm.nih.gov/pubmed/27378259",
        "http://www.ncbi.nlm.nih.gov/pubmed/20625963",
        "http://www.ncbi.nlm.nih.gov/pubmed/19555515",
        "http://www.ncbi.nlm.nih.gov/pubmed/31750030",
        "http://www.ncbi.nlm.nih.gov/pubmed/33458578"
      ]
    },
    {
      "id": "63f741a633942b094c000009",
      "type": "list",
      "body": "What are the active components of Opdualag?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8719180",
          "text": "We build on the developmental approaches of previous researchers and propose that the individual components of active sleep (e.g., myoclonic twitches, rapid eye movements) exhibit unique developmental and phylogenetic histories and may serve independent functions in the developing organism.",
          "offsetInBeginSection": 319,
          "offsetInEndSection": 610,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28663910",
          "text": "Our results suggest collagen, elastin, keratin, cell nucleus, triolein, ceramide, melanin and water are the most important model components.",
          "offsetInBeginSection": 1065,
          "offsetInEndSection": 1205,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32477195",
          "text": "The rationale, design, and potential advantages of this approach will be illustrated with reference to the IMPROVE-2 study, which conducts a fractional factorial design to investigate which elements (e.g., thought challenging, activity scheduling, compassion, relaxation, concreteness, functional analysis) within therapist-supported internet-delivered CBT are most effective at reducing symptoms of depression in 767 adults with major depression.",
          "offsetInBeginSection": 1333,
          "offsetInEndSection": 1780,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17465184",
          "text": "The core components of the model are: situational characteristics, crime and disorder, fear of crime or disorder, and physical activity.",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 369,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36472472",
          "text": "As of mid-November, 12 antibody therapeutics had been granted first approvals in either the United States or European Union (tebentafusp (Kimmtrak), faricimab (Vabysmo), sutimlimab (Enjaymo), relatlimab (Opdualag), tixagevimab/cilgavimab (Evusheld), mosunetuzumab (Lunsumio), teclistamab (TECVAYLI), spesolimab (SPEVIGO), tremelimumab (Imjudo; combo with durvalumab), nirsevimab (Beyfortus), mirvetuximab soravtansine (ELAHERE\u2122), and teplizumab (TZIELD)), including 4 bispecific antibodies and 1 ADC.",
          "offsetInBeginSection": 224,
          "offsetInEndSection": 724,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23433172",
          "text": "rhage and commonly entails prophylactic administration of a uterotonic agent, controlled cord traction, and uterine massage. While oxytocin is the fir",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 261,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26291134",
          "text": "Components of asthma self-management education include having been taught to what to do during an asthma attack and receiving an asthma action plan.",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 586,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35543970",
          "text": "Both drugs are immunoglobulin G4 (IgG4) monoclonal antibodies developed to target immune checkpoints, with nivolumab targeting the programmed cell death protein 1 (PD-1) receptor and relatlimab being a newly developed, first-in-class drug targeting the lymphocyte-activation gene 3 (LAG-3) protein.",
          "offsetInBeginSection": 219,
          "offsetInEndSection": 517,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23967064",
          "text": "BACKGROUND\nIncreasing active travel (primarily walking and cycling) has been widely advocated for reducing obesity levels and achieving other population health benefits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10956396",
          "text": "Human peripheral blood mononuclear cells (PBMCs) from healthy purified protein derivative-positive subjects were incubated for 7 days with whole BCG and various fractions (BCG cell wall, plasma membrane, cytosol, purified polysaccharides as glucan or arabinomannan, purified native proteins from BCG culture filtrate, recombinant 22 kDa protein, phosphate transporter PstS-2 and -3 proteins).",
          "offsetInBeginSection": 412,
          "offsetInEndSection": 804,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23967064",
        "http://www.ncbi.nlm.nih.gov/pubmed/28663910",
        "http://www.ncbi.nlm.nih.gov/pubmed/35782791",
        "http://www.ncbi.nlm.nih.gov/pubmed/32477195",
        "http://www.ncbi.nlm.nih.gov/pubmed/8719180",
        "http://www.ncbi.nlm.nih.gov/pubmed/35543970",
        "http://www.ncbi.nlm.nih.gov/pubmed/23433172",
        "http://www.ncbi.nlm.nih.gov/pubmed/36472472",
        "http://www.ncbi.nlm.nih.gov/pubmed/10956396",
        "http://www.ncbi.nlm.nih.gov/pubmed/12685603"
      ]
    },
    {
      "id": "640f8641201352f04a00002c",
      "type": "factoid",
      "body": "Where in the body would  Schlemm's canal be found",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7377264",
          "text": "These observations suggested that the site of increased resistance to aqueous humor outflow in congenital glaucoma could be found in abnormalities of the trabecular meshwork and the internal wall of Schlemm's canal.",
          "offsetInBeginSection": 742,
          "offsetInEndSection": 957,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/824223",
          "text": "The following regions of the eye were examined: ciliary body, iris, Schlemm's canal, juxtacanalicular connective tissue, and trabecular meshwork.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9761282",
          "text": "itions significantly influence the apparent pore density in the inner-wall endothelium of Schlemm's canal. In the present study, the manner in which f",
          "offsetInBeginSection": 47,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12201347",
          "text": "equences on the filtration function.\n\n\nMATERIAL AND METHODS\nthe inner wall endothelium of Schlemm's canal was examined in 9 non-glaucomatous subjects ",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35636488",
          "text": "Peripheral, autonomic, and sensory nerve fibers were found to be present adjacent to Schlemm's canal outer wall endothelium, collector channel endothelium, and in the different regions of the distal outflow vasculature.",
          "offsetInBeginSection": 1299,
          "offsetInEndSection": 1518,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691920",
          "text": "RESULTS\nSubjects with high myopia had a significantly larger Schlemm's canal diameter in the nasal (188.1\u00a0\u00b1\u00a085.6\u00a0\u03bcm vs 127.4\u00a0\u00b1\u00a046.7\u00a0\u03bcm, P\u00a0<\u00a00.001), temporal (200.1\u00a0\u00b1\u00a07.2\u00a0\u03bcm vs 147.6\u00a0\u00b1\u00a068.1\u00a0\u03bcm, P\u00a0=\u00a00.001) quadrants and average value (173.1\u00a0\u00b1\u00a048.1\u00a0\u03bcm vs 137.3\u00a0\u00b1\u00a039.6\u00a0\u03bcm, P\u00a0=\u00a00.001), and larger Schlemm's canal area in the nasal (7333.2\u00a0\u00b1\u00a03877.7\u00a0\u03bcm2 vs 3833.2\u00a0\u00b1\u00a02094.7\u00a0\u03bcm2 , P\u00a0<\u00a00.001), temporal (7274.8\u00a0\u00b1\u00a03247.4\u00a0\u03bcm2 vs 4631.1\u00a0\u00b1\u00a02431.9\u00a0\u03bcm2 , P\u00a0<\u00a00.001) inferior (5512\u00a0\u00b1\u00a02504.9\u00a0\u03bcm2 vs 3922.6\u00a0\u00b1\u00a01935.6\u00a0\u03bcm2 , P\u00a0=\u00a00.003) quadrants and average value(6165.4\u00a0\u00b1\u00a02080.5\u00a0\u03bcm2 vs 4044.4\u00a0\u00b1\u00a01581.1\u00a0\u03bcm2 , P\u00a0<\u00a00.001).",
          "offsetInBeginSection": 671,
          "offsetInEndSection": 1269,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/111203",
          "text": "Erythrocytes appeared to traverse the inner wall of Schlemm's canal through the cytoplasm of individual endothelial cells, rather than between adjacent endothelial cells -- a mechanism similar to that employed by red and white blood cells elsewhere in the body.",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 710,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9761282",
          "text": "form two morphologically and functionally distinct populations in the inner wall of Schlemm's canal. The dependence of intracellular pore density on p",
          "offsetInBeginSection": 1394,
          "offsetInEndSection": 1544,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1426078",
          "text": "(2) Weibel-Palade bodies were found in the endothelium of aqueous veins and in the inner and outer wall endothelium of Schlemm's canal.",
          "offsetInBeginSection": 1122,
          "offsetInEndSection": 1257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10901471",
          "text": "In 14 patients (48%) no evidence of the deroofing of Schlemm's canal was found within the excised deep scleral flap, although intraoperatively the dissection seemed to have been too superficial in only 5 patients.",
          "offsetInBeginSection": 1140,
          "offsetInEndSection": 1353,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7928181",
        "http://www.ncbi.nlm.nih.gov/pubmed/12201347",
        "http://www.ncbi.nlm.nih.gov/pubmed/9761282",
        "http://www.ncbi.nlm.nih.gov/pubmed/29691920",
        "http://www.ncbi.nlm.nih.gov/pubmed/28613427",
        "http://www.ncbi.nlm.nih.gov/pubmed/24827370",
        "http://www.ncbi.nlm.nih.gov/pubmed/35636488",
        "http://www.ncbi.nlm.nih.gov/pubmed/28527653",
        "http://www.ncbi.nlm.nih.gov/pubmed/26997786",
        "http://www.ncbi.nlm.nih.gov/pubmed/10581564"
      ]
    },
    {
      "id": "643c446357b1c7a31500002f",
      "type": "yesno",
      "body": "Can reinfection occur after SARS-CoV-2 infection?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35358491",
          "text": "BACKGROUND\nReinfection after primary SARS-CoV-2 infection is uncommon in adults, but little is known about the risks, characteristics, severity, or outcomes of reinfection in children.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35262003",
          "text": "Conclusion\nComparative genomic analyses from 14 patients confirm that SARS-CoV-2 reinfection can occur.",
          "offsetInBeginSection": 1681,
          "offsetInEndSection": 1784,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34716320",
          "text": "Understanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2 infection can inform subsequent protection and risk of reinfection, however large-scale representative studies are limited.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33791729",
          "text": "Thus, patients with solid organ transplantation, or patients who are otherwise immunosuppressed, who recover from infection with SARS-CoV-2 may not develop sufficient protective immunity and are at risk of reinfection.",
          "offsetInBeginSection": 1770,
          "offsetInEndSection": 1988,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35358491",
          "text": "The reinfection rate after primary infection was 0\u00b768% overall, 0\u00b773% in adults compared with 0\u00b718% in children age younger than 5 years, 0\u00b724% in those aged 5-11 years, and 0\u00b749% in those aged 12-16 years.",
          "offsetInBeginSection": 1352,
          "offsetInEndSection": 1558,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33315049",
          "text": "CONCLUSIONS\nIf this case is representative of most patients with coronavirus disease 2019, long-lived protective immunity against SARS-CoV-2 after primary infection might not be likely.",
          "offsetInBeginSection": 1600,
          "offsetInEndSection": 1785,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34632431",
          "text": "Reinfection by SARS-CoV-2 under endemic conditions would likely occur between 3 months and 5\u00b71 years after peak antibody response, with a median of 16 months.",
          "offsetInBeginSection": 1596,
          "offsetInEndSection": 1754,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33257644",
          "text": "and IgG antibodies were all positive. CONCLUSIONS Reinfection with SARS-CoV-2 is a strong possibility. This case raises concerns that asymptomatic inf",
          "offsetInBeginSection": 1236,
          "offsetInEndSection": 1386,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34632431",
          "text": "As the COVID-19 pandemic continues, reinfection is likely to become increasingly common.",
          "offsetInBeginSection": 2244,
          "offsetInEndSection": 2332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35743421",
          "text": "al SARS-CoV-2 clinical presentation, but there are no data about the risk change after SARS-CoV-2 vaccination. We evaluated the rate of reinfection in",
          "offsetInBeginSection": 53,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35338554",
        "http://www.ncbi.nlm.nih.gov/pubmed/34468184",
        "http://www.ncbi.nlm.nih.gov/pubmed/34382616",
        "http://www.ncbi.nlm.nih.gov/pubmed/33315049",
        "http://www.ncbi.nlm.nih.gov/pubmed/33219681",
        "http://www.ncbi.nlm.nih.gov/pubmed/35665315",
        "http://www.ncbi.nlm.nih.gov/pubmed/35935779",
        "http://www.ncbi.nlm.nih.gov/pubmed/32616673",
        "http://www.ncbi.nlm.nih.gov/pubmed/34367645",
        "http://www.ncbi.nlm.nih.gov/pubmed/34632431"
      ]
    },
    {
      "id": "644009c557b1c7a315000041",
      "type": "factoid",
      "body": "What is the mode of inheritance of Friedreich\u2019s ataxia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1000412",
          "text": "The increased parental consanguinity, the lack of affected individuals in other generations, and the lack of significance of extrinsic etiological variables, all suggested an autosomal recessive mode of inheritance, and this was confirmed by formal genetic analyses, employing several different methods.",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 592,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35720220",
          "text": "Ataxia-telangiectasia (AT) is a type of primary immunodeficiency characterized by an autosomal recessive mode of inheritance and usually presents with progressive cerebellar ataxia in early life.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19462216",
          "text": "t the condition is hereditary and that the mode of inheritance is autosomal recessive. Homozygotes are smaller in size than the wild-type but have a n",
          "offsetInBeginSection": 103,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3469025",
          "text": "ataxia and other cerebellar symptoms. The mode of inheritance was autosomal dominant. Stress or emotion precipitated attacks. Examination between atta",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8669758",
          "text": " cerebellar degeneration of a new clinical form in cats having an autosomal recessive mode of inheritance.\n\n\nCLINICAL RELEVANCE\nWhen cerebellar dysfun",
          "offsetInBeginSection": 1354,
          "offsetInEndSection": 1504,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16082159",
          "text": "d have a similar phenotype. The mode of inheritance appears to be autosomal recessive. We think that the affected siblings may have a new type of auto",
          "offsetInBeginSection": 775,
          "offsetInEndSection": 925,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1124985",
          "text": " ataxia as the most prominent feature. The mode of inheritance is autosomal recessive. The basic defect remains obscure, but recent investigations hav",
          "offsetInBeginSection": 221,
          "offsetInEndSection": 371,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4003033",
          "text": "d PEG show cerebellar atrophy. The pedigree analysis indicates an autosomal recessive mode of inheritance. The condition falls between the ataxic synd",
          "offsetInBeginSection": 415,
          "offsetInEndSection": 565,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16376507",
          "text": "m a Jordanian family. The mode of inheritance of this syndrome is autosomal recessive. We performed a genome-wide screen for linkage and fine mapped t",
          "offsetInBeginSection": 474,
          "offsetInEndSection": 624,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2718740",
          "text": " peripheral neuropathy. Mode of inheritance was in all likelihood autosomal dominant. Blood components were typed for 19 conventional chromosome marke",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 491,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30591515",
        "http://www.ncbi.nlm.nih.gov/pubmed/8687210",
        "http://www.ncbi.nlm.nih.gov/pubmed/8125487",
        "http://www.ncbi.nlm.nih.gov/pubmed/2718740",
        "http://www.ncbi.nlm.nih.gov/pubmed/4003033",
        "http://www.ncbi.nlm.nih.gov/pubmed/12224135",
        "http://www.ncbi.nlm.nih.gov/pubmed/22527681",
        "http://www.ncbi.nlm.nih.gov/pubmed/4004161",
        "http://www.ncbi.nlm.nih.gov/pubmed/19462216",
        "http://www.ncbi.nlm.nih.gov/pubmed/35720220"
      ]
    },
    {
      "id": "641790a3690f196b5100002c",
      "type": "summary",
      "body": "What is the difference between Duchenne muscular Dystrophy and Becker muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26974331",
          "text": "Our results indicate that muscle biopsies from Becker muscular dystrophy patients have fewer numbers of regenerating fibres and reduced utrophin intensity compared to muscle biopsies from Duchenne muscular dystrophy patients.",
          "offsetInBeginSection": 1469,
          "offsetInEndSection": 1694,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15158318",
          "text": "INTRODUCTION\nDuchenne and Becker muscular dystrophy are X-linked and affect mainly males.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 89,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7194435",
          "text": "As with Duchenne patients, a high proportion of non-Duchenne muscular dystrophy patients showed a pattern of a lower verbal scale IQ in relation to their nonverbal, performance scale IQ.",
          "offsetInBeginSection": 224,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16834926",
          "text": "DMD phenotype was significantly less common in patients with exon deletions/duplications at the 5' hotspot, whereas all 4 small mutations associated with mental retardation were located in the 3' end of the gene.",
          "offsetInBeginSection": 862,
          "offsetInEndSection": 1074,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28576279",
          "text": "Muscular dystrophy analysis by Western blot showed reduced dystrophin (20% of normal) for both antibodies (C and N-terminal), allowing the diagnosis of Becker muscular dystrophy.",
          "offsetInBeginSection": 1157,
          "offsetInEndSection": 1335,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
          "text": "r 10,000) male births and Becker muscular dystrophy at 1 in 18,518 (0.5 per 10,000) male births. To estimate the population-based prevalence of Duchen",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 820,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10734267",
          "text": "It is worth noting that both Duchenne muscular dystrophy and Becker muscular dystrophy patients with normal intelligence do not show deletions in the Dp140 regulatory regions.",
          "offsetInBeginSection": 956,
          "offsetInEndSection": 1131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1549217",
          "text": "Duchenne muscular dystrophy patients express little or no dystrophin, while patients with the milder Becker variant produce dystrophin of altered size or quantity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258295",
          "text": "Rarely, other types of muscular dystrophies are also associated with epilepsy including Duchenne and Becker muscular dystrophy, facioscapulohumeral dystrophy, congenital muscular dystrophy with partial and complete deficiency of laminin alpha2 chain, and limb-girdle muscular dystrophy 2A with calpain deficiency.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 516,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8894415",
          "text": "cular dystrophy, where there is absence of dystrophin in Duchenne muscular dystrophy and reduced amounts in Becker muscular dystrophy. Not all of the ",
          "offsetInBeginSection": 768,
          "offsetInEndSection": 918,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7833192",
        "http://www.ncbi.nlm.nih.gov/pubmed/26066469",
        "http://www.ncbi.nlm.nih.gov/pubmed/7635950",
        "http://www.ncbi.nlm.nih.gov/pubmed/8309507",
        "http://www.ncbi.nlm.nih.gov/pubmed/28393671",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
        "http://www.ncbi.nlm.nih.gov/pubmed/164552",
        "http://www.ncbi.nlm.nih.gov/pubmed/22103559",
        "http://www.ncbi.nlm.nih.gov/pubmed/19555515",
        "http://www.ncbi.nlm.nih.gov/pubmed/16322188"
      ]
    },
    {
      "id": "63f56dc533942b094c000001",
      "type": "summary",
      "body": "What is Lance-Adams syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/369491",
          "text": "A patient with postanoxic action myoclonus (Lance-Adams syndrome) was severely disabled with this movement disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367330",
          "text": "bing significant improvement with phenobarbital in a patient with multidrug-resistant Lance-Adams syndrome. We suggest that phenobarbital is an effect",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35530854",
          "text": "Lance-Adams syndrome (LAS) is a rare complication of successful cardiopulmonary resuscitation, often accompanied by action myoclonus.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22506225",
          "text": "Lance-Adams syndrome (LAS) is a rare complication of successful cardiopulmonary resuscitation and is often accompanied by action myoclonus.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9422152",
          "text": "Posthypoxic myoclonus (Lance-Adams' syndrome) is a rare complication of cardiorespiratory arrest.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28808513",
          "text": "Lance-Adams syndrome (LAS) is an uncommon neurological disorder characterized by the development of chronic post-hypoxic myoclonus.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35415010",
          "text": "Background\nLance Adams syndrome is a chronic post-hypoxic myoclonus.\n\n\nPhenomenology Shown\nThis video abstract illustrates Lance Adams Syndrome with m",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977784",
          "text": "It is not common for a patient who survives cardiac arrest to experience significant neurologic impairment such as acute and chronic post-hypoxic myoclonus, known as Lance-Adams syndrome.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32117660",
          "text": "Lance-Adams syndrome (LAS) is chronic\u00a0post-hypoxic myoclonus that is often associated with sudden lapses in muscle tone (negative myoclonus) in the legs, causing a disabling \"bouncy gait.\"",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137720",
          "text": "INTRODUCTION\nChronic post-anoxic myoclonus, also known as Lance-Adams syndrome, may develop following hypoxic brain injury, and is resistant to pharmacological therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19604197",
        "http://www.ncbi.nlm.nih.gov/pubmed/22506225",
        "http://www.ncbi.nlm.nih.gov/pubmed/27708982",
        "http://www.ncbi.nlm.nih.gov/pubmed/17910113",
        "http://www.ncbi.nlm.nih.gov/pubmed/27630463",
        "http://www.ncbi.nlm.nih.gov/pubmed/35415010",
        "http://www.ncbi.nlm.nih.gov/pubmed/24228149",
        "http://www.ncbi.nlm.nih.gov/pubmed/35220777",
        "http://www.ncbi.nlm.nih.gov/pubmed/33842137",
        "http://www.ncbi.nlm.nih.gov/pubmed/17209360"
      ]
    },
    {
      "id": "643def7057b1c7a31500003a",
      "type": "summary",
      "body": "What does mitapivat do?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990",
          "text": "Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\u00a0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-thalassemia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
          "text": "We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) \u03b1-thalassaemia or NTD \u03b2-thalassaemia.",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 477,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781",
          "text": "EXPERT OPINION\nMitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD.",
          "offsetInBeginSection": 754,
          "offsetInEndSection": 899,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
          "text": "In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 293,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
          "text": " kinase deficiency receiving regular transfusions, and is the first disease-modifying agent approved in this disease.\n\n\nFUNDING\nAgios Pharmaceuticals.",
          "offsetInBeginSection": 2467,
          "offsetInEndSection": 2617,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
          "text": "BACKGROUND\nMitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964",
          "text": "Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607",
          "text": "These factors can be modulated by mitapivat, which activates erythrocyte pyruvate kinase (PKR) and improves sickling kinetics in SCD patients.",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 466,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35366607",
          "text": "l benefits in HbSS mice. Mitapivat further increased ATP without significantly changing 2,3-DPG or hemoglobin levels, and decreased levels of leukocyt",
          "offsetInBeginSection": 971,
          "offsetInEndSection": 1121,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
          "text": "In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis.",
          "offsetInBeginSection": 104,
          "offsetInEndSection": 332,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
        "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
        "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
        "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
        "http://www.ncbi.nlm.nih.gov/pubmed/31483964",
        "http://www.ncbi.nlm.nih.gov/pubmed/36124781",
        "http://www.ncbi.nlm.nih.gov/pubmed/36260990",
        "http://www.ncbi.nlm.nih.gov/pubmed/35366607",
        "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
        "http://www.ncbi.nlm.nih.gov/pubmed/33822774"
      ]
    },
    {
      "id": "64371a4257b1c7a315000029",
      "type": "factoid",
      "body": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671982",
          "text": "The presence of operons (polycistronic transcription units formed of functionally related genes) in prokaryotic genomes offers such an alternative.",
          "offsetInBeginSection": 809,
          "offsetInEndSection": 956,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17671982"
      ]
    },
    {
      "id": "6440377c57b1c7a315000049",
      "type": "factoid",
      "body": "What is the active ingredient of Xipere?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32036096",
          "text": "In the present study, we aimed to assess the long-term effects of the active ingredient acetamiprid and a broadly used commercial formulation (Assail\u00ae 70) on the non-target freshwater gastropod Biomphalaria straminea using a battery of biomarkers.",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26798041",
          "text": "In this review, we examine the current state of research on ginseng, including the main active ingredient ginsenoside, its pharmacological effects on the cardiovascular system, and mechanisms of action.",
          "offsetInBeginSection": 262,
          "offsetInEndSection": 464,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458150",
          "text": "The present study evaluated the toxicity and teratogenic effects of the active ingredient clomazone and its two formulations (Rampa\u00ae EC and GAT Cenit 36 CS, both containing 360g a.i./l of clomazone) on zebrafish embryos.",
          "offsetInBeginSection": 334,
          "offsetInEndSection": 554,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150308",
          "text": "The objective of the present study was to assess the tolerance to glyphosate (the active ingredient and a commercial formulation) of contrasting soils with (H) and without (NH) history of exposure.",
          "offsetInBeginSection": 349,
          "offsetInEndSection": 546,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31326750",
          "text": "Worms were exposed to different concentrations of the active ingredient (glyphosate in monoisopropylamine salt) and its commercial formulation.",
          "offsetInBeginSection": 737,
          "offsetInEndSection": 880,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21929291",
          "text": "RESULTS\nSignificant skin lightening activity of the extract of A. hypogaea and its active ingredient resveratrol was observed on the tail melanophores of tadpole.",
          "offsetInBeginSection": 555,
          "offsetInEndSection": 717,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21929291",
          "text": "PURPOSE\nThe present work was carried out to determine the effects of ethanolic extracts of Arachis hypogaea and its active ingredient resveratrol on the isolated tail melanophores of the Bufo melanostictus to find the mechanism of skin lightening at the cellular level.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22913829",
          "text": "e flow properties and drug release, the active ingredient being lidocaine hydrochloride. Besides the role of a synthetic polymer which ensures that th",
          "offsetInBeginSection": 275,
          "offsetInEndSection": 425,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15967309",
          "text": "A survey of the multi-stable isotopic composition of an active pharmaceutical ingredient (API), naproxen, was performed to assess the potential of Isotope Ratio Mass Spectrometry (IRMS) to distinguish the provenance of APIs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29927291",
          "text": "To illustrate their hypothesis, Li and Julian compared the role of developmental relationships in effective interventions to the role that fluoride plays in toothpaste: it is the active ingredient that directly and most powerfully contributes to the intended outcome.",
          "offsetInBeginSection": 515,
          "offsetInEndSection": 782,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29927291",
        "http://www.ncbi.nlm.nih.gov/pubmed/24448465",
        "http://www.ncbi.nlm.nih.gov/pubmed/34518657",
        "http://www.ncbi.nlm.nih.gov/pubmed/19796480",
        "http://www.ncbi.nlm.nih.gov/pubmed/21929291",
        "http://www.ncbi.nlm.nih.gov/pubmed/25739525",
        "http://www.ncbi.nlm.nih.gov/pubmed/26491365",
        "http://www.ncbi.nlm.nih.gov/pubmed/30877537",
        "http://www.ncbi.nlm.nih.gov/pubmed/35790158",
        "http://www.ncbi.nlm.nih.gov/pubmed/15967309"
      ]
    },
    {
      "id": "64163568690f196b5100001b",
      "type": "list",
      "body": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26754139",
          "text": "Large deletions and duplications are most common, but small mutations have been found as well.",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24643206",
          "text": "ystrophin gene that ablate functional protein expression. Although exonic deletions are the most common Duchenne muscular dystrophy lesion, duplicatio",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18160999",
          "text": "Duplications spanning one or more exons have been found to be the second most common disease-causing mutation in the dystrophin gene.",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33039804",
          "text": "Duchenne muscular dystrophy (DMD), an inherited disease caused by the dystrophin gene mutation, is the most common muscular dystrophy in children and is clinically characterized by progressive muscle degeneration and severe cardiomyopathy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25677308",
          "text": "of muscular dystrophy caused by a mutation in the dystrophin gene on the X chromosome. Clinical observations show that in addition to progressive musc",
          "offsetInBeginSection": 65,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27506452",
          "text": "It is caused by mutations in the dystrophin gene, leading to absence of muscular dystrophin and to progressive degeneration of skeletal muscle.",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7833192",
          "text": "New mutations in the dystrophin gene are common and such mutations cause one third of the cases with Duchenne and Becker muscular dystrophy.",
          "offsetInBeginSection": 691,
          "offsetInEndSection": 831,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26582133",
          "text": "Duchenne muscular dystrophy (DMD), caused by mutations at the dystrophin gene, is the most common form of muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": " the most frequent muscular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births. It is due to mutations in the dystroph",
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15528407",
          "text": "Most mutations in the dystrophin gene create a frameshift or a stop in the mRNA and are associated with severe Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7833192",
        "http://www.ncbi.nlm.nih.gov/pubmed/26754139",
        "http://www.ncbi.nlm.nih.gov/pubmed/18160999",
        "http://www.ncbi.nlm.nih.gov/pubmed/25677308",
        "http://www.ncbi.nlm.nih.gov/pubmed/27506452",
        "http://www.ncbi.nlm.nih.gov/pubmed/19158079",
        "http://www.ncbi.nlm.nih.gov/pubmed/26582133",
        "http://www.ncbi.nlm.nih.gov/pubmed/25996334",
        "http://www.ncbi.nlm.nih.gov/pubmed/24643206",
        "http://www.ncbi.nlm.nih.gov/pubmed/28802771"
      ]
    },
    {
      "id": "63ee5eeaf36125a426000002",
      "type": "yesno",
      "body": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17384673",
          "text": "Because Art deficient mice represent a model for radiation-sensitive severe combined immunodeficiency, our findings suggest that these patients may be at risk for both lymphoid and non-lymphoid cancers.",
          "offsetInBeginSection": 1035,
          "offsetInEndSection": 1237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18701881",
          "text": "Defective NHEJ and subsequent failure of V(D)J recombination leads to severe combined immunodeficiency disease (SCID).",
          "offsetInBeginSection": 243,
          "offsetInEndSection": 361,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25917813",
          "text": "Patients with ARTEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular radiosensitivity, but hypomorphic mutations can cause milder phenotypes (leaky SCID).",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 450,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24230999",
          "text": "nt of T-lymphocytes and B-lymphocytes. Most patients manifest a severe combined immunodeficiency during infancy. We report 2 siblings with combined im",
          "offsetInBeginSection": 100,
          "offsetInEndSection": 250,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18560421",
          "text": "Patients with mutations in the Artemis gene display a complete absence of T- and B lymphocytes, together with increased cellular radiosensitivity; this leads to a radiosensitive severe combined immunodeficiency (RS-SCID).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16540517",
          "text": "Null mutations in Artemis confer a condition described as RS-SCID, in which patients display radiosensitivity combined with severe combined immunodeficiency.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21663454",
          "text": "epair and V(D)J recombination. Deficiency of Artemis results in a B- T- radiosensitive severe combined immunodeficiency, which may potentially be trea",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15032591",
          "text": "Mutations in nine different genes have been found to cause the human severe combined immunodeficiency syndrome.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19011808",
          "text": "Inherited hypomorphic mutations in the recombination activating genes 1 and 2 (RAG1 and RAG2) and in ARTEMIS genes and more recently defects in IL7RA, and RMRP genes have been described to be responsible of this peculiar immunodeficiency.",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15723659",
          "text": "A defect in Artemis causes human radiosensitive-severe combined immunodeficiency.",
          "offsetInBeginSection": 205,
          "offsetInEndSection": 286,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18505430",
        "http://www.ncbi.nlm.nih.gov/pubmed/12727634",
        "http://www.ncbi.nlm.nih.gov/pubmed/18223550",
        "http://www.ncbi.nlm.nih.gov/pubmed/27611239",
        "http://www.ncbi.nlm.nih.gov/pubmed/11908269",
        "http://www.ncbi.nlm.nih.gov/pubmed/18701881",
        "http://www.ncbi.nlm.nih.gov/pubmed/12921762",
        "http://www.ncbi.nlm.nih.gov/pubmed/20674517",
        "http://www.ncbi.nlm.nih.gov/pubmed/15032591",
        "http://www.ncbi.nlm.nih.gov/pubmed/24069355"
      ]
    },
    {
      "id": "640c821c201352f04a000023",
      "type": "yesno",
      "body": "Is Wilson's disease described as an iron storage disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984578",
          "text": "ve determination of elevated liver iron content. Wilson's disease represents a copper storage disease. Prominent clinical features are hepatomegaly an",
          "offsetInBeginSection": 434,
          "offsetInEndSection": 584,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704483",
          "text": "Wilson's disease is an autosomal recessive disorder in which the liver does not properly release copper into bile, resulting in prominent copper accumulation in various tissues.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168129",
          "text": "Wilson's disease is one such\u00a0hereditary disease\u00a0that creates chaos in tissues, usually the brain and liver, via deposition of abnormal amounts of copper in them.",
          "offsetInBeginSection": 337,
          "offsetInEndSection": 498,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/742642",
          "text": "A patient in whom hypoparathyroidism developed as a complication of posttransfusional iron storage disease is described.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11054133",
          "text": "More than 60 mutations of the Wilson's disease gene have been described so far.",
          "offsetInBeginSection": 53,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1306026",
          "text": "Wilson's disease is rare autosomal-recessive disorder originated on the basis of metabolic copper over-storage.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34341141",
          "text": "Wilson's disease is an autosomal-recessive disorder of copper metabolism caused by mutations in ATP7B and associated with neurological, psychiatric, ophthalmological and hepatic manifestations.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12925721",
          "text": "d might be expected to be associated with cancer induction, as iron is in haemochromatosis. However, liver cancer is currently believed to be extremel",
          "offsetInBeginSection": 121,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11787982",
          "text": "PROJECT\nWilson's disease (WD) is an inherited disorder of copper metabolism characterised by juvenile liver cirrhosis and by neurological symptoms.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8114295",
          "text": "Hemochromatosis and Wilson's disease are known as iron and copper accumulation disorders, respectively.",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 683,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8114295",
        "http://www.ncbi.nlm.nih.gov/pubmed/11054133",
        "http://www.ncbi.nlm.nih.gov/pubmed/34341141",
        "http://www.ncbi.nlm.nih.gov/pubmed/34289020",
        "http://www.ncbi.nlm.nih.gov/pubmed/33175593",
        "http://www.ncbi.nlm.nih.gov/pubmed/35326301",
        "http://www.ncbi.nlm.nih.gov/pubmed/12412992",
        "http://www.ncbi.nlm.nih.gov/pubmed/25704483",
        "http://www.ncbi.nlm.nih.gov/pubmed/36381061",
        "http://www.ncbi.nlm.nih.gov/pubmed/31179300"
      ]
    },
    {
      "id": "643c9b4057b1c7a315000032",
      "type": "summary",
      "body": "What are promoters?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7768327",
          "text": "We have engineered GH3 cells with reporter genes under control of the growth hormone and prolactin promoters and measured protein production.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3315851",
          "text": "The rpoH transcripts are monocistronic and originate from at least three promoters.",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 690,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32197056",
          "text": "Cell-type- and condition-specific profiles of gene expression require coordination between protein-coding gene promoters and cis-regulatory sequences called enhancers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020586",
          "text": "BACKGROUND\nThe main function of gene promoters appears to be the integration of different gene products in their biological pathways in order to maintain homeostasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36369346",
          "text": "Transcription at most promoters is divergent, initiating at closely spaced oppositely oriented core promoters to produce sense transcripts along with often unstable upstream antisense transcripts (uasTrx).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16432200",
          "text": "Seventy-two percent of promoters belong to the class with high CpG content (HCG), and 28% are in the class whose CpG content is characteristic of the overall genome (low CpG content).",
          "offsetInBeginSection": 601,
          "offsetInEndSection": 784,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8585944",
          "text": "Our studies of the promoters of the myeloid CSF receptors (M, GM, and G) in cell lines have led to the findings that the promoters are small, and are all activated by the PU.1 and C/EBP proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057214",
          "text": "and histone methylation can prime the promoters of immune-related genes required for disease defense. So what are the links between Snf2-mediated ATP-",
          "offsetInBeginSection": 665,
          "offsetInEndSection": 815,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22914767",
          "text": "WHAT IS KNOWN ALREADY\nNanog and Oct4 genes play critical roles in the establishment and maintenance of pluripotency during normal early embryonic development, and both are negatively regulated through the methylation of their promoters.",
          "offsetInBeginSection": 339,
          "offsetInEndSection": 575,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21549717",
          "text": "We characterize their number, mismatches to the consensus sequence, and locations in bidirectional and unidirectional promoter sequences in human and mouse.",
          "offsetInBeginSection": 85,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21549717",
        "http://www.ncbi.nlm.nih.gov/pubmed/22788094",
        "http://www.ncbi.nlm.nih.gov/pubmed/23020586",
        "http://www.ncbi.nlm.nih.gov/pubmed/7768327",
        "http://www.ncbi.nlm.nih.gov/pubmed/3315851",
        "http://www.ncbi.nlm.nih.gov/pubmed/27557757",
        "http://www.ncbi.nlm.nih.gov/pubmed/16432200",
        "http://www.ncbi.nlm.nih.gov/pubmed/24169404",
        "http://www.ncbi.nlm.nih.gov/pubmed/8585944",
        "http://www.ncbi.nlm.nih.gov/pubmed/32197056"
      ]
    },
    {
      "id": "6440084357b1c7a31500003e",
      "type": "yesno",
      "body": "Is omaveloxolone an activator of NFkB?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33068037",
          "text": "rodegenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and red",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24243820",
          "text": "Network, GSEA and transcription factor binding site analyses suggested that NFkB is a common activator for the 180 genes.",
          "offsetInBeginSection": 1073,
          "offsetInEndSection": 1194,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30656180",
          "text": "Omaveloxolone, an Nrf2 activator and NF-kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 322,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16781372",
          "text": "Plaques were analyzed for macrophages (CD68), T-lymphocytes (CD3), inflammatory cells (HLA-DR), ubiquitin-proteasome activity, nuclear factor kappa B (NFkB), inhibitory kappa B (IkB)-beta, nitrotyrosine, matrix metalloproteinase (MMP)-9, and collagen content (immunohistochemistry and enzyme-linked immunosorbent assay).",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 1014,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32410268",
          "text": "Omaveloxolone is a potent activator of Nrf2, a master transcriptional regulator of a multitude of cytoprotective functions, including antioxidative, anti-inflammatory, and mitochondrial bioenergetic effects.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17117296",
          "text": "OPG binds to the receptor activator of NFkB and prevents osteoclast differentiation, activity and survival.",
          "offsetInBeginSection": 364,
          "offsetInEndSection": 471,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29486768",
          "text": "Both the molecular and behavioral effects of LPS treatment were significantly attenuated by systemic NK1R antagonism, suggesting that NK1R stimulation lies upstream of NFkB activation following systemic LPS administration and is at least in part responsible for NFkB activation.",
          "offsetInBeginSection": 2005,
          "offsetInEndSection": 2283,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21945475",
          "text": "Factors such as receptor activator of NFkB ligand (RANKL) may integrate signals from both hormones to orchestrate their joint actions on the epithelial cell hierarchy.",
          "offsetInBeginSection": 288,
          "offsetInEndSection": 455,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9150386",
          "text": "Such mutant NFKB-2 proteins have lost the ability to repress transcription that is typical of NFKB-2 subunit p52, and function as constitutive transcriptional activators.",
          "offsetInBeginSection": 287,
          "offsetInEndSection": 457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18324676",
          "text": "ly accompanied by skeletal metastasis. Receptor activator of NFkB ligand (RANKL) is a key pro-osteoclastic factor. Targeting RANKL decreases establish",
          "offsetInBeginSection": 336,
          "offsetInEndSection": 486,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31118567",
        "http://www.ncbi.nlm.nih.gov/pubmed/29929436",
        "http://www.ncbi.nlm.nih.gov/pubmed/28043969",
        "http://www.ncbi.nlm.nih.gov/pubmed/8570092",
        "http://www.ncbi.nlm.nih.gov/pubmed/21945475",
        "http://www.ncbi.nlm.nih.gov/pubmed/22354849",
        "http://www.ncbi.nlm.nih.gov/pubmed/16980077",
        "http://www.ncbi.nlm.nih.gov/pubmed/12221720",
        "http://www.ncbi.nlm.nih.gov/pubmed/29486768",
        "http://www.ncbi.nlm.nih.gov/pubmed/7981153"
      ]
    },
    {
      "id": "6441057657b1c7a315000052",
      "type": "factoid",
      "body": "What is the most commonly used pain scale for the measurement of pain in children?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30180088",
          "text": "tate an update of this work, most notably growing use of the 11-point numeric rating scale (NRS-11). Our aim was to review the measurement properties ",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 588,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31246094",
          "text": "The commonly used scales of measurement were examined: VAS, VSN, CAS, FPS and the Oucher SCALE.",
          "offsetInBeginSection": 1164,
          "offsetInEndSection": 1259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29551662",
          "text": "The Face, Legs, Activity, Cry, and Consolability (FLACC) scale is one of the most commonly and widely used behavioral observation pain scales.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34300223",
          "text": "ensity rated, and the only tool used for this assessment was the numeric rating scale (NRS). Children with burns most frequently received a single ana",
          "offsetInBeginSection": 720,
          "offsetInEndSection": 870,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30179284",
          "text": "Of the 312 trials that reported pain intensity, 303 (97%) also specified pain assessment tools, in which the most common was the visual analogue scale (24%) followed by the Children's Hospital of Eastern Ontario Pain Scale (18%).",
          "offsetInBeginSection": 1103,
          "offsetInEndSection": 1332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36204486",
          "text": "tions, particularly low back pain and neck pain, and (3) the Tampa Scale of Kinesiophobia is the most commonly used tool for measuring kinesiophobia. ",
          "offsetInBeginSection": 906,
          "offsetInEndSection": 1056,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9789182",
          "text": "Although this study indicates that patients prefer the faces and color scales to the most commonly used visual analog and adjective scales, further research is needed to determine the potential impact of preferred tools on pain intervention.",
          "offsetInBeginSection": 1007,
          "offsetInEndSection": 1248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307699",
          "text": "this experience and to assess and monitor treatment responses. The intensity of pain is the parameter most commonly assessed. In this article, we desc",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 270,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31246094",
          "text": "The commonly used scales of measurement were examined: VAS, VSN, CAS, FPS and the Oucher SCALE.",
          "offsetInBeginSection": 1164,
          "offsetInEndSection": 1259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20921070",
          "text": " data. When given a choice between faces scales, children preferred the WBFPRS. Confounding of pain intensity with affect caused by use of smiling and",
          "offsetInBeginSection": 1320,
          "offsetInEndSection": 1470,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22302082",
        "http://www.ncbi.nlm.nih.gov/pubmed/34300223",
        "http://www.ncbi.nlm.nih.gov/pubmed/30059352",
        "http://www.ncbi.nlm.nih.gov/pubmed/9789182",
        "http://www.ncbi.nlm.nih.gov/pubmed/16489954",
        "http://www.ncbi.nlm.nih.gov/pubmed/17877522",
        "http://www.ncbi.nlm.nih.gov/pubmed/30179284",
        "http://www.ncbi.nlm.nih.gov/pubmed/30180088",
        "http://www.ncbi.nlm.nih.gov/pubmed/12148408",
        "http://www.ncbi.nlm.nih.gov/pubmed/2786893"
      ]
    },
    {
      "id": "6402c71f201352f04a00000a",
      "type": "summary",
      "body": "What is the mechanism of action of daridorexant?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36098936",
          "text": "BACKGROUND AND OBJECTIVE\nThe dual orexin receptor antagonist daridorexant, studied in two phase III trials, dose-dependently improved objective and subjective sleep variables and daytime functioning in adults with insomnia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36045942",
          "text": "Pharmacotherapy for insomnia falls into four classes based on mechanism of action: benzodiazepine receptor agonists (BZRAs), histamine receptor antagonists, melatonin receptor agonists, and dual orexin receptor antagonists (DORAs).",
          "offsetInBeginSection": 332,
          "offsetInEndSection": 563,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33205362",
          "text": "BACKGROUND\nDaridorexant\u00a0(ACT-541468) is a potent dual orexin receptor antagonist under development for the treatment of sleep disorders.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
          "text": "OBJECTIVE\nTo evaluate the dose-response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insomnia disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953863",
          "text": "INTERPRETATION\nDaridorexant induced a dose-dependent reduction in wake time after sleep onset in subjects with insomnia disorder (Clinicaltrials.gov NCT02839200).",
          "offsetInBeginSection": 1576,
          "offsetInEndSection": 1738,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
          "text": "OBJECTIVE\nTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
          "text": "BACKGROUND\nThe dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
          "text": "BACKGROUND AND OBJECTIVE\nDaridorexant is a new dual orexin receptor antagonist currently in late-stage clinical development for the treatment of insomnia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": "Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34415378",
          "text": "By specific binding to both orexin receptors, daridorexant inhibits the actions of the wake-promoting orexin (also called hypocretin) neuropeptides.",
          "offsetInBeginSection": 693,
          "offsetInEndSection": 841,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/31781552",
        "http://www.ncbi.nlm.nih.gov/pubmed/35298826",
        "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
        "http://www.ncbi.nlm.nih.gov/pubmed/32134851",
        "http://www.ncbi.nlm.nih.gov/pubmed/33205362",
        "http://www.ncbi.nlm.nih.gov/pubmed/35426136",
        "http://www.ncbi.nlm.nih.gov/pubmed/34002356",
        "http://www.ncbi.nlm.nih.gov/pubmed/34371524",
        "http://www.ncbi.nlm.nih.gov/pubmed/34121345"
      ]
    },
    {
      "id": "64257c9c690f196b5100004b",
      "type": "factoid",
      "body": "What is DILI-CAT used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31712149",
          "text": "ry (CILI) model, alcohol induced-liver injury (AILI) model and drug-induced liver injury (DILI) model, respectively. The results showed that PNP80b-2 ",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 569,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21349301",
          "text": "logists, researchers, and regulatory authorities to assess the probability of suspected causal agents. However, several limitations of this scale have",
          "offsetInBeginSection": 714,
          "offsetInEndSection": 864,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31443562",
          "text": "r method obtain an accuracy of 77.25%, and the accuracy of the test set was 81.67%. This model could be used for drug-induced liver injury prediction.",
          "offsetInBeginSection": 913,
          "offsetInEndSection": 1063,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36174069",
          "text": "n be assessed and used to quantitatively develop a computer-assisted DILI causality assessment-tool (DILI-CAT). Therefore, we evaluated drug-specific ",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29981923",
          "text": "These tools have been developed and widely used in the past few years for the prediction of pathways induced from both hepatotoxic as well as hepatoprotective Chinese drugs and for the identification of DILI specific biomarkers for prognostic purpose.",
          "offsetInBeginSection": 833,
          "offsetInEndSection": 1084,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27842770",
          "text": "ering an antidote. Liver support systems are used for long-term support or as a bridge to transplantation and are effective for improving encephalopat",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 577,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35266155",
          "text": "AIM\nWe utilised a novel DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30582289",
          "text": " DILI with or without acute liver failure. Given the anti-inflammatory effects of corticosteroids, they have been widely used in DILI in clinical prac",
          "offsetInBeginSection": 387,
          "offsetInEndSection": 537,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36174069",
          "text": "CONCLUSIONS\nDILI-CAT is a data-driven, diagnostic tool built to define drug-specific phenotypes for DILI adjudication.",
          "offsetInBeginSection": 1458,
          "offsetInEndSection": 1576,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36110542",
          "text": "The utility of pharmacist consultation for drug-induced liver injury (DILI) management has not been explored.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27842770",
        "http://www.ncbi.nlm.nih.gov/pubmed/31443562",
        "http://www.ncbi.nlm.nih.gov/pubmed/30582289",
        "http://www.ncbi.nlm.nih.gov/pubmed/36174069",
        "http://www.ncbi.nlm.nih.gov/pubmed/36110542",
        "http://www.ncbi.nlm.nih.gov/pubmed/20564754",
        "http://www.ncbi.nlm.nih.gov/pubmed/35266155",
        "http://www.ncbi.nlm.nih.gov/pubmed/29981923",
        "http://www.ncbi.nlm.nih.gov/pubmed/31712149",
        "http://www.ncbi.nlm.nih.gov/pubmed/21349301"
      ]
    },
    {
      "id": "6429e1b857b1c7a315000008",
      "type": "summary",
      "body": "What is the significance of a persistently positive RT-PCR for weeks after illness?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17386116",
          "text": "Fecal samples were frequently SARS-CoV RT-PCR positive beyond 40 days, and occasional sera still had SARS-CoV detected after 3 weeks of illness.",
          "offsetInBeginSection": 693,
          "offsetInEndSection": 837,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33029620",
          "text": "Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus.",
          "offsetInBeginSection": 328,
          "offsetInEndSection": 539,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12668264",
          "text": "Samples stored at 4 degrees C for up to a week prior to fixation were positive while samples stored at room temperature were positive at 74 h but became negative after 96 h. Fixation of fresh tissue in formalin for 1 week prior to processing resulted in a mild decrease in signal strength compared with tissue fixed for 24-48 h. Real time RT-PCR improves diagnosis of BVD infection by allowing prospective and retrospective identification of BVD virus in tissues processed routinely and stored for histologic evaluation.",
          "offsetInBeginSection": 531,
          "offsetInEndSection": 1051,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807362",
          "text": "There was a significant decrease in the prevalence of RT-PCR positivity at 24 hours after surgery compared with before surgery.",
          "offsetInBeginSection": 982,
          "offsetInEndSection": 1109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34506421",
          "text": "However, replication competent live viruses were not recovered beyond two to three weeks from onset of symptoms in mild to severe cases of COVID-19.",
          "offsetInBeginSection": 125,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33227028",
          "text": "After six weeks of confinement, the positive RT-PCR rate dropped significantly to 10.5% (p<0.001) and even 2.2% during the two last weeks.",
          "offsetInBeginSection": 781,
          "offsetInEndSection": 919,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34240023",
          "text": "IgM and IgG antibody responses become positive several days after the onset of symptoms, and robust antibody responses are detectable in the second week of illness.",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 863,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33227028",
          "text": "After six weeks of confinement, the positive RT-PCR rate dropped significantly to 10.5% (p<0.001) and even 2.2% during the two last weeks.",
          "offsetInBeginSection": 781,
          "offsetInEndSection": 919,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17407041",
          "text": "PCR and culture of samples obtained < or = 2 weeks after illness onset and PCR of samples obtained > 2 weeks after illness onset proved to be most diagnostically useful.",
          "offsetInBeginSection": 397,
          "offsetInEndSection": 566,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35470069",
          "text": "Out of 482 studied patients, 8.7% tested positive after more than four weeks and were considered prolonged convertors.",
          "offsetInBeginSection": 725,
          "offsetInEndSection": 843,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15200815",
        "http://www.ncbi.nlm.nih.gov/pubmed/9652844",
        "http://www.ncbi.nlm.nih.gov/pubmed/26305826",
        "http://www.ncbi.nlm.nih.gov/pubmed/33029620",
        "http://www.ncbi.nlm.nih.gov/pubmed/35251723",
        "http://www.ncbi.nlm.nih.gov/pubmed/11807362",
        "http://www.ncbi.nlm.nih.gov/pubmed/12668264",
        "http://www.ncbi.nlm.nih.gov/pubmed/35470069",
        "http://www.ncbi.nlm.nih.gov/pubmed/8758291",
        "http://www.ncbi.nlm.nih.gov/pubmed/34506421"
      ]
    },
    {
      "id": "644029f857b1c7a315000042",
      "type": "summary",
      "body": "What is the genetic cause of Freidreich's ataxia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32734377",
          "text": "Genetic testing confirmed a c.4552C\u2009>\u2009A mutation in exon 25 of the NOTCH3 gene.",
          "offsetInBeginSection": 759,
          "offsetInEndSection": 838,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16806050",
          "text": "ess, encephalopathy, Freidreich's ataxia, and diseases due to mitochondrial DNA mutations. We also describe several genetic approaches for gene manipu",
          "offsetInBeginSection": 658,
          "offsetInEndSection": 808,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25765228",
          "text": "Friedreich's Ataxia (FRDA) is a very common cause of hereditary autosomal recessive ataxia among western Europeans.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2618587",
          "text": "e normal in 2 of the 4 cases. The remaining two cases showed cerebellar atrophy. Inheritance is probably autosomal recessive in the majority of cases.",
          "offsetInBeginSection": 841,
          "offsetInEndSection": 991,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29325611",
          "text": "The most common of these diseases is Friedreich ataxia, caused by mutation of the frataxin gene, but recent advances in genetic analysis have greatly broadened the ever-expanding number of causative genes to over 50.",
          "offsetInBeginSection": 366,
          "offsetInEndSection": 582,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30746381",
          "text": "pinal cord revealed a normal anatomy. Screening results for the spinocerebellar ataxia gene were also negative. We thus proposed to expand the scope o",
          "offsetInBeginSection": 636,
          "offsetInEndSection": 786,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28724389",
          "text": "However, we would underline the importance of considering hereditary ataxia due to isolated vitamin E deficiency as a specific and treatable cause of child ataxia.",
          "offsetInBeginSection": 228,
          "offsetInEndSection": 391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965395",
          "text": "A genetic cause was identified in 156 (13%) of sporadic cases with other causes being alcohol excess (12%) and cerebellar variant of multiple system atrophy (11%).",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 959,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15681888",
          "text": "Ataxia with isolated Vit E deficiency (AVED) is an Autosomal Recessive genetic disorder with a mutation in the alpha tocopherol transfer protein gene (TTPA).",
          "offsetInBeginSection": 340,
          "offsetInEndSection": 497,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15475256",
          "text": "This indicates that Friedreich ataxia in Mexican Mestizos is due to genetic admixture of European mutant FRDA genes in the Native American gene pool that existed prior to contact with Europeans.",
          "offsetInBeginSection": 907,
          "offsetInEndSection": 1101,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11843630",
        "http://www.ncbi.nlm.nih.gov/pubmed/11960886",
        "http://www.ncbi.nlm.nih.gov/pubmed/27328862",
        "http://www.ncbi.nlm.nih.gov/pubmed/7225958",
        "http://www.ncbi.nlm.nih.gov/pubmed/32653672",
        "http://www.ncbi.nlm.nih.gov/pubmed/32734377",
        "http://www.ncbi.nlm.nih.gov/pubmed/31750392",
        "http://www.ncbi.nlm.nih.gov/pubmed/32246862",
        "http://www.ncbi.nlm.nih.gov/pubmed/15681888",
        "http://www.ncbi.nlm.nih.gov/pubmed/20338762"
      ]
    },
    {
      "id": "6442869857b1c7a31500005d",
      "type": "list",
      "body": "Which diagnostic tests are used for the diagnosis of FSHD?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34071558",
          "text": "Here, we present a comprehensive analysis of the currently used diagnostic methods (Southern blotting and molecular combing) against a new qPCR-based approach for FSHD1 diagnosis.",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 456,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33303865",
          "text": "ilobase repeats, termed D4Z4, located on chromosome 4q35. Assessment of size of D4Z4 alleles is commonly used for FSHD diagnosis. However, the extende",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25098592",
          "text": "to predict due to its high variability. Although measures like MMT and the Brooke Scale are often used, there is a lack of more specific outcome measu",
          "offsetInBeginSection": 1318,
          "offsetInEndSection": 1468,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10544225",
          "text": " caused by the size reduction of a polymorphic repeat array on 4q35. Probe p13E-11 recognises this chromosomal rearrangement and is generally used for",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10371529",
          "text": "n.\n\n\nMETHODS\nPaired digests of genomic DNA (EcoRI only and EcoRI/BlnI double digest), followed by pulsed field gel electrophoresis (PFGE), were used t",
          "offsetInBeginSection": 861,
          "offsetInEndSection": 1011,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19501370",
          "text": "All patients underwent medical and neurological evaluations, subjective evaluation of sleep and full-night laboratory-based polysomnography.",
          "offsetInBeginSection": 505,
          "offsetInEndSection": 645,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592052",
          "text": "A valuable molecular diagnostic test for FSHD has been created with the use of p13E-11 probe to detect the EcoR I/Bln I double digestion fragment which is usually smaller in FSHD patient than in normal indivdual.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 663,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17131163",
          "text": "Complicating factors for molecular diagnosis of FSHD are the phenotypically neutral 10q D4Z4 arrays, cross-hybridizing sequences elsewhere in the genome, deletions including the genomic p13E-11 sequence and part of D4Z4, translocations between 4q and 10q D4Z4 arrays, and the extremely high G + C content of D4Z4 arrays (73%).",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 808,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567298",
          "text": " number of repetitive elements (D4Z4) on chromosome 4q35 (4qA allele). Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD wi",
          "offsetInBeginSection": 576,
          "offsetInEndSection": 726,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10371529",
          "text": "METHODS\nPaired digests of genomic DNA (EcoRI only and EcoRI/BlnI double digest), followed by pulsed field gel electrophoresis (PFGE), were used to establish the molecular diagnosis of FSHD in 82 unrelated index cases (46 familial, 24 proven sporadic with de novo mutations, and 12 with uncertain family history).",
          "offsetInBeginSection": 866,
          "offsetInEndSection": 1178,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10371529",
        "http://www.ncbi.nlm.nih.gov/pubmed/17131163",
        "http://www.ncbi.nlm.nih.gov/pubmed/12778451",
        "http://www.ncbi.nlm.nih.gov/pubmed/17060574",
        "http://www.ncbi.nlm.nih.gov/pubmed/22551571",
        "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
        "http://www.ncbi.nlm.nih.gov/pubmed/26215877",
        "http://www.ncbi.nlm.nih.gov/pubmed/34486074",
        "http://www.ncbi.nlm.nih.gov/pubmed/25150707",
        "http://www.ncbi.nlm.nih.gov/pubmed/26115655"
      ]
    },
    {
      "id": "64040d73201352f04a000010",
      "type": "yesno",
      "body": "Can Efgartigimod be used for myasthenia gravis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31718587",
          "text": "Pyridostigmine and prednisolone were useful for myasthenia gravis while dobutamine was most commonly used for takotsubo syndrome.",
          "offsetInBeginSection": 823,
          "offsetInEndSection": 952,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35621832",
          "text": "However, with the novel neonatal Fc receptor antagonist efgartigimod, levels of all immunoglobulin G subfractions are reduced, addressing an important aspect of the underlying pathophysiology of gMG.",
          "offsetInBeginSection": 662,
          "offsetInEndSection": 861,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30851266",
          "text": "We therefore tested efgartigimod (ARGX-113), a new neonatal Fc receptor blocker, in a mouse model for MuSK myasthenia gravis.",
          "offsetInBeginSection": 974,
          "offsetInEndSection": 1099,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12220686",
          "text": "Autoantibodies against AChR and other muscle antigens can be used for the diagnosis of myasthenia gravis and related disorders.",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35608642",
          "text": "ment topics starting with Fc receptor inhibitors and the Federal Drug Administration approval of efgartigimod. Some uncertainties regarding the use of",
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35349079",
          "text": "The FcRn blocker efgartigimod, a humanized IgG1-derived Fc fragment, which competitively inhibits the FcRn, has recently been approved for the treatment of myasthenia gravis and is currently under investigation in CIDP.",
          "offsetInBeginSection": 1777,
          "offsetInEndSection": 1996,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34146511",
          "text": "BACKGROUND\nThere is an unmet need for treatment options for generalised myasthenia gravis that are effective, targeted, well tolerated, and can be used in a broad population of patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32833750",
          "text": "Three new biologic agents showed promising results in phase-II controlled myasthenia gravis trials: Zilucoplan, a subcutaneous macrocyclic peptide inhibiting complement C5; Efgartigimod, an IgG1-derived Fc fragment binding to neonatal FcRn receptor; and Rozanolixizumab, a high-affinity anti-FcRn monoclonal antibody.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1276,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32052202",
          "text": "Eculizumab was found to be safe in a small phase 2 trial for use in Guillain-Barr\u00e9 syndrome.",
          "offsetInBeginSection": 807,
          "offsetInEndSection": 899,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34277203",
          "text": "Myasthenia gravis is typically well controlled using acetylcholinesterase inhibitors, steroids, immunosuppressant agents, and/or thymectomies.",
          "offsetInBeginSection": 313,
          "offsetInEndSection": 455,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31718587",
        "http://www.ncbi.nlm.nih.gov/pubmed/35179720",
        "http://www.ncbi.nlm.nih.gov/pubmed/35349079",
        "http://www.ncbi.nlm.nih.gov/pubmed/15610702",
        "http://www.ncbi.nlm.nih.gov/pubmed/36227228",
        "http://www.ncbi.nlm.nih.gov/pubmed/30851266",
        "http://www.ncbi.nlm.nih.gov/pubmed/32052202",
        "http://www.ncbi.nlm.nih.gov/pubmed/35608642",
        "http://www.ncbi.nlm.nih.gov/pubmed/34146511",
        "http://www.ncbi.nlm.nih.gov/pubmed/718069"
      ]
    },
    {
      "id": "6422e7ba690f196b51000044",
      "type": "yesno",
      "body": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27063424",
          "text": "Recently, polymer nanoparticles have been demonstrated to penetrate readily through the healthy brain when delivered by CED, and size has been shown to be a critical factor for nanoparticle penetration.",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 571,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26315960",
          "text": "Conventional antioxidant therapies have been less effective in preventing neuronal damage caused by oxidative stress due to their inability to cross the blood brain barrier.",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 280,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34726310",
          "text": "Here, based on high-resolution transmission electron microscopy experiments of an intracranial glioblastoma model, it is shown that ligand-modified nanoparticles can traverse the blood-brain barrier, endocytose into the lysosomes of glioblastoma cells, and undergo endolysosomal escape upon photochemical ionization.",
          "offsetInBeginSection": 307,
          "offsetInEndSection": 623,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33709285",
          "text": "Quercetin-biapigenin PCL-loaded nanoparticles (Papp of approximately 80\u2009\u00d7\u200910-6\u00a0cm/s) revealed to be more permeable than free compounds (Papp of approximately 50\u2009\u00d7\u200910-6\u00a0cm/s).",
          "offsetInBeginSection": 995,
          "offsetInEndSection": 1169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16554356",
          "text": "Nanoparticles coated with polysorbates have previously been shown to enable the transport of several drugs across the blood-brain barrier, which under normal circumstances is impermeable to these compounds.",
          "offsetInBeginSection": 118,
          "offsetInEndSection": 324,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24938893",
          "text": "Cell penetrating peptides (CPPs) possessing powerful transmembrane capacity have been shown to be effective transport vectors for bioactive molecules and an attractive alternative to traditional active targeting approaches.",
          "offsetInBeginSection": 378,
          "offsetInEndSection": 601,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23256496",
          "text": "Nanoparticles (NPs) have previously shown great promise in taking advantage of this increased vascular permeability in other cancers, which results in increased accumulation in these cancers over time due to the accompanying loss of an effective lymph system.",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 485,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16603451",
          "text": "Various drug delivery systems with diverse surfacial characteristics have been reported for effective translocation of drugs across Blood-brain barrier.",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30173122",
          "text": "Cerium oxide nanoparticles have been shown to defend against blood brain barrier damage in cerebral ischemic brain stroke.",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 265,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29932327",
          "text": "Ceria nanoparticles, acting as an effective and recyclable ROS scavenger, have been shown to be highly effective in neuroprotection.",
          "offsetInBeginSection": 249,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23256496",
        "http://www.ncbi.nlm.nih.gov/pubmed/33709285",
        "http://www.ncbi.nlm.nih.gov/pubmed/32330214",
        "http://www.ncbi.nlm.nih.gov/pubmed/24585360",
        "http://www.ncbi.nlm.nih.gov/pubmed/16603451",
        "http://www.ncbi.nlm.nih.gov/pubmed/27063424",
        "http://www.ncbi.nlm.nih.gov/pubmed/29932327",
        "http://www.ncbi.nlm.nih.gov/pubmed/32661727",
        "http://www.ncbi.nlm.nih.gov/pubmed/26315960",
        "http://www.ncbi.nlm.nih.gov/pubmed/30173122"
      ]
    },
    {
      "id": "6429e85e57b1c7a315000009",
      "type": "factoid",
      "body": "What process involves metabolite-sensing mRNAs to control gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26247154",
          "text": "ne expression through a cell-to-cell communication mechanism called quorum sensing. This phenomenon involves the production, detection and the respons",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12756322",
          "text": "These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression.",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15363903",
          "text": "The process of mRNA decay is integral to the post-transcriptional control of gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19303767",
          "text": "These and earlier structures constitute the majority of widespread riboswitch classes and, together with riboswitch folding studies, improve our understanding of the mechanistic principles involved in riboswitch-mediated gene expression control.",
          "offsetInBeginSection": 608,
          "offsetInEndSection": 853,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32459844",
          "text": "slated at a given time, tissue, and/or developmental stage. Ribosome profiling or ribo-seq is one such technology revolutionizing our ability to analy",
          "offsetInBeginSection": 657,
          "offsetInEndSection": 807,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28375729",
          "text": "that regulate gene expression in response to fluctuating metabolite concentrations. Known primarily from bacteria, riboswitches couple specific ligand",
          "offsetInBeginSection": 39,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20435898",
          "text": "The regulatory process is usually mediated by modulating the accessibility of specific sequence information of the expression platforms via metabolite-induced RNA conformational rearrangement.",
          "offsetInBeginSection": 386,
          "offsetInEndSection": 578,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20061809",
          "text": "f associated genes in response to elevated concentrations of cellular metabolites. Metabolite binding stabilizes the evolutionarily conserved receptor",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 293,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17993623",
          "text": "Our data reveal a mechanism whereby metabolite-dependent alteration of RNA folding controls splicing and alternative 3' end processing of mRNAs.",
          "offsetInBeginSection": 630,
          "offsetInEndSection": 774,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20009507",
          "text": "bacterial mRNAs, where they control gene expression by transcriptional or translational attenuation. However, the recent investigation of additional r",
          "offsetInBeginSection": 425,
          "offsetInEndSection": 575,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23653333",
        "http://www.ncbi.nlm.nih.gov/pubmed/23169642",
        "http://www.ncbi.nlm.nih.gov/pubmed/19303767",
        "http://www.ncbi.nlm.nih.gov/pubmed/19101979",
        "http://www.ncbi.nlm.nih.gov/pubmed/17993623",
        "http://www.ncbi.nlm.nih.gov/pubmed/34086280",
        "http://www.ncbi.nlm.nih.gov/pubmed/20435898",
        "http://www.ncbi.nlm.nih.gov/pubmed/20009507",
        "http://www.ncbi.nlm.nih.gov/pubmed/20061809",
        "http://www.ncbi.nlm.nih.gov/pubmed/17468745"
      ]
    },
    {
      "id": "6440360557b1c7a315000047",
      "type": "summary",
      "body": "What is Concerta\u00ae?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29708762",
          "text": "Participants underwent a 4-week trial of long-acting MPH treatment (Concerta\u00ae), with weekly dosing increases until a therapeutic dose was reached.",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 575,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297867",
          "text": ". Primary analysis was by intention-to-treat (ITT). The study drug, methylphenidate (as Concerta(\u00ae) ), was up-titrated over 2 weeks to a maximum dose ",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 707,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12648029",
          "text": "ied-release formulations of MPH, a 20mg capsule (Ritalin) LA) and an 18 mg tablet (Concerta). A total of 19 plasma samples was collected over 24 hours",
          "offsetInBeginSection": 392,
          "offsetInEndSection": 542,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22583957",
          "text": "ed with fluoxetine 40 mg daily. Finally, on a dosage of 378 mg extended-release methylphenidate (Concerta\u00ae), his symptoms of Attention Deficit Hyperac",
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1783,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084448",
          "text": "OBJECTIVE\nThe authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS(\u00ae) MPH) HCl (Concerta(\u00ae), Raritan, NJ) CII in children with ADHD.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276244",
          "text": "METHODS\nTo investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting smoking abstinence, we conducted a randomized, double-blind, placebo-controlled, phase II study of once-a-day osmotic-release oral system methylphenidate (OROS-MPH, Concerta\u00ae) at a target dose of 54-mg/day for 8 weeks compared with placebo in 80 adult cigarette smokers.",
          "offsetInBeginSection": 560,
          "offsetInEndSection": 929,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20015823",
          "text": "Here, we report a case of a 14-year-old boy with ADHD treated chronically with the long-acting form of methylphenidate (Concerta), and who was scheduled to receive orthopedic surgery under general anesthesia.",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 689,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11768842",
          "text": "OBJECTIVE\nThe goal of this study was to estimate the total expected costs for the treatment and management of school-age children with ADHD using 6 commonly prescribed pharmacotherapies: methylphenidate immediate-release/extended-release (MPH IR/ER), methylphenidate immediate-release (MPH IR), Metadate CD (branded MPH IR/ER), Concerta (branded MPH ER), Ritalin (branded MPH IR), and Adderall (a combination of dextroamphetamine and amphetamine salts).",
          "offsetInBeginSection": 404,
          "offsetInEndSection": 857,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18561524",
          "text": "An 18-year-old obese man with a body mass index of 40, diagnosed with attention-deficit hyperactivity disorder and treated with methylphenidate (Concerta) was acutely admitted to hospital with hypoxia and dyspnoea.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25120227",
          "text": "These latter formulations include the 12 h preparation Concerta(\u00ae) (osmotic-release oral system [OROS] MPH), which utilizes an osmotic pump system, designed to overcome the difficulties of multiple daily dosing.",
          "offsetInBeginSection": 1368,
          "offsetInEndSection": 1579,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18561524",
        "http://www.ncbi.nlm.nih.gov/pubmed/20015823",
        "http://www.ncbi.nlm.nih.gov/pubmed/22084448",
        "http://www.ncbi.nlm.nih.gov/pubmed/12648029",
        "http://www.ncbi.nlm.nih.gov/pubmed/21276244",
        "http://www.ncbi.nlm.nih.gov/pubmed/25692005",
        "http://www.ncbi.nlm.nih.gov/pubmed/22972578",
        "http://www.ncbi.nlm.nih.gov/pubmed/11768842",
        "http://www.ncbi.nlm.nih.gov/pubmed/16350601",
        "http://www.ncbi.nlm.nih.gov/pubmed/22583957"
      ]
    },
    {
      "id": "641794e7690f196b51000036",
      "type": "list",
      "body": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28393671",
          "text": "The 5 most commonly reported conditions in males with Duchenne were cognitive deficits (38.4%), constipation (31.7%), anxiety (29.3%), depression (27.4%), and obesity (19.5%).",
          "offsetInBeginSection": 512,
          "offsetInEndSection": 687,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354150",
          "text": "Using a questionnaire-based study, we assessed the parent-reported prevalence of attention-deficit hyperactivity disorders (ADHDs), autism spectrum disorders, and obsessive-compulsive disorders in a group of 351 males with Duchenne muscular dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 251,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35839922",
          "text": "OBJECTIVE\nTo estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
          "text": "In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 396,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29779439",
          "text": "Increased rates of clinically significant internalizing disorders (obsessive compulsive disorder, anxiety, and depression) have been demonstrated in males with Duchenne muscular dystrophy, and a Duchenne muscular dystrophy neuropsychiatric syndrome has been suggested.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
          "text": "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder.",
          "offsetInBeginSection": 107,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3728255",
          "text": "set muscular dystrophy, is X-linked and is associated with cardiac and mental abnormalities. Becker's muscular dystrophy is similar to but milder than",
          "offsetInBeginSection": 57,
          "offsetInEndSection": 207,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258295",
          "text": "Rarely, other types of muscular dystrophies are also associated with epilepsy including Duchenne and Becker muscular dystrophy, facioscapulohumeral dystrophy, congenital muscular dystrophy with partial and complete deficiency of laminin alpha2 chain, and limb-girdle muscular dystrophy 2A with calpain deficiency.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 516,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25660133",
          "text": " cognitive and learning disabilities as well as neurobehavioral disorders, some of which have been associated with disruption of dystrophin isoforms. Retrospective cohort of 59 boys investigated the cognitive and neurobehavioral profile of boys with Duchenne muscular dystrophy. Full-scale IQ of < 70 was seen in 27%; learning disability in 44%, intellectual disability in 19%; attention-deficit/hyperactivity disorder in 32%; autism spectrum disorders in 15%; and anxiety in 27%.",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 572,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357214",
          "text": "Lower urinary tract symptoms were the most common urological diagnosis (32% of patients).",
          "offsetInBeginSection": 592,
          "offsetInEndSection": 681,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/3728255",
        "http://www.ncbi.nlm.nih.gov/pubmed/23357214",
        "http://www.ncbi.nlm.nih.gov/pubmed/25660133",
        "http://www.ncbi.nlm.nih.gov/pubmed/26136844",
        "http://www.ncbi.nlm.nih.gov/pubmed/7979925",
        "http://www.ncbi.nlm.nih.gov/pubmed/35839922",
        "http://www.ncbi.nlm.nih.gov/pubmed/27506452",
        "http://www.ncbi.nlm.nih.gov/pubmed/19258295",
        "http://www.ncbi.nlm.nih.gov/pubmed/17217326",
        "http://www.ncbi.nlm.nih.gov/pubmed/28393671"
      ]
    },
    {
      "id": "63ee5c78f36125a426000001",
      "type": "list",
      "body": "Which interleukins are affected by Dupilumab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34253801",
          "text": "Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36214355",
          "text": "Dupilumab, a human monoclonal antibody that blocks interleukins IL-4 and IL-13, is a recently added systematic treatment option with an emerging evidence base.",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 322,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32184610",
          "text": "Dupilumab, which blocks the receptors for interleukin-4 and interleukin-13, has been effective in reducing asthma exacerbations, improving forced expiratory volume in one second (FEV1), and reducing oral corticosteroid use.",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35174052",
          "text": "ients with moderate-to-severe atopic dermatitis, inhibits interleukins 4 and 13. It is an effective treatment option for atopic dermatitis, but facial",
          "offsetInBeginSection": 113,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32125741",
          "text": "pilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed ",
          "offsetInBeginSection": 232,
          "offsetInEndSection": 382,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31564057",
          "text": "International clinical studies in adults with moderate-to-severe AD have evaluated the efficacy and safety of dupilumab, which blocks interleukin-4 and interleukin-13, key molecules in type 2 inflammation.",
          "offsetInBeginSection": 2091,
          "offsetInEndSection": 2296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34791679",
          "text": "Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of the type 2 inflammation seen in allergic rhinitis, thereby inhibiting their signaling.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 379,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29939132",
          "text": "Dupilumab inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response.",
          "offsetInBeginSection": 680,
          "offsetInEndSection": 797,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31564057",
          "text": "n monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13. International phase II and III studies have evaluated the",
          "offsetInBeginSection": 28,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36451848",
          "text": "Dupilumab is a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, which are key and central drivers of type 2 inflammation.",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 305,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36013001",
        "http://www.ncbi.nlm.nih.gov/pubmed/35657197",
        "http://www.ncbi.nlm.nih.gov/pubmed/36214355",
        "http://www.ncbi.nlm.nih.gov/pubmed/32184610",
        "http://www.ncbi.nlm.nih.gov/pubmed/36451848",
        "http://www.ncbi.nlm.nih.gov/pubmed/30851191",
        "http://www.ncbi.nlm.nih.gov/pubmed/31564057",
        "http://www.ncbi.nlm.nih.gov/pubmed/31917498",
        "http://www.ncbi.nlm.nih.gov/pubmed/26836729",
        "http://www.ncbi.nlm.nih.gov/pubmed/31693426"
      ]
    },
    {
      "id": "64316f8e57b1c7a315000016",
      "type": "list",
      "body": "What cells are used to regenerate cartilage?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16625212",
          "text": " to maintain its functional phenotype for a long period. Utilizing tissue stem cells is one approach to overcome such difficulties. We show here the p",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34829895",
          "text": "The use of mesenchymal stromal cells (MSCs) for tissue engineering of hyaline cartilage is a topical area of regenerative medicine that has already entered clinical practice.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28692374",
          "text": "ver, current surgical therapies have a number of disadvantages. Mesenchymal stem cells have been suggested as a potential alternative therapy, with a ",
          "offsetInBeginSection": 377,
          "offsetInEndSection": 527,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129782",
          "text": "Currently, ex vivo expanded chondrocytes or bone marrow-derived mesenchymal stem cells are used to regenerate the damaged cartilage.",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637149",
          "text": "Regenerated cartilage can be derived from various cell types, including chondrocytes, pluripotent stem cells, and mesenchymal stem cells.",
          "offsetInBeginSection": 684,
          "offsetInEndSection": 821,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29511444",
          "text": "Cartilage tissue engineering, involving a combination of cells, scaffolds, and growth factors, is increasingly used in cartilage regeneration.",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 320,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
          "text": "In this investigation, we assessed the chondrogenic ability of human dental pulp stem cells (hDPSCs) to regenerate cartilage in vitro and in vivo.",
          "offsetInBeginSection": 612,
          "offsetInEndSection": 758,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26990234",
          "text": "rged as a new treatment modality to regenerate AC. Adipose stem cells/adipose-derived stromal cells (ASCs) have gained attention due to their abundanc",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 349,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27510262",
          "text": "One of the most promising sources of cellular regenerative medicine is from mesenchymal stem cells (MSCs).",
          "offsetInBeginSection": 412,
          "offsetInEndSection": 518,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726343",
          "text": "Multipotent mesenchymal stromal cells (MSCs) are primitive cells capable of restoring damaged mesenchyme and with the ability to differentiate into mature cells of bone, cartilage, muscle, fat, nerve or fibrous tissues.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26559963",
        "http://www.ncbi.nlm.nih.gov/pubmed/22023629",
        "http://www.ncbi.nlm.nih.gov/pubmed/35473517",
        "http://www.ncbi.nlm.nih.gov/pubmed/9648028",
        "http://www.ncbi.nlm.nih.gov/pubmed/30423782",
        "http://www.ncbi.nlm.nih.gov/pubmed/28654049",
        "http://www.ncbi.nlm.nih.gov/pubmed/21696723",
        "http://www.ncbi.nlm.nih.gov/pubmed/32430067",
        "http://www.ncbi.nlm.nih.gov/pubmed/27721375",
        "http://www.ncbi.nlm.nih.gov/pubmed/31527619"
      ]
    },
    {
      "id": "6429eb8457b1c7a31500000a",
      "type": "yesno",
      "body": "Is adenosine methylation an epigenetic modification?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35152204",
          "text": "As the major mechanisms causing the variability in the expression of drug metabolizing enzymes, transcriptional regulation by transcription factors, epigenetic regulation including DNA methylation, and posttranscriptional regulation by microRNA are well known.",
          "offsetInBeginSection": 222,
          "offsetInEndSection": 482,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291060",
          "text": "Recent advances in epigenetics have revealed that RNA methylation, an epigenetic modification, has a pivotal role in vascular events.",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 644,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32961299",
          "text": "Whilst DNA cytosine methylation is the oldest and most well-studied epigenetic modification, basking in its glory days, it may be soon overshadowed by the new kid on the block: RNA adenosine methylation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35721189",
          "text": "The adenosine signaling pathway is reported to be involved in cancer pathology and participates in the development of tumors by altering DNA methylation.",
          "offsetInBeginSection": 829,
          "offsetInEndSection": 982,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28202385",
          "text": "In addition, the long-term effects of altered adenosine signaling appear to be mediated by alterations in DNA methylation, an epigenetic process critical for normal development.",
          "offsetInBeginSection": 2073,
          "offsetInEndSection": 2250,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30465529",
          "text": "Epigenetic modifications include the chemical modifications on DNA, RNA and proteins characterized by altered gene expression and function without any changes in the gene sequence.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31188932",
          "text": "Methylation of the N6 position of adenosine (m6A) is a post-transcriptional epigenetic modification of RNA.",
          "offsetInBeginSection": 116,
          "offsetInEndSection": 223,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19281759",
          "text": "DNA methylation on cytosine is an epigenetic modification and is essential for gene regulation and genome stability in vertebrates.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22608085",
          "text": "Methylation of the N(6) position of adenosine (m(6)A) is a posttranscriptional modification of RNA with poorly understood prevalence and physiological relevance.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35032318",
          "text": "N6-methyladenosine (m6A) is a dynamic reversible methylation modification of the adenosine N6 position and is the most common chemical epigenetic modification among mRNA post-transcriptional modifications, including methylation, demethylation, and recognition.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34281602",
        "http://www.ncbi.nlm.nih.gov/pubmed/35152204",
        "http://www.ncbi.nlm.nih.gov/pubmed/31188932",
        "http://www.ncbi.nlm.nih.gov/pubmed/31113923",
        "http://www.ncbi.nlm.nih.gov/pubmed/22608085",
        "http://www.ncbi.nlm.nih.gov/pubmed/30465529",
        "http://www.ncbi.nlm.nih.gov/pubmed/23533770",
        "http://www.ncbi.nlm.nih.gov/pubmed/33961946",
        "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
        "http://www.ncbi.nlm.nih.gov/pubmed/36291060"
      ]
    },
    {
      "id": "6440393157b1c7a31500004a",
      "type": "factoid",
      "body": "Which year was XIPERE approved by the FDA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32358811",
          "text": "Two CAR-T products, Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) were Food and Drug Administration (FDA)-approved in the USA in late 2017, with the FDA commissioner Scott Gottlieb heralding 'a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer'.",
          "offsetInBeginSection": 420,
          "offsetInEndSection": 748,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35420754",
          "text": "nd biosimilars than on drugs not in those categories. Some plans covered 2018 FDA-approved drugs more generously than others, which has implications f",
          "offsetInBeginSection": 1533,
          "offsetInEndSection": 1683,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33632776",
          "text": "The agency also authorized the use of several cancer therapeutics for new indications.",
          "offsetInBeginSection": 49,
          "offsetInEndSection": 135,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35500185",
          "text": "Substantial controversy arose in 2021 when the Food and Drug Administration (FDA) approved the Alzheimer's disease drug aducanumab (Aduhelm) under its accelerated approval program despite a nearly unanimous negative advisory committee vote.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 240,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8935886",
          "text": "In 1995, the Food and Drug Administration (FDA) approved 28 new molecular entities (NMEs), 26 of which are for therapeutic use and two of which are diagnostic agents.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32927064",
          "text": "nistration (FDA) green-lighted the marketing of 53 therapeutic agents in 2019. This rate of approvals was consistent with the 5-year running average. ",
          "offsetInBeginSection": 25,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34416511",
          "text": "The dominant therapeutic area was oncology, accounting for twenty-three new approvals, including thirteen new chemical entities, four new diagnostic agents, and thirteen biologic drugs.",
          "offsetInBeginSection": 350,
          "offsetInEndSection": 535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29610284",
          "text": "The agency also approved two chimeric antigen receptor T-cell therapies for blood cancers.",
          "offsetInBeginSection": 49,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27359262",
          "text": "ations (NDAs) and seven biologic license applications (BLAs) as of 31 December 2014. The FDA granted orphan designation to five DMTs. There was one DM",
          "offsetInBeginSection": 878,
          "offsetInEndSection": 1028,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31099931",
          "text": "e-containing drugs approved by the food and drug administration (FDA) in 2018. The newly approved pharmaceuticals feature several types of aromatic F ",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 403,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35420754",
        "http://www.ncbi.nlm.nih.gov/pubmed/30372706",
        "http://www.ncbi.nlm.nih.gov/pubmed/29023264",
        "http://www.ncbi.nlm.nih.gov/pubmed/31099931",
        "http://www.ncbi.nlm.nih.gov/pubmed/8935886",
        "http://www.ncbi.nlm.nih.gov/pubmed/33632776",
        "http://www.ncbi.nlm.nih.gov/pubmed/35500185",
        "http://www.ncbi.nlm.nih.gov/pubmed/34416511",
        "http://www.ncbi.nlm.nih.gov/pubmed/29610284",
        "http://www.ncbi.nlm.nih.gov/pubmed/27359262"
      ]
    },
    {
      "id": "64412c2757b1c7a315000055",
      "type": "yesno",
      "body": "Can breastfeeding be used to alleviate the procedural pain in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17716448",
          "text": "CONCLUSION\nUsing NIPS, it has been demonstrated that breastfeeding is analgesic in neonates during venepuncture and previous venepuncture/s and site of venepuncture do not seem to affect pain scores.",
          "offsetInBeginSection": 1277,
          "offsetInEndSection": 1476,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014760",
          "text": "Breastfeeding during blood collection did not reduce pain indices or interfere with the acquisition of breastfeeding skills.",
          "offsetInBeginSection": 1454,
          "offsetInEndSection": 1578,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23748256",
          "text": "Results indicate that 20% to 30% glucose solutions have analgesic effects and can be recommended as an alternative to sucrose for procedural pain reduction in healthy term and preterm neonates.",
          "offsetInBeginSection": 1663,
          "offsetInEndSection": 1856,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19851165",
          "text": "UNLABELLED\nBreastfeeding may be useful for relieving procedural pain experienced by neonates.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467598",
          "text": "There is no need for the additional input of classical music on breast feeding in clinic to relieve procedural pain.",
          "offsetInBeginSection": 1808,
          "offsetInEndSection": 1924,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16856069",
          "text": "OBJECTIVES\nThe primary objective of this review was to evaluate the effectiveness of breastfeeding or supplemental breast milk in reducing procedural pain in neonates.",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 683,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235618",
          "text": "OBJECTIVES\nThe primary objective was to evaluate the effectiveness of breastfeeding or supplemental breast milk in reducing procedural pain in neonates.",
          "offsetInBeginSection": 516,
          "offsetInEndSection": 668,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19943866",
          "text": "Participants acknowledged the efficacy breastfeeding and oral sucrose during short-term procedures but skin-to-skin contact and massage were less recognised as useful.",
          "offsetInBeginSection": 1047,
          "offsetInEndSection": 1214,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687988",
          "text": "Some nonpharmacological pain management methods are used for effective pain treatment.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091580",
          "text": "reastfeeding or sucrose for procedural pain, however, breastfeeding rates remain poorly utilised. The use of a pain assessment tool increased from 14%",
          "offsetInBeginSection": 852,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19051617",
        "http://www.ncbi.nlm.nih.gov/pubmed/19021937",
        "http://www.ncbi.nlm.nih.gov/pubmed/17716448",
        "http://www.ncbi.nlm.nih.gov/pubmed/21091580",
        "http://www.ncbi.nlm.nih.gov/pubmed/27420164",
        "http://www.ncbi.nlm.nih.gov/pubmed/17661578",
        "http://www.ncbi.nlm.nih.gov/pubmed/31535510",
        "http://www.ncbi.nlm.nih.gov/pubmed/15853545",
        "http://www.ncbi.nlm.nih.gov/pubmed/23235618",
        "http://www.ncbi.nlm.nih.gov/pubmed/24060767"
      ]
    },
    {
      "id": "64042000201352f04a000020",
      "type": "yesno",
      "body": "Can lenacapavir be used for HIV?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34370418",
          "text": "Promising new data were presented on lenacapavir, an investigational HIV capsid inhibitor given as a subcutaneous injection every 6 months.",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 407,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
          "text": "Lenacapavir can be administered orally either daily or weekly and subcutaneously up to every 6\u200amonths.",
          "offsetInBeginSection": 498,
          "offsetInEndSection": 600,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35762376",
          "text": "Investigational inhibitors including islatravir, lenacapavir, and bNAbs are promising for use as PrEP due to their potential for sustained delivery and low risk of cross-resistance to currently used antiretrovirals, but surveillance for emergence of resistance mutations in more HIV-1 gene regions (gag, env) will be important as the same drugs are being developed for HIV therapy.",
          "offsetInBeginSection": 796,
          "offsetInEndSection": 1177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30453934",
          "text": "HIV service data can be used for surveillance purposes, when prerequisite variables are collected from a large number people, if the quality assessment is conducted.",
          "offsetInBeginSection": 2135,
          "offsetInEndSection": 2300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36202818",
          "text": "The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair HIV-1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores.",
          "offsetInBeginSection": 803,
          "offsetInEndSection": 1011,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35935095",
          "text": "A combination of plant-derived anti-HIV compounds like protease inhibitors and nucleoside analogs, which are commonly used to treat HIV infection, might be explored in clinical trials for the treatment of COVID-19.",
          "offsetInBeginSection": 961,
          "offsetInEndSection": 1175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35762376",
          "text": "PURPOSE OF REVIEW\nTo review current laboratory and clinical data on the frequency and relative risk of drug resistance and range of mutations selected from approved and investigational antiretroviral agents used for preexposure prophylaxis (PrEP) of HIV-1 infection, including tenofovir disproxil fumarate (TDF)-based oral PrEP, dapivirine ring, injectable cabotegravir (CAB), islatravir, lenacapavir and broadly neutralizing antibodies (bNAbs).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 445,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387",
          "text": "Lenacapavir is a first-in-class capsid inhibitor that showed substantial antiviral activity in a phase 1b study.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33625040",
          "text": "long-acting injectable therapy for the management of HIV in recent years that has the potential to revolutionise HIV care as we know it. This review summarises the data and outlines the potential challenges in the field of long-acting antiretroviral therapy (ART).\n\n\nRECENT FINDINGS\nIn recent years, monthly and two monthly long-acting injectable ART in the form of cabotegravir and rilpivirine has shown safety and efficacy in large-scale phase 3 randomised control trials. Also, agents with novel mechanisms of action, such as Lenacapavir, have been tested in early-phase studies and are currently being tested in phase 2-3 clinical trials; if successful, this may allow six-monthly dosing schedules.",
          "offsetInBeginSection": 60,
          "offsetInEndSection": 762,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33337617",
          "text": "long-acting injectable therapy for the management of HIV in recent years that has the potential to revolutionise HIV care as we know it. This review summarises the data and outlines the potential challenges in the field of long-acting antiretroviral therapy (ART).\n\n\nRECENT FINDINGS\nIn recent years, monthly and two monthly long-acting injectable ART in the form of cabotegravir and rilpivirine has shown safety and efficacy in large-scale phase 3 randomised control trials. Also, agents with novel mechanisms of action, such as Lenacapavir, have been tested in early-phase studies and are currently being tested in phase 2-3 clinical trials; if successful, this may allow six-monthly dosing schedules.",
          "offsetInBeginSection": 60,
          "offsetInEndSection": 762,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33625040",
        "http://www.ncbi.nlm.nih.gov/pubmed/35935095",
        "http://www.ncbi.nlm.nih.gov/pubmed/35544387",
        "http://www.ncbi.nlm.nih.gov/pubmed/34370418",
        "http://www.ncbi.nlm.nih.gov/pubmed/30453934",
        "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
        "http://www.ncbi.nlm.nih.gov/pubmed/33337617",
        "http://www.ncbi.nlm.nih.gov/pubmed/35762376",
        "http://www.ncbi.nlm.nih.gov/pubmed/36202818"
      ]
    },
    {
      "id": "6415b3b4690f196b51000009",
      "type": "factoid",
      "body": "What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22441034",
          "text": "The eNpHR-expressing PCs were then illuminated by orange laser (593 nm) either during 30\u00b0 head-up or 30\u00b0 head-down tilts.",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1448,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
          "text": "By using Cal-Light to drive expression of the inhibitory receptor halorhodopsin (eNpHR), which responds to yellow light, we temporarily inhibit the lever-pressing behavior, confirming that the labeled neurons mediate the behavior.",
          "offsetInBeginSection": 661,
          "offsetInEndSection": 891,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21850224",
          "text": "nsduced rats increased frequency of simple spike in response to blue laser illumination. Similarly, most light-responsive PCs (93.8%) in eNpHR-transdu",
          "offsetInBeginSection": 910,
          "offsetInEndSection": 1060,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483674",
          "text": " retino-tectal pathway. We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal g",
          "offsetInBeginSection": 441,
          "offsetInEndSection": 591,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483674",
          "text": "Several weeks after the injection, whole-cell recordings made from sSC neurons in slice preparations revealed that yellow laser illumination of the eNpHR-expressing retino-tectal axons, putatively synapsing onto the recorded cells, effectively inhibited EPSCs evoked by electrical stimulation of the optic nerve layer.",
          "offsetInBeginSection": 724,
          "offsetInEndSection": 1042,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1333616",
          "text": "ollowing 3 s of continuous illumination of Pho81BR cells with green light (550 +/- 20 nm). This effect is abolished by low concentrations of the proto",
          "offsetInBeginSection": 823,
          "offsetInEndSection": 973,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31816591",
          "text": "RESULTS\nUsing MEA technology, phasic increases of extracellular glutamate were recorded immediately upon application of blue light/488\u2009nm to DG of rats previously transfected with an AAV 2/5 vector containing an (excitatory) channelrhodopsin-2 transcript.",
          "offsetInBeginSection": 696,
          "offsetInEndSection": 951,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30948823",
          "text": "fy the first channelrhodopsins as well as a halorhodopsin that respond to red light in the peripheral nerve. Combining two channelrhodopsins with spec",
          "offsetInBeginSection": 500,
          "offsetInEndSection": 650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255969",
          "text": "Channelrhodopsin, the most famous example, is an unselective cation channel, which opens when exposed to blue light, thus mediating the depolarisation of the expressing cell.",
          "offsetInBeginSection": 171,
          "offsetInEndSection": 345,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625509",
          "text": "We show that HaloR-expressing retinal ganglion cells respond to light with rapid hyperpolarization and suppression of spike activity.",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 524,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30948823",
        "http://www.ncbi.nlm.nih.gov/pubmed/23366158",
        "http://www.ncbi.nlm.nih.gov/pubmed/19625509",
        "http://www.ncbi.nlm.nih.gov/pubmed/31443492",
        "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
        "http://www.ncbi.nlm.nih.gov/pubmed/28255969",
        "http://www.ncbi.nlm.nih.gov/pubmed/31816591",
        "http://www.ncbi.nlm.nih.gov/pubmed/17375185",
        "http://www.ncbi.nlm.nih.gov/pubmed/1333616",
        "http://www.ncbi.nlm.nih.gov/pubmed/21925140"
      ]
    },
    {
      "id": "6429fad757b1c7a31500000e",
      "type": "factoid",
      "body": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029071",
          "text": "The RNA polymerase II cofactor PC4 globally regulates transcription of protein-encoding genes through interactions with unwinding DNA, the basal transcription machinery and transcription activators.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3027566",
          "text": "exerted by cis-acting regulatory DNA elements classified as promoter and enhancer sequences. These elements are composed of a number of different prot",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21478871",
          "text": "hat limits the replicative lifespan of cells. The cytoplasmic polyadenylation element binding protein (CPEB) promotes polyadenylation by nucleating a ",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 315,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8628262",
          "text": "The RNA polymerase II and III human small nuclear RNA promoters have a common basal element, the proximal sequence element, which binds the TATA box-binding protein-containing complex SNAPc.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1736286",
          "text": "The TATA box-binding factor TFIID plays a primary role in the process of transcription initiation by RNA polymerase II and its regulation by various gene-specific factors.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35715826",
          "text": "may play a role in transcription. Here, we show that the splicing factor SF3B2 binds to gene regulatory elements and mRNA to modulate transcription an",
          "offsetInBeginSection": 251,
          "offsetInEndSection": 401,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17558417",
          "text": "Our structure captures the duplex-unwinding reaction, shows that initial strand separation does not require ATP and identifies a prominent beta-hairpin loop as the unwinding element.",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 437,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24453987",
          "text": "The four-subunit Negative Elongation Factor (NELF) is a major regulator of RNA Polymerase II (Pol II) pausing.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19292868",
          "text": "Furthermore, we found evidence of sterol-regulated binding of SREBP-1 and RNA polymerase II to HCFC1 and FLNA.",
          "offsetInBeginSection": 1074,
          "offsetInEndSection": 1184,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1849267",
          "text": "e Drosophila RNA polymerase II complex or the yeast transcription factor TFIID. These data suggest that transposase represses transcription by prevent",
          "offsetInBeginSection": 586,
          "offsetInEndSection": 736,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1734283",
        "http://www.ncbi.nlm.nih.gov/pubmed/35715826",
        "http://www.ncbi.nlm.nih.gov/pubmed/7729424",
        "http://www.ncbi.nlm.nih.gov/pubmed/8413225",
        "http://www.ncbi.nlm.nih.gov/pubmed/24453987",
        "http://www.ncbi.nlm.nih.gov/pubmed/2236033",
        "http://www.ncbi.nlm.nih.gov/pubmed/8628262",
        "http://www.ncbi.nlm.nih.gov/pubmed/24029071",
        "http://www.ncbi.nlm.nih.gov/pubmed/1849267",
        "http://www.ncbi.nlm.nih.gov/pubmed/15231738"
      ]
    },
    {
      "id": "64402e7757b1c7a315000044",
      "type": "factoid",
      "body": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7229661",
          "text": "nd crossover trial in 20 patients with ataxia. These patients, who include 7 with Friedreich's ataxia, 7 with mixed spinocerebellar ataxia and 6 will ",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3465425",
          "text": "Vigabatrin (gamma-vinyl GABA; GVG), an irreversible inhibitor of GABA-transaminase, at a daily dose of 2-4 g, and a placebo were each administered orally for 4 months to 14 patients with cerebellar ataxia (9 with Friedreich's ataxia, 5 with olivopontocerebellar atrophy), in a double-blind, placebo-controlled crossover study.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2505370",
          "text": "and placebo were given intramuscularly over a period of one month each. Sixteen patients with Friedreich's disease and 14 patients with different form",
          "offsetInBeginSection": 289,
          "offsetInEndSection": 439,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8795596",
          "text": "OBJECTIVE\nA group of 27 patients with Friedreich's ataxia and another group of 30 patients with olivopontocerebellar atrophies were each randomly divided into two subgroups, one receiving placebo and the other amantadine hydrochloride (AH; 200 mg daily) for three to four months.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 279,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "text": "or-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). Subjects were randomized 2:1 to receive either RT0",
          "offsetInBeginSection": 403,
          "offsetInEndSection": 553,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7733838",
          "text": "ective follow-up study at two university hospitals.\n\n\nPATIENTS\nWe studied 19 patients with Friedreich's ataxia, 13 with cerebellar atrophy, and seven ",
          "offsetInBeginSection": 411,
          "offsetInEndSection": 561,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7229661",
          "text": "Mild but significant improvement in upper limb co-ordination was noted in 3 patients with Friedreich's ataxia, 3 with mixed ataxia and 4 patients with primary cerebellar degeneration.",
          "offsetInBeginSection": 475,
          "offsetInEndSection": 658,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7049340",
          "text": "A clinical and biochemical evaluation of twenty-two patients with Friedreich's Ataxia and ten normal controls was undertaken in 1980 to assess the effect of lecithin and linoleic acid supplements on the course of the disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566998",
          "text": "tered with ClinicalTrials.gov, number NCT02069509.\n\n\nFINDINGS\nWe enrolled 592 patients with genetically confirmed Friedreich's ataxia between Sept 15,",
          "offsetInBeginSection": 1265,
          "offsetInEndSection": 1415,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19384216",
          "text": "A total of 214 patients (147 male) were included in the trial, mean age 59 years (range, 24-85 years).",
          "offsetInBeginSection": 1355,
          "offsetInEndSection": 1457,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25566998",
        "http://www.ncbi.nlm.nih.gov/pubmed/33770527",
        "http://www.ncbi.nlm.nih.gov/pubmed/7229661",
        "http://www.ncbi.nlm.nih.gov/pubmed/7049340",
        "http://www.ncbi.nlm.nih.gov/pubmed/27839651",
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
        "http://www.ncbi.nlm.nih.gov/pubmed/9347392",
        "http://www.ncbi.nlm.nih.gov/pubmed/7733839",
        "http://www.ncbi.nlm.nih.gov/pubmed/8795596",
        "http://www.ncbi.nlm.nih.gov/pubmed/3465425"
      ]
    },
    {
      "id": "64425ce357b1c7a315000059",
      "type": "factoid",
      "body": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3472424",
          "text": "The age-adjusted prevalence rates, on 31 December 1985, per 100,000 population were 6 for Duchenne dystrophy, 3.7 for limb-girdle dystrophy, 0.8 for facioscapulohumeral dystrophy, 0.6 for opthalmoplegia-plus and 7.9 for HMSN (6.4 and 1.5 for Types I and II, respectively).",
          "offsetInBeginSection": 452,
          "offsetInEndSection": 724,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17986494",
          "text": "Facioscapulohumeral dystrophy (FSHD) is the third most common inherited muscular dystrophy after Duchenne dystrophy and myotonic dystrophy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10655933",
          "text": "phy (FSHD), an autosomal dominant disorder with an incidence of 10-20 cases per million. In this patient, sensitivity to an initial dose of vecuronium",
          "offsetInBeginSection": 187,
          "offsetInEndSection": 337,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20180344",
          "text": "phy is clinically mainly characterized by progressive weakness of the facial, shoulder and upper arm muscles. It is an autosomal dominant heriditary d",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24717985",
          "text": "Facioscapulohumeral muscular dystrophy cases with facial weakness before the age of 5 and signs of shoulder weakness by the age of 10 are defined as early onset.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12868502",
          "text": "Facioscapulohumeral muscular dystrophy is an autosomal dominant disorder resulting from an unusual genetic mechanism.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8894417",
          "text": "Facioscapulohumeral dystrophy is an autosomal dominant muscular dystrophy, the gene for which is localized to 4q35.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11761483",
          "text": "Facioscapulohumeral muscular dystrophy is caused by partial deletion of the D4Z4 repeat array on chromosome 4q35.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030947",
          "text": "In 13% of families in which D4Z4 alleles with 4-8 repeats segregate, the diagnosis of facioscapulohumeral muscular dystrophy was reported only in one generation.",
          "offsetInBeginSection": 1701,
          "offsetInEndSection": 1862,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14683629",
          "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly inherited muscular dystrophy with a distinctive clinical presentation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/3472424",
        "http://www.ncbi.nlm.nih.gov/pubmed/15106171",
        "http://www.ncbi.nlm.nih.gov/pubmed/27215221",
        "http://www.ncbi.nlm.nih.gov/pubmed/11761483",
        "http://www.ncbi.nlm.nih.gov/pubmed/24882751",
        "http://www.ncbi.nlm.nih.gov/pubmed/16545566",
        "http://www.ncbi.nlm.nih.gov/pubmed/17151338",
        "http://www.ncbi.nlm.nih.gov/pubmed/8894417",
        "http://www.ncbi.nlm.nih.gov/pubmed/24030947",
        "http://www.ncbi.nlm.nih.gov/pubmed/35251661"
      ]
    },
    {
      "id": "63f581e933942b094c000007",
      "type": "factoid",
      "body": "Risdiplam is used for treatment of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34141064",
          "text": "The discovery of small molecule splicing modifiers and the development of risdiplam for the treatment of spinal muscular atrophy (SMA) have firmly established proof of concept for this exciting new platform and transformed a scientific curiosity into a viable technology to target disease.",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 422,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35040693",
          "text": "comparisons between risdiplam and other approved treatments for spinal muscular atrophy (SMA). Patients & methods: Individual patient data from risdip",
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33919699",
          "text": "Recently, a small-molecule splicing modifier, risdiplam, was also approved for the treatment of SMA, highlighting small molecules as important warheads in the arsenal for regulating RNA splicing.",
          "offsetInBeginSection": 555,
          "offsetInEndSection": 750,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33044711",
          "text": "herapeutics Inc and the SMA Foundation for the treatment of the spinal muscular atrophy. The small molecule is designed to treat spinal muscular atrop",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 291,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34283224",
          "text": "approved small-molecule splicing modulator for the treatment of spinal muscular atrophy (SMA). Previous studies demonstrated that risdiplam analogues ",
          "offsetInBeginSection": 23,
          "offsetInEndSection": 173,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620695",
          "text": "ines Agency for the treatment of patients \u22652 months of age with spinal muscular atrophy-is presented here as a case study. Risdiplam is a low-turnover",
          "offsetInBeginSection": 659,
          "offsetInEndSection": 809,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34745484",
          "text": "he only orally administered drug approved by the FDA for the treatment of SMA. It not only provides a good therapeutic window to systemic tissues but ",
          "offsetInBeginSection": 1009,
          "offsetInEndSection": 1159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36244364",
          "text": "motor neuron 2 (SMN2) gene and is approved for the treatment of spinal muscular atrophy. The FIREFISH study is investigating the safety and efficacy o",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34942136",
          "text": "BACKGROUND\nRisdiplam is an oral small molecule approved for the treatment of patients with spinal muscular atrophy, with approval for use in patients with type 2 and type 3 spinal muscular atrophy granted on the basis of unpublished data.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620695",
          "text": "l of motor neuron 2 mRNA splicing modifier for the treatment of spinal muscular atrophy. The approach taken to characterize the absorption, distributi",
          "offsetInBeginSection": 1701,
          "offsetInEndSection": 1851,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35567422",
        "http://www.ncbi.nlm.nih.gov/pubmed/33919699",
        "http://www.ncbi.nlm.nih.gov/pubmed/34287987",
        "http://www.ncbi.nlm.nih.gov/pubmed/34320287",
        "http://www.ncbi.nlm.nih.gov/pubmed/34141064",
        "http://www.ncbi.nlm.nih.gov/pubmed/34745484",
        "http://www.ncbi.nlm.nih.gov/pubmed/34942136",
        "http://www.ncbi.nlm.nih.gov/pubmed/30302786",
        "http://www.ncbi.nlm.nih.gov/pubmed/34283224",
        "http://www.ncbi.nlm.nih.gov/pubmed/36382958"
      ]
    },
    {
      "id": "641c5201690f196b51000040",
      "type": "list",
      "body": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (NfL).",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35243826",
          "text": "ory of neurological disorders), plasma NfL levels were associated with inner retinal atrophy and outer retinal thickening. Our findings indicate that ",
          "offsetInBeginSection": 466,
          "offsetInEndSection": 616,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420461",
          "text": "In the PD group, NfL levels were significantly elevated in patients with advanced Hoehn-Yahr stage and patients with dementia (p < 0.001).",
          "offsetInBeginSection": 859,
          "offsetInEndSection": 997,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34311152",
          "text": "Our results shown that plasma NfL levels increased with an increase in cognitive impairment across the three groups of PD patients: PD with normal cognition (PD-NC), 17.9\u00a0\u00b1\u00a08.9\u00a0pg/ml; PD with mild cognitive impairment (PD-MCI),21.9\u00a0\u00b1\u00a010.3\u00a0pg/ml; and PD dementia (PDD), 35.7\u00a0\u00b1\u00a021.7\u00a0pg/ml.",
          "offsetInBeginSection": 374,
          "offsetInEndSection": 661,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29630554",
          "text": "In Alzheimer's disease (AD), neurofilament light chain (NFL), a neurofilament subunit, is elevated in the cerebrospinal fluid and blood.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 330,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
          "text": "Within the CKD sample, NfL level is associated with abnormal kidney function and brain structure.",
          "offsetInBeginSection": 1749,
          "offsetInEndSection": 1846,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420461",
          "text": "In the PD group, NfL levels were significantly elevated in patients with advanced Hoehn-Yahr stage and patients with dementia (p < 0.001).",
          "offsetInBeginSection": 859,
          "offsetInEndSection": 997,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29937097",
          "text": "ng number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with prog",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35415973",
          "text": "RESULTS\nNeurofilament light chain levels were associated with grip strength and SMI (P\u00a0=\u00a00.005 and P\u00a0=\u00a00.045, respectively) and were significantly elevated in sarcopenic individuals, compared with non-sarcopenic participants (P\u00a0<\u00a00.001).",
          "offsetInBeginSection": 1168,
          "offsetInEndSection": 1405,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30967444",
          "text": "Its levels increase in cerebrospinal fluid (CSF) and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including inflammatory, neurodegenerative, traumatic and cerebrovascular diseases.",
          "offsetInBeginSection": 299,
          "offsetInEndSection": 526,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36213006",
          "text": "Higher plasma NFL associated with worse clinical outcomes including the need for mechanical ventilation, intensive care, prolonged hospitalization, and greater functional disability at discharge.",
          "offsetInBeginSection": 317,
          "offsetInEndSection": 512,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
        "http://www.ncbi.nlm.nih.gov/pubmed/29630554",
        "http://www.ncbi.nlm.nih.gov/pubmed/31420461",
        "http://www.ncbi.nlm.nih.gov/pubmed/35243826",
        "http://www.ncbi.nlm.nih.gov/pubmed/30967444",
        "http://www.ncbi.nlm.nih.gov/pubmed/36213006",
        "http://www.ncbi.nlm.nih.gov/pubmed/34311152",
        "http://www.ncbi.nlm.nih.gov/pubmed/35088243",
        "http://www.ncbi.nlm.nih.gov/pubmed/29937097",
        "http://www.ncbi.nlm.nih.gov/pubmed/35415973"
      ]
    },
    {
      "id": "643c183b57b1c7a31500002c",
      "type": "list",
      "body": "What are the most common assays to profile chromatin accessibility?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827879",
          "text": "nd disease, most assays of chromatin structure recover only population averages. We have developed DNA methyltransferases (MTases) as probing agents o",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 352,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538187",
          "text": "BaGFoot is robust to different accessibility assays (DNase-seq, ATAC-seq), all examined peak-calling programs, and a variety of cut bias correction approaches.",
          "offsetInBeginSection": 656,
          "offsetInEndSection": 815,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36251758",
          "text": "nly one type of activity-such as transcription, chromatin accessibility, DNA methylation, or 3D chromatin architecture-for each cell. To enable a mult",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 283,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36251758",
        "http://www.ncbi.nlm.nih.gov/pubmed/25827879",
        "http://www.ncbi.nlm.nih.gov/pubmed/28538187"
      ]
    },
    {
      "id": "64402f6f57b1c7a315000045",
      "type": "list",
      "body": "What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35765222",
          "text": "RESULTS\nSixteen participants received RT001 (5.6\u2009\u00b1\u20091.6 g/day; dose range, 1.92 to 8.64\u2009g/day) for a mean period of 10.8\u2009\u00b1\u20097.1\u00a0months.",
          "offsetInBeginSection": 699,
          "offsetInEndSection": 832,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "text": "Subjects were randomized 2:1 to receive either RT001 (1.8 or 9.0 g/day), or a matching dose of nondeuterated ethyl linoleate as comparator for 28 days.",
          "offsetInBeginSection": 503,
          "offsetInEndSection": 654,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2505370",
          "text": "The authors performed a double-blind, double cross-over, four-month trial, where TRH, at the daily dose of 2 and 4 mg, and placebo were given intramuscularly over a period of one month each.",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 360,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11753809",
          "text": "In this randomized controlled double blind phase III study women received 20 mg tamoxifen daily and either 160 mg Octreoid-Depot i. m. injection once a month or a placebo injection.",
          "offsetInBeginSection": 443,
          "offsetInEndSection": 624,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22411849",
          "text": "Treatment consisted of a 6-month scaling-up phase, in which erythropoietin was administered intravenously at the following doses: 20,000 IU every 3 weeks, 40,000 IU every 3 weeks, and 40,000 IU every 2 weeks.",
          "offsetInBeginSection": 675,
          "offsetInEndSection": 883,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
          "text": "DESIGN/METHODS\nWe conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort).",
          "offsetInBeginSection": 340,
          "offsetInEndSection": 502,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23623245",
          "text": " with OXC) were included in our analysis. At high doses (OXC 1200mg, ESL 1200mg and LCM 400mg) there was an increased risk of AE-related study withdra",
          "offsetInBeginSection": 1356,
          "offsetInEndSection": 1506,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1924660",
          "text": "le of 93 depressed outpatients. Venlafaxine doses of 25 mg t.i.d., 75 mg t.i.d., and 125 mg t.i.d. were compared to placebo. Patients receiving venlaf",
          "offsetInBeginSection": 273,
          "offsetInEndSection": 423,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115192",
          "text": "Following prospective confirmation of treatment resistance, patients were randomized (1:1:1) to 10\u00a0weeks double-blind treatment with Lu AF35700 10\u00a0mg or 20\u00a0mg, or active comparator (risperidone or olanzapine).",
          "offsetInBeginSection": 551,
          "offsetInEndSection": 760,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24794816",
          "text": "METHODS\nIn this exploratory, open-label, dose-escalation study in the UK, male and female patients (aged 18 years or older) with Friedreich's ataxia were given single doses (phase 1) and repeated daily doses of 2-8 g oral nicotinamide for 5 days (phase 2) and 8 weeks (phase 3).",
          "offsetInBeginSection": 557,
          "offsetInEndSection": 835,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23623245",
        "http://www.ncbi.nlm.nih.gov/pubmed/11753809",
        "http://www.ncbi.nlm.nih.gov/pubmed/24794816",
        "http://www.ncbi.nlm.nih.gov/pubmed/1924660",
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
        "http://www.ncbi.nlm.nih.gov/pubmed/36115192",
        "http://www.ncbi.nlm.nih.gov/pubmed/35765222",
        "http://www.ncbi.nlm.nih.gov/pubmed/2505370",
        "http://www.ncbi.nlm.nih.gov/pubmed/27737664",
        "http://www.ncbi.nlm.nih.gov/pubmed/22411849"
      ]
    },
    {
      "id": "6440f85c57b1c7a315000051",
      "type": "list",
      "body": "What are the most common pain scales used to measure pain in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26474183",
          "text": "atient's report on the pain sensation. Verbal scales, visual analog scales (VAS) or numeric rating scales (NRS) count among the most common tools, whi",
          "offsetInBeginSection": 141,
          "offsetInEndSection": 291,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7918713",
          "text": "The most frequently used measures are numerical and verbal rating (category) scales of pain intensity and affect.",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 285,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19005869",
          "text": "Pain was measured by three pain assessment tools (Bernese Pain Scale for Neonates, Premature Infant Pain Profile and Visual Analogue Scale)\n\n\nRESULTS\nMorphine did not lead to any pain relief from ETS as measured by three pain scales.",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 1015,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108085",
          "text": "The analgesics most commonly used to treat neonatal pain were acetaminophen (52%) and lidocaine (45%).",
          "offsetInBeginSection": 864,
          "offsetInEndSection": 966,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504",
          "text": "A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS.",
          "offsetInBeginSection": 427,
          "offsetInEndSection": 522,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18368832",
          "text": "e most common manipulation in hospital units. Pain control using the rating scales for neonatal acute pain and its analgesia are necessary as the cons",
          "offsetInBeginSection": 40,
          "offsetInEndSection": 190,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29282767",
          "text": "The most frequently used scales were different versions of Astrid Lindgren's Pain Scale (ALPS) in Sweden and Echelle Douleur Inconfort Noveau-Ne (EDIN), ALPS and Premature Infant Pain Profile (PIPP) in Norway.",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 986,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945293",
          "text": "The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followed by the Neonatal Infant Acute Pain Assessment Scale (23.5%) and the Premature Infant Pain Profile-Revised (20.6%).",
          "offsetInBeginSection": 1832,
          "offsetInEndSection": 2048,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30534623",
          "text": "RESULTS\nThe results indicate that the Faces Pain Scale-Revised is the most preferred scale, followed by a Verbal Rating Scale.",
          "offsetInBeginSection": 777,
          "offsetInEndSection": 903,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26553356",
          "text": "The CRIES (C-Crying; R-Requires increased oxygen administration; I-Increased vital signs; E-Expression; S-Sleeplessness) scale was that used in most Units.",
          "offsetInBeginSection": 1079,
          "offsetInEndSection": 1234,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26474183",
        "http://www.ncbi.nlm.nih.gov/pubmed/29945293",
        "http://www.ncbi.nlm.nih.gov/pubmed/30534623",
        "http://www.ncbi.nlm.nih.gov/pubmed/27518484",
        "http://www.ncbi.nlm.nih.gov/pubmed/36360416",
        "http://www.ncbi.nlm.nih.gov/pubmed/32801846",
        "http://www.ncbi.nlm.nih.gov/pubmed/27108085",
        "http://www.ncbi.nlm.nih.gov/pubmed/35962565",
        "http://www.ncbi.nlm.nih.gov/pubmed/21514052",
        "http://www.ncbi.nlm.nih.gov/pubmed/29282767"
      ]
    },
    {
      "id": "6402c3fd201352f04a000009",
      "type": "yesno",
      "body": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36058230",
          "text": "INTERPRETATION\nWe found no sign of benefit of transdermal glyceryl trinitrate started within 3 h of symptom onset in the prehospital setting in patients with presumed acute stroke.",
          "offsetInBeginSection": 3506,
          "offsetInEndSection": 3686,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27873224",
          "text": "When administered as a transdermal patch during the acute and subacute phases after stroke, GTN was safe, lowered blood pressure, maintained cerebral blood flow, and did not induce cerebral steal or alter functional outcome.",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 408,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30475165",
          "text": "Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure in acute stroke and may improve outcome.",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30738649",
          "text": "INTERPRETATION\nPrehospital treatment with transdermal GTN does not seem to improve functional outcome in patients with presumed stroke.",
          "offsetInBeginSection": 2864,
          "offsetInEndSection": 2999,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24003041",
          "text": "ng) for 7 days with the first dose given by paramedics. The primary outcome was SBP at 2 hours.\n\n\nRESULTS\nOf a planned 80 patients, 41 (25 GTN, 16 no ",
          "offsetInBeginSection": 561,
          "offsetInEndSection": 711,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25465108",
          "text": "INTERPRETATION\nIn patients with acute stroke and high blood pressure, transdermal glyceryl trinitrate lowered blood pressure and had acceptable safety but did not improve functional outcome.",
          "offsetInBeginSection": 1925,
          "offsetInEndSection": 2115,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10511361",
          "text": "CONCLUSION\nAt doses required for acute tocolysis, transdermal glyceryl trinitrate had minimal effects on maternal pulse, BP, and FHR, and significantly fewer adverse cardiovascular effects than intravenous ritodrine.",
          "offsetInBeginSection": 1401,
          "offsetInEndSection": 1617,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2898636",
          "text": "In a randomised controlled trial in 427 men with chronic stable angina continuous use of 5 mg transdermal glyceryl trinitrate (GTN) showed no advantage over placebo in terms of efficacy (anginal attack rates and sublingual GTN consumption) or quality of life (as measured with the sickness impact profile and a health index of disability).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33402412",
          "text": "The 2016 meta-analysis and 2017 Cochrane review showed that transdermal GTN was beneficial in a small patient subgroup with stroke onset \u22646\u2009hours.",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 305,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9819872",
          "text": "Transdermal glyceryl trinitrate (5 mg/day) did not affect maternal cardiovascular, uterine artery or fetal arterial Doppler parameters.",
          "offsetInBeginSection": 1931,
          "offsetInEndSection": 2066,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36058230",
        "http://www.ncbi.nlm.nih.gov/pubmed/31973594",
        "http://www.ncbi.nlm.nih.gov/pubmed/2898636",
        "http://www.ncbi.nlm.nih.gov/pubmed/10511361",
        "http://www.ncbi.nlm.nih.gov/pubmed/25465108",
        "http://www.ncbi.nlm.nih.gov/pubmed/27873224",
        "http://www.ncbi.nlm.nih.gov/pubmed/30738649",
        "http://www.ncbi.nlm.nih.gov/pubmed/21609410",
        "http://www.ncbi.nlm.nih.gov/pubmed/31587658",
        "http://www.ncbi.nlm.nih.gov/pubmed/23979751"
      ]
    },
    {
      "id": "6431f7de57b1c7a31500001b",
      "type": "factoid",
      "body": "What gene is mutated in Friedreich's ataxia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9153129",
          "text": "for the GAA trinucleotide repeat expansion recently found within the gene X25 on chromosome 9. All 56 were found to be homozygous for the expansion, w",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2899844",
          "text": "We report the assignment of the gene mutation for this disorder to chromosome 9p22-CEN by genetic linkage to an anonymous DNA marker MCT112 and the interferon-beta gene probe.",
          "offsetInBeginSection": 546,
          "offsetInEndSection": 721,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12244768",
          "text": "However, DNA-diagnostic testing based upon the detection of expanded GAA-repeats in the X25-gene, has shown that the clinical spectrum is broader than was previously assumed.",
          "offsetInBeginSection": 566,
          "offsetInEndSection": 740,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9527151",
          "text": "Molecular genetic analysis showed the absence of the frataxin gene expansion.",
          "offsetInBeginSection": 419,
          "offsetInEndSection": 496,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11748752",
          "text": "for the clinical presentation of FA and for the presence of the mutated FA gene. The relationship of the expanded gene sequence to the severity of dis",
          "offsetInBeginSection": 554,
          "offsetInEndSection": 704,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24848865",
          "text": "Friedreich's ataxia is a rare hereditary disease and although the gene defect has already been identified as a deficiency of the mitochondrial protein frataxin, the pathophysiology is still unknown.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12174969",
          "text": "een described as a feature of the disease. The association between the frataxin gene mutation and mitochondrial myopathy in this case suggests that se",
          "offsetInBeginSection": 582,
          "offsetInEndSection": 732,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10686465",
          "text": "The expansion of a GAA triplet repeat within the first intron of the frataxin gene, which causes Friedreich's ataxia, was not identified in any of the patients.",
          "offsetInBeginSection": 415,
          "offsetInEndSection": 575,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9271239",
          "text": "Deletion of YDL120, the yeast homologue of the human gene responsible for Friedreich's ataxia, elicits decreased cellular respiration associated with decreased cytochrome c oxidase activity and, in certain nuclear backgrounds, mitochondrial DNA is lost.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11269509",
          "text": "It is caused by an unstable GAA trinucleotide repeat expansion (>120 repeats) in the first intron of the frataxin gene on chromosome 9 (9q13) in both alleles.",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32979145",
        "http://www.ncbi.nlm.nih.gov/pubmed/9266741",
        "http://www.ncbi.nlm.nih.gov/pubmed/32368540",
        "http://www.ncbi.nlm.nih.gov/pubmed/17659792",
        "http://www.ncbi.nlm.nih.gov/pubmed/11269509",
        "http://www.ncbi.nlm.nih.gov/pubmed/11970939",
        "http://www.ncbi.nlm.nih.gov/pubmed/10596471",
        "http://www.ncbi.nlm.nih.gov/pubmed/8815938",
        "http://www.ncbi.nlm.nih.gov/pubmed/7952239",
        "http://www.ncbi.nlm.nih.gov/pubmed/26989534"
      ]
    },
    {
      "id": "643ff48a57b1c7a31500003d",
      "type": "yesno",
      "body": "Is omaveloxolone a suppressor of Nrf2?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32102665",
          "text": "Conversely, inhibition of miR-941 elevated Keap1 expression and activity in endometrial cells, resulting in suppression of Nrf2 activation.",
          "offsetInBeginSection": 1039,
          "offsetInEndSection": 1178,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34524728",
          "text": "r is a key regulator in cellular oxidative stress response, and acts as a tumor suppressor. Aberrant activation of NRF2 has been implicated in promoti",
          "offsetInBeginSection": 28,
          "offsetInEndSection": 178,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27263465",
          "text": "NRF2 has been traditionally considered as a tumor suppressor because its cytoprotective functions are deemed to be the main cellular defense mechanism against exogenous and endogenous insults, including xenobiotics and oxidative stress.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24322982",
          "text": "Cell-based and in vitro biochemical analyses demonstrated that despite its inability to suppress NRF2 activity, the R320Q \"superbinder\" mutant maintained the ability to ubiquitinate NRF2.",
          "offsetInBeginSection": 1043,
          "offsetInEndSection": 1230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33068037",
          "text": "generative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces",
          "offsetInBeginSection": 65,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35308167",
          "text": "Importantly, these effects were blocked by pretreatment with ML385, a selective inhibitor of Nrf2.",
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1091,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15086909",
          "text": "Therefore, Nrf2 deficiency acts as a suppressor of the autoimmune accelerating gene lpr.",
          "offsetInBeginSection": 1705,
          "offsetInEndSection": 1793,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28411557",
          "text": "Although Nrf2 was firstly perceived as a tumor suppressor that inhibits tumor initiation and cancer metastasis, more recent data reveal its role also as a pro-oncogenic factor.",
          "offsetInBeginSection": 348,
          "offsetInEndSection": 524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253260",
          "text": "Comparatively, lithium, an inhibitor of the Nrf2 suppressor GSK-3, prevented A\u03b242 toxicity by mechanisms independent of Nrf2.",
          "offsetInBeginSection": 727,
          "offsetInEndSection": 852,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109674",
          "text": "However, despite the immensely intricate level of control the cellular environment imposes on Nrf2 activity, there are many opportunities for perturbations to arise in the signaling events that favor carcinogenesis and, therefore, implicate Nrf2 as both a tumor suppressor and a protooncogene.",
          "offsetInBeginSection": 478,
          "offsetInEndSection": 771,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31118567",
        "http://www.ncbi.nlm.nih.gov/pubmed/32986742",
        "http://www.ncbi.nlm.nih.gov/pubmed/24866179",
        "http://www.ncbi.nlm.nih.gov/pubmed/23174755",
        "http://www.ncbi.nlm.nih.gov/pubmed/31704266",
        "http://www.ncbi.nlm.nih.gov/pubmed/35308167",
        "http://www.ncbi.nlm.nih.gov/pubmed/33737068",
        "http://www.ncbi.nlm.nih.gov/pubmed/28253260",
        "http://www.ncbi.nlm.nih.gov/pubmed/22215675",
        "http://www.ncbi.nlm.nih.gov/pubmed/31018701"
      ]
    },
    {
      "id": "64410f8057b1c7a315000054",
      "type": "yesno",
      "body": "Can salivary cortisol be used to evaluate pain in neonates?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25545416",
          "text": "saturations were recorded. Pain levels were assessed by the Bernese Pain Scale for Neonates.\n\n\nRESULTS\nSalivary cortisol was significantly lower 25 mi",
          "offsetInBeginSection": 649,
          "offsetInEndSection": 799,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32551828",
          "text": "CONCLUSION\nConsidering the multiple challenges involved in obtaining valid saliva samples in this population, salivary cortisol may not be a feasible biomarker of physiological stress in people with dementia and chronic pain.",
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1483,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30612596",
          "text": "However, there is no study in neonates assessing both behavioural and physiological indicators of stress simultaneously during ambulance transportation.",
          "offsetInBeginSection": 285,
          "offsetInEndSection": 437,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246458",
          "text": "KC did not affect salivary cortisol levels in preterm neonates, but levels in both the KC and SC groups decreased over time from DOL five to ten.",
          "offsetInBeginSection": 1235,
          "offsetInEndSection": 1380,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15115248",
          "text": "In conclusion, it is feasible to collect microlitre volumes of saliva and analyse even very low concentrations of cortisol in newborns.",
          "offsetInBeginSection": 1392,
          "offsetInEndSection": 1527,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32551828",
          "text": "Although salivary cortisol is used as a biomarker of stress in people with dementia, few studies have reported the feasibility of collection methods to assess salivary cortisol in nursing home residents with both dementia and chronic pain.",
          "offsetInBeginSection": 60,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26023551",
          "text": "CONCLUSION\nMusic therapy can be easily used in the breast milk expression room as a method to increase breast milk secretion in mothers who are stressed because of their neonates being admitted in NICU.",
          "offsetInBeginSection": 1872,
          "offsetInEndSection": 2074,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19183121",
          "text": "MEASUREMENTS\nPain was assessed by the Bernese Pain Scale for Neonates (BPSN), the Premature Infant Pain Profile (PIPP) and the Visual Analogue Scale (VAS).",
          "offsetInBeginSection": 390,
          "offsetInEndSection": 545,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3598773",
          "text": "We suggest that salivary cortisol is a useful, noninvasive method of studying adrenocortical status in the newborn infant.",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 743,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25078034",
          "text": "CONCLUSIONS\nCortisol levels from saliva or urine samples were shown to be useful surrogate markers for plasma cortisol levels in neonates.",
          "offsetInBeginSection": 1531,
          "offsetInEndSection": 1669,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15115248",
        "http://www.ncbi.nlm.nih.gov/pubmed/3598773",
        "http://www.ncbi.nlm.nih.gov/pubmed/32551828",
        "http://www.ncbi.nlm.nih.gov/pubmed/21155041",
        "http://www.ncbi.nlm.nih.gov/pubmed/16326367",
        "http://www.ncbi.nlm.nih.gov/pubmed/30612596",
        "http://www.ncbi.nlm.nih.gov/pubmed/19171296",
        "http://www.ncbi.nlm.nih.gov/pubmed/9973669",
        "http://www.ncbi.nlm.nih.gov/pubmed/26023551",
        "http://www.ncbi.nlm.nih.gov/pubmed/25545416"
      ]
    },
    {
      "id": "6402c0d5201352f04a000008",
      "type": "yesno",
      "body": "Does nintedanib improve response rate in patients with bladder cancer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30010751",
          "text": "lusions\nThe study failed to meet both co-primary end points. Nintedanib did not improve OS and was associated with a significant but modest increase i",
          "offsetInBeginSection": 1889,
          "offsetInEndSection": 2039,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35421369",
          "text": "INTERPRETATION\nThe addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle-invasive bladder cancer.",
          "offsetInBeginSection": 2749,
          "offsetInEndSection": 2913,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27587436",
          "text": "Nintedanib WoO induced tumor reoxygenation in 24.5% of the patients; those not reoxygenating showed a trend toward higher chance of experiencing RCB-III (6.4-fold; P = 0.09).",
          "offsetInBeginSection": 1368,
          "offsetInEndSection": 1542,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33239000",
          "text": "Nintedanib reduces the rate of FVC decline both in patients who lose weight on treatment and those who do not.",
          "offsetInBeginSection": 1720,
          "offsetInEndSection": 1830,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30929823",
          "text": "Thirty-seven percent (10/27) had stable disease, while 56% (15/27) had progressive disease.",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34439322",
          "text": "axel combination in second- and further-line settings (n = 59). Overall response rate, defined as the combined rates of complete and partial responses",
          "offsetInBeginSection": 1436,
          "offsetInEndSection": 1586,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32193228",
          "text": "CONCLUSIONS\nAlthough tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls.",
          "offsetInBeginSection": 1449,
          "offsetInEndSection": 1595,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31694906",
          "text": "Moreover, our findings support that patients with ADC may be more responsive to antifibrotic drugs targeting their stromal TGF\u03b21/SMAD3 activation.",
          "offsetInBeginSection": 1707,
          "offsetInEndSection": 1853,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35012901",
          "text": "Among 64 patients with a documented response, the objective response rate was 50% (n = 32; one complete response and 31 partial responses) and the disease control rate was 86% (n = 55).",
          "offsetInBeginSection": 1163,
          "offsetInEndSection": 1348,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31179001",
          "text": "Introduction\nNintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36386456",
        "http://www.ncbi.nlm.nih.gov/pubmed/30010751",
        "http://www.ncbi.nlm.nih.gov/pubmed/31179001",
        "http://www.ncbi.nlm.nih.gov/pubmed/31282758",
        "http://www.ncbi.nlm.nih.gov/pubmed/35421369",
        "http://www.ncbi.nlm.nih.gov/pubmed/35012901",
        "http://www.ncbi.nlm.nih.gov/pubmed/9749086",
        "http://www.ncbi.nlm.nih.gov/pubmed/31694906",
        "http://www.ncbi.nlm.nih.gov/pubmed/30929823",
        "http://www.ncbi.nlm.nih.gov/pubmed/31778047"
      ]
    },
    {
      "id": "6419fa3d690f196b5100003c",
      "type": "summary",
      "body": "What is the difference between siRNA and Antisense oligonucleotide therapeutics",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35482908",
          "text": "Here, we describe different strategies for delivering RNA drugs to the CNS and review recent advances in clinical development of ASO drugs and siRNA-based therapeutics for the treatment of neurological diseases and neuromuscular disorders.Abbreviations 2'-MOE: 2'-O-(2-methoxyethyl); 2'-O-Me: 2'-O-methyl; 2'-F: 2'-fluoro; AD: Alzheimer's disease; ALS: Amyotrophic lateral sclerosis; ALSFRS-R: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; ARC: Antibody siRNA Conjugate; AS: Angelman Syndrome; ASGRP: Asialoglycoprotein receptor; ASO: Antisense oligonucleotide; AxD: Alexander Disease; BBB: Blood brain barrier; Bp: Basepair; CNM: Centronuclear myopathies; CNS: Central Nervous System; CPP: Cell-penetrating Peptide; CSF: Cerebrospinal fluid; DMD: Duchenne muscular dystrophy; DNA: Deoxyribonucleic acid; FAP: Familial amyloid polyneuropathy; FALS: Familial amyotrophic lateral sclerosis; FDA: The United States Food and Drug Administration; GalNAc: N-acetylgalactosamine; GoF: Gain of function; hATTR: Hereditary transthyretin amyloidosis; HD: Huntington's disease; HRQOL: health-related quality of life; ICV: Intracerebroventricular; IT: Intrathecal; LNA: Locked nucleic acid; LoF: Loss of function; mRNA: Messenger RNA; MS: Multiple Sclerosis; MSA: Multiple System Atrophy; NBE: New Biological Entity; NCE: New Chemical Entity; NHP: Nonhuman primate; nt: Nucleotide; PD: Parkinson's disease; PNP: Polyneuropathy; PNS: Peripheral nervous system; PS: Phosphorothioate; RISC: RNA-Induced Silencing Complex; RNA: Ribonucleic acid; RNAi: RNA interference; s.c.: Subcutaneous; siRNA: Small interfering RNA; SMA: Spinal muscular atrophy; SMN: Survival motor neuron; TTR: Transthyretin.",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 2307,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31072142",
          "text": "INTRODUCTION\nOligonucleotide therapeutics such as antisense oligonucleotides and siRNA requires chemical modifications and nano-sized carriers to circumvent stability problems in vivo, to reach target tissues, and to overcome tissue and cellular barriers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 255,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16101440",
          "text": "tracellular cascade is quite different. siRNA could prove to be more powerful and longer lasting than antisense. Several DNA therapeutics are currentl",
          "offsetInBeginSection": 1138,
          "offsetInEndSection": 1288,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22353142",
          "text": "However, a major impediment to the maturation of this field of oligonucleotide-based therapeutics remains: these relatively large and often highly charged molecules don't easily cross cellular membranes, making it difficult for them to reach their sites of action in the cytosol or nucleus.",
          "offsetInBeginSection": 421,
          "offsetInEndSection": 711,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17041803",
          "text": "While antisense oligonucleotides, ribozymes and siRNAs suppress the expression of a protein by complementary hybridizing with their target mRNA, aptamers bind like antibodies to their target protein and thereby inhibit its function.",
          "offsetInBeginSection": 400,
          "offsetInEndSection": 632,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36332914",
          "text": "herapeutics in various ways including both its mechanism of action and clinical pharmacology characteristics. These unique characteristics, along with",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36339619",
          "text": "Oligonucleotide-based therapeutics are of intermediate size with much-improved selectivity towards the target and fewer off-target effects than small molecules.",
          "offsetInBeginSection": 502,
          "offsetInEndSection": 662,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15294073",
          "text": "It is often believed that small interfering RNA (siRNA) is at least 10-fold more effective than the single-stranded antisense oligonucleotide for silencing the same target gene in the same cells.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31509944",
          "text": "However, targeting non-hepatic diseases with oligonucleotide therapeutics has remained problematic for several reasons, including targeting specific cell types and endosomal escape.",
          "offsetInBeginSection": 408,
          "offsetInEndSection": 589,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32591626",
          "text": "Oligonucleotide therapeutics use short interfering RNA (siRNA) or antisense oligonucleotide (ASO) molecules to exploit endogenous systems-neutralizing target RNA to prevent subsequent protein translation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25662226",
        "http://www.ncbi.nlm.nih.gov/pubmed/31072142",
        "http://www.ncbi.nlm.nih.gov/pubmed/36332914",
        "http://www.ncbi.nlm.nih.gov/pubmed/18483081",
        "http://www.ncbi.nlm.nih.gov/pubmed/16213482",
        "http://www.ncbi.nlm.nih.gov/pubmed/31509944",
        "http://www.ncbi.nlm.nih.gov/pubmed/17041803",
        "http://www.ncbi.nlm.nih.gov/pubmed/28106744",
        "http://www.ncbi.nlm.nih.gov/pubmed/36339619",
        "http://www.ncbi.nlm.nih.gov/pubmed/15294073"
      ]
    },
    {
      "id": "644036cf57b1c7a315000048",
      "type": "summary",
      "body": "What is Yutiq?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36444172",
          "text": "Purpose\nOur case emphasizes the utility of long-acting intravitreal fluocinolone implants (YUTIQ) for managing recalcitrant forms of non-infectious posterior uveitis, NIPU.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35793136",
          "text": "PURPOSE\nTo evaluate the efficacy of the fluocinolone acetonide intravitreal implant (Yutiq) as monotherapy for uveitis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31663454",
          "text": "This article will review the pharmacology and preliminary clinical data of the 0.18\u00a0mg fluocinolone acetonide intravitreal implant (YUTIQ\u2122), to show its efficacy and safety in the treatment of noninfectious posterior uveitis.",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 793,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36444172",
        "http://www.ncbi.nlm.nih.gov/pubmed/31663454",
        "http://www.ncbi.nlm.nih.gov/pubmed/35793136"
      ]
    },
    {
      "id": "643f9eeb57b1c7a31500003c",
      "type": "factoid",
      "body": "What is the incidence of Duchenne Muscular Dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29066903",
          "text": "Approximately 25% of patients with Duchenne muscular dystrophy have a long bone fracture, and 1% to 22% of fractures have a chance to develop fat embolism syndrome.",
          "offsetInBeginSection": 766,
          "offsetInEndSection": 930,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
          "text": "Males with Becker muscular dystrophy have a high incidence of learning difficulties.",
          "offsetInBeginSection": 1803,
          "offsetInEndSection": 1887,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035",
          "text": "Duchenne muscular dystrophy is the most common muscle disease found in male children.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1251722",
          "text": "In a retrospective study of hospital and autopsy records of 19 male subjects with the Duchenne type of progressive muscular dystrophy the incidence of cardiac involvement of the heart almost invariably develop heart failure; an early sign may be persistent tachycardia and, possibly, electrocardiographic changes, in case of which institution of digitalis treatment should be considered.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 387,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26697447",
          "text": "rder, is the most common muscular dystrophy with an incidence in boys of about 200 per million births. It presents in early childhood leading to death",
          "offsetInBeginSection": 51,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7322666",
          "text": "To investigate a possible disorder of adenine nucleotide turnover in Duchenne muscular dystrophy, we evaluated 15 patients with mild Duchenne muscular dystrophy, eight patients with severe muscular dystrophy, seven patients with other neuromuscular disorders, and eight patients with hypogammaglobulinemia but no muscle disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7635950",
          "text": "Duchenne muscular dystrophy is a fatal disorder characterized by progressive muscular weakness, wasting, and severe muscle contractures in later disease stages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33662889",
          "text": "aused by mutations in the DMD gene, resulting in cardiomyopathy in all affected children by 18 years. Although cardiomyopathy is now the leading cause",
          "offsetInBeginSection": 43,
          "offsetInEndSection": 193,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102647",
          "text": "Duchenne muscular dystrophy is caused by mutations in the DMD gene that disrupt the open reading frame and prevent the full translation of its protein product, dystrophin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752877",
          "text": "Duchenne muscular dystrophy, an X-linked disorder, has an incidence of one in 5000 boys and presents in early childhood with proximal muscle weakness.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
        "http://www.ncbi.nlm.nih.gov/pubmed/31311695",
        "http://www.ncbi.nlm.nih.gov/pubmed/29066903",
        "http://www.ncbi.nlm.nih.gov/pubmed/7635950",
        "http://www.ncbi.nlm.nih.gov/pubmed/8309507",
        "http://www.ncbi.nlm.nih.gov/pubmed/14678803",
        "http://www.ncbi.nlm.nih.gov/pubmed/32270339",
        "http://www.ncbi.nlm.nih.gov/pubmed/7922631",
        "http://www.ncbi.nlm.nih.gov/pubmed/1251722",
        "http://www.ncbi.nlm.nih.gov/pubmed/1279966"
      ]
    },
    {
      "id": "6402ba49201352f04a000004",
      "type": "list",
      "body": "Which drugs were studied in the TRICOTEL study?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28567538",
          "text": "We calculated the following 3-year retention rates: lacosamide 77.1% (N\u00a0=\u00a0137), lamotrigine 68.3% (N\u00a0=\u00a0177), levetiracetam 66.7% (N\u00a0=\u00a0319), clobazam 65.6% (N\u00a0=\u00a0130), topiramate 61.6% (N\u00a0=\u00a0178), zonisamide 60.4% (N\u00a0=\u00a0103), pregabalin 54.6% (N\u00a0=\u00a0127), and gabapentin 40.2% (N\u00a0=\u00a066).",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 965,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19025833",
          "text": "High repeat to consultation ratios were recorded for ranitidine, temazepam and diazepan.Conclusions-Wide interpractice variation in repeat prescribing and associated diagnoses revealed poor consensus among practices.",
          "offsetInBeginSection": 1311,
          "offsetInEndSection": 1527,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12183908",
          "text": "Conformational analysis of five I1-receptor agonists in the neutral form (clonidine, moxonidine, rilmenidine, phentolamine, and phencyclidine) and one antagonist of I1-receptors (idazoxane) was carried out by means of the MM2 method.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 233,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28567538",
          "text": "Lacosamide, levetiracetam, and clobazam were the most effective AEDs in the elderly.",
          "offsetInBeginSection": 966,
          "offsetInEndSection": 1050,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19025833",
          "text": " gastrointestinal drugs, cardiovascular drugs, central nervous system drugs, dressings and appliances (p < 0.0001). There was wide interpractice variation in repeat prescribing (both overall and for individual anatomical groups) and associated diagnoses. High repeat to consultation ratios were recorded for ranitidine, temazepam and diazepan",
          "offsetInBeginSection": 1056,
          "offsetInEndSection": 1398,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28567538",
          "text": "We calculated the following 3-year retention rates: lacosamide 77.1% (N\u00a0=\u00a0137), lamotrigine 68.3% (N\u00a0=\u00a0177), levetiracetam 66.7% (N\u00a0=\u00a0319), clobazam 65.6% (N\u00a0=\u00a0130), topiramate 61.6% (N\u00a0=\u00a0178), zonisamide 60.4% (N\u00a0=\u00a0103), pregabalin 54.6% (N\u00a0=\u00a0127), and gabapentin 40.2% (N\u00a0=\u00a066).",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 965,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19025833",
        "http://www.ncbi.nlm.nih.gov/pubmed/28567538",
        "http://www.ncbi.nlm.nih.gov/pubmed/12183908"
      ]
    },
    {
      "id": "6431f6a857b1c7a315000018",
      "type": "summary",
      "body": "How is amniotic fluid produced?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7270010",
          "text": "Since both foetal and maternal prolactin secretion are suppressed by bromocriptine our results suggest that amniotic fluid prolactin is produced by extrapituitary tissues, which do not contain dopamine receptors.",
          "offsetInBeginSection": 277,
          "offsetInEndSection": 489,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1812157",
          "text": "To study the effect of oligohydramnios on lung growth and biochemical lung development in fetal rabbits, amniotic fluid was drained through a tube inserted into the maternal peritoneal cavity on the 23 day of gestation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33969779",
          "text": "l, mesothelial, and fibroblast cells after exposure to bacterial lipopolysaccharide or pro-inflammatory molecules. The primary aim of this study was t",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 247,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7716201",
          "text": "ancement produced by ingested placenta; amniotic fluid injected SC or IP does not produce enhancement. The present study was designed to distinguish b",
          "offsetInBeginSection": 438,
          "offsetInEndSection": 588,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9264083",
          "text": "estion of amniotic fluid enhances the antinociception produced by nicotine injection. In Experiment 1A, enhancement of morphine-mediated antinocicepti",
          "offsetInBeginSection": 485,
          "offsetInEndSection": 635,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9618058",
          "text": "It is produced by the decidua and by fetal tissues, and it is thought to play an important role in fetal growth.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7085854",
          "text": "These data suggest that PRL produced by decidua and found in amniotic fluid is a biologically active hormone.",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 729,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22439042",
          "text": "Amniotic fluid (AF), routinely used for prenatal diagnosis, contains large amounts of proteins produced by the amnion epithelial cells, fetal tissues, fetal excretions and placental tissuesAlthough many amniotic fluid proteins have been identified and are currently used to detect potential fetal anomalies, little is known about the functions of these proteins and how they interact with one another.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 401,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1933405",
          "text": " stimulation, late pregnancy, footshock), but not that produced by aspirin injection. The present series of experiments employed quaternary naltrexone",
          "offsetInBeginSection": 173,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/424113",
          "text": "This study demonstrated that such elevated levels can be produced by urography with an iodinated medium, by thyroid extract therapy, and by vaginal therapy with an iodinated agent.",
          "offsetInBeginSection": 466,
          "offsetInEndSection": 646,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/7270010",
        "http://www.ncbi.nlm.nih.gov/pubmed/10229907",
        "http://www.ncbi.nlm.nih.gov/pubmed/3973451",
        "http://www.ncbi.nlm.nih.gov/pubmed/1801021",
        "http://www.ncbi.nlm.nih.gov/pubmed/33969779",
        "http://www.ncbi.nlm.nih.gov/pubmed/424113",
        "http://www.ncbi.nlm.nih.gov/pubmed/6190415",
        "http://www.ncbi.nlm.nih.gov/pubmed/1471670",
        "http://www.ncbi.nlm.nih.gov/pubmed/2497808",
        "http://www.ncbi.nlm.nih.gov/pubmed/26412552"
      ]
    },
    {
      "id": "6415c252690f196b51000011",
      "type": "factoid",
      "body": "Which cancer is the BCG vaccine used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34060492",
          "text": "While its roles for TB prevention and bladder cancer immunotherapy are widely appreciated, over the past century, BCG has been also studied for nontraditional purposes, which include (a) prevention of viral infections and nontuberculous mycobacterial infections, (b) cancer immunotherapy aside from bladder cancer, and (c) immunologic diseases, including multiple sclerosis, type 1 diabetes, and atopic diseases.",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 951,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7984457",
          "text": "This paper describes how it can be used as an alternative to cytotoxic agents in the treatment of bladder cancer.",
          "offsetInBeginSection": 57,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12174744",
          "text": "CONCLUSIONS\nThe BCG vaccine injected in prostatic tissue of patients with prostatic cancer, produces an increase of cytotoxic T lymphocytes and natural killer cells, with antitumoral action.",
          "offsetInBeginSection": 914,
          "offsetInEndSection": 1104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21977071",
          "text": "Herein, we describe gluteal tuberculosis abscess due to inadvertently injected BCG a patient with bladder cancer.",
          "offsetInBeginSection": 97,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34875601",
          "text": " protection from various infections and is used in the treatment of bladder cancer. By 2020, at least five technologies had already been established f",
          "offsetInBeginSection": 774,
          "offsetInEndSection": 924,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34055652",
          "text": "the approval of the Bacillus Calmette-Gu\u00e9rin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuven",
          "offsetInBeginSection": 115,
          "offsetInEndSection": 265,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6347154",
          "text": "Fifty-two patients with locally advanced squamous cell cancer were entered into a randomized trial of BCG vaccine following definitive local therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30600132",
          "text": "as a vaccine for tuberculosis 100 years ago and used as therapy for bladder cancer 40 years ago. More recently, BCG has shown therapeutic promise for ",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34062708",
          "text": "with anti-PD-1 antibody, which stimulates T cell responses against the melanoma. Finally, trained immunity is discussed, and reprogramming events to s",
          "offsetInBeginSection": 1211,
          "offsetInEndSection": 1361,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31181358",
          "text": "miliary disease, more so in children, and also for the treatment of bladder cancer.\n\n\nCASE DESCRIPTION\nThe following case of brain tuberculoma is a bo",
          "offsetInBeginSection": 324,
          "offsetInEndSection": 474,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34742127",
        "http://www.ncbi.nlm.nih.gov/pubmed/34062708",
        "http://www.ncbi.nlm.nih.gov/pubmed/6347154",
        "http://www.ncbi.nlm.nih.gov/pubmed/35804844",
        "http://www.ncbi.nlm.nih.gov/pubmed/34983348",
        "http://www.ncbi.nlm.nih.gov/pubmed/12649188",
        "http://www.ncbi.nlm.nih.gov/pubmed/7984457",
        "http://www.ncbi.nlm.nih.gov/pubmed/26268434",
        "http://www.ncbi.nlm.nih.gov/pubmed/33754600",
        "http://www.ncbi.nlm.nih.gov/pubmed/30805444"
      ]
    },
    {
      "id": "641791b9690f196b51000030",
      "type": "list",
      "body": "What are the most common congenital muscular dystrophies?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31105770",
          "text": "We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries (Pubmed, Scopus and Google Scholar) including the more common forms of muscular dystrophies such as dystrophinopathies, dystroglycanopathies, myotonic dystrophies, facioscapulohumeral dystrophy, limb-girdle muscular dystrophy, congenital myotonia, and congenital myopathies.",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 561,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29933045",
          "text": "In this review, we summarize the clinical features of two of the most common congenital muscular dystrophies, COL6-related dystrophies and LAMA2-related dystrophies, which are caused by mutations in muscle ECM and basement membrane proteins.",
          "offsetInBeginSection": 630,
          "offsetInEndSection": 871,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25653289",
          "text": "The most common forms were those with \u03b1-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin \u03b12 deficiency (24.11%) and collagen VI deficiency (20.24%).",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 784,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25987458",
          "text": "y, even excluding the common forms Duchenne Muscular Dystrophy, Myotonic Dystrophy and Facioscapulohumeral Dystrophy. Unfortunately, even by critical ",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 360,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794464",
          "text": "This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies.",
          "offsetInBeginSection": 558,
          "offsetInEndSection": 924,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35562158",
          "text": "Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.",
          "offsetInBeginSection": 399,
          "offsetInEndSection": 606,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23622361",
          "text": "This chapter reviews the most common forms of congenital muscular dystrophies, including laminin \u03b1-2 (merosin) deficiency, Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, rigid spine syndrome, and glycosylation disorders of \u03b1-dystroglycan.",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 451,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32444167",
          "text": "Congenital LAMA2 related muscular dystrophy (LAMA2-RD), the most commonly recognized type of congenital muscular dystrophies, has been described in patients' cohorts from Europe and the UK but not from Middle-Eastern.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794464",
          "text": "This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies.",
          "offsetInBeginSection": 558,
          "offsetInEndSection": 924,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34628793",
          "text": "Most frequent muscular dystrophies found in the Mexican population were dystrophinopathies, dysferlinopathies and calpainopathies.",
          "offsetInBeginSection": 540,
          "offsetInEndSection": 670,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33200426",
        "http://www.ncbi.nlm.nih.gov/pubmed/25653289",
        "http://www.ncbi.nlm.nih.gov/pubmed/10682317",
        "http://www.ncbi.nlm.nih.gov/pubmed/25987458",
        "http://www.ncbi.nlm.nih.gov/pubmed/23622361",
        "http://www.ncbi.nlm.nih.gov/pubmed/34628793",
        "http://www.ncbi.nlm.nih.gov/pubmed/23288328",
        "http://www.ncbi.nlm.nih.gov/pubmed/29376585",
        "http://www.ncbi.nlm.nih.gov/pubmed/31794464",
        "http://www.ncbi.nlm.nih.gov/pubmed/32444167"
      ]
    },
    {
      "id": "63eeed0af36125a426000007",
      "type": "factoid",
      "body": "What disease can be treated with Teclistamab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396",
          "text": "clistamab is a novel treatment approach for relapsed or refractory multiple myeloma. At the recommended phase 2 dose, teclistamab showed promising eff",
          "offsetInBeginSection": 2701,
          "offsetInEndSection": 2851,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33227097",
          "text": "Cytokine release syndrome is the most common adverse event, which can be adequately managed with tocilizumab or steroids.",
          "offsetInBeginSection": 481,
          "offsetInEndSection": 602,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396",
          "text": "METHODS\nThis open-label, single-arm, phase 1 study enrolled patients with multiple myeloma who were relapsed, refractory, or intolerant to established therapies.",
          "offsetInBeginSection": 434,
          "offsetInEndSection": 595,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344765",
          "text": "Currently over 90% of children and adolescents with Hodgkin's disease (HD) can be cured thanks to use of multidrug chemotherapy (CT) combined with involved-field radiotherapy (IF-RT).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36321843",
          "text": "bispecific T-cell engager teclistamab for patients with relapsed or refractory multiple myeloma. In the clinical trial that led to its approval, patie",
          "offsetInBeginSection": 25,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130580",
          "text": "PRACTICAL RECOMMENDATIONS\nApart from localized renal cell carcinoma, angiomyolipoma and oncocytoma can be treated by thermal ablation.",
          "offsetInBeginSection": 1242,
          "offsetInEndSection": 1376,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36352205",
          "text": "y Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma. Teclistamab was recently granted conditional approval",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004",
          "text": " (MajesTEC-1) is evaluating teclistamab in patients with relapsed/refractory multiple myeloma.\n\n\nPATIENTS AND METHODS\nTo estimate the efficacious ther",
          "offsetInBeginSection": 250,
          "offsetInEndSection": 400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453",
          "text": "rrant further evaluation of this bispecific antibody for the treatment of MM. Phase 1 clinical trials (monotherapy, #NCT03145181; combination therapy,",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1664,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166",
          "text": " rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were commo",
          "offsetInBeginSection": 1994,
          "offsetInEndSection": 2144,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21344765",
        "http://www.ncbi.nlm.nih.gov/pubmed/36352205",
        "http://www.ncbi.nlm.nih.gov/pubmed/35749004",
        "http://www.ncbi.nlm.nih.gov/pubmed/28130580",
        "http://www.ncbi.nlm.nih.gov/pubmed/34388396",
        "http://www.ncbi.nlm.nih.gov/pubmed/33227097",
        "http://www.ncbi.nlm.nih.gov/pubmed/7572694",
        "http://www.ncbi.nlm.nih.gov/pubmed/36321843",
        "http://www.ncbi.nlm.nih.gov/pubmed/35661166",
        "http://www.ncbi.nlm.nih.gov/pubmed/32956453"
      ]
    },
    {
      "id": "643d3e6157b1c7a315000034",
      "type": "list",
      "body": "Please list the natriuretic peptides.",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8392634",
          "text": "Natriuretic peptides family consists of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP), while receptors for these natriuretic peptides comprise at least three subtypes, i.e.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382054",
          "text": "Natriuretic peptide family consists of several hormones produced by cardiomyocyte, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18703404",
          "text": "Four major natriuretic peptides have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and Dendroaspis-type natriuretic peptide (DNP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871602",
          "text": "The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12843686",
          "text": "Four types of natriuretic peptides have been found thus far: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and Dendroaspis natriuretic peptide (DNP).",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 299,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11476733",
          "text": "The natriuretic peptides - atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide - comprise a family of proteins that participate in the integrated control of intravascular volume and arterial blood pressure.",
          "offsetInBeginSection": 111,
          "offsetInEndSection": 351,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28848655",
          "text": "Among their properties are vasodilation, natriuresis, diuresis, and inhibition of cardiac remodeling.",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7496058",
          "text": "The natriuretic peptide family consists of three members: atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783635",
          "text": "They consist of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide and are elevated in patients with left ventricular dysfunction.",
          "offsetInBeginSection": 128,
          "offsetInEndSection": 293,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965966",
          "text": "The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12224050",
        "http://www.ncbi.nlm.nih.gov/pubmed/18078063",
        "http://www.ncbi.nlm.nih.gov/pubmed/7496058",
        "http://www.ncbi.nlm.nih.gov/pubmed/31771521",
        "http://www.ncbi.nlm.nih.gov/pubmed/34871602",
        "http://www.ncbi.nlm.nih.gov/pubmed/11476733",
        "http://www.ncbi.nlm.nih.gov/pubmed/11405605",
        "http://www.ncbi.nlm.nih.gov/pubmed/14963664",
        "http://www.ncbi.nlm.nih.gov/pubmed/12783635",
        "http://www.ncbi.nlm.nih.gov/pubmed/19886866"
      ]
    },
    {
      "id": "63f9ee5c33942b094c000014",
      "type": "yesno",
      "body": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30100395",
          "text": "While SRRM4 overexpression enhances SOX2 expression in both time- and dose-dependent manners in DU145 cells, RNA depletion of SOX2 compromises SRRM4-mediated stimulation of pluripotency genes.",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1670,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382513",
          "text": "Up-regulation of SRRM4 establishes neuronal splicing patterns in neuroendocrine prostate cancer.",
          "offsetInBeginSection": 1429,
          "offsetInEndSection": 1525,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28106138",
          "text": "Our results suggest that SRRM4 controls neurite outgrowth through regulation of alternative splicing of protrudin transcripts.",
          "offsetInBeginSection": 1221,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28106138",
          "text": "SRRM4 was found to promote splicing of protrudin pre-mRNA so as to include a microexon (exon L) encoding seven amino acids in a neuron-specific manner.",
          "offsetInBeginSection": 537,
          "offsetInEndSection": 688,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33207694",
          "text": "titive matrix 4 (SRRM4). Overexpressing SRRM4, known for regulating ME inclusion in mRNAs critical for neural differentiation, in human HEK293 cells r",
          "offsetInBeginSection": 1247,
          "offsetInEndSection": 1397,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12213192",
          "text": "The polypyrimidine tract binding protein (PTB) has been implicated as a negative regulator for exon splicing, whereas the brain-specific homolog of PTB, termed nPTB, promotes exon splicing exclusively in neurons.",
          "offsetInBeginSection": 98,
          "offsetInEndSection": 310,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35858306",
          "text": "Despite the fact that both proteins positively regulate retina microexons in\u00a0vitro, only Srrm3 is highly expressed in mature photoreceptors.",
          "offsetInBeginSection": 672,
          "offsetInEndSection": 812,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
          "text": ". Inclusion of microexons in mRNA transcripts is mediated by the SF Serine/Arginine Repetitive Matrix 4 (SRRM4), whose expression is largely restricted to neural tissues. However, microexons have been largely overlooked in prior analyses of splicing in cancer, as their small size necessitates specialized computational approaches for their detection. Here, we demonstrate that despite having low expression in normal nonneural tissues, SRRM4 is further silenced in tumors, resulting in the suppression of normal microexon inclusion",
          "offsetInBeginSection": 302,
          "offsetInEndSection": 834,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9645964",
          "text": "The upstream negative element controls the neuronal splicing while the downstream one represses the muscle-specific splicing in neuronal cells.",
          "offsetInBeginSection": 1089,
          "offsetInEndSection": 1232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35113929",
          "text": "How the two related proteins regulate different sets of neuronal exons is unclear.",
          "offsetInBeginSection": 483,
          "offsetInEndSection": 565,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34746789",
        "http://www.ncbi.nlm.nih.gov/pubmed/32403054",
        "http://www.ncbi.nlm.nih.gov/pubmed/34312180",
        "http://www.ncbi.nlm.nih.gov/pubmed/27180064",
        "http://www.ncbi.nlm.nih.gov/pubmed/25525873",
        "http://www.ncbi.nlm.nih.gov/pubmed/28382513",
        "http://www.ncbi.nlm.nih.gov/pubmed/21884984",
        "http://www.ncbi.nlm.nih.gov/pubmed/20040591",
        "http://www.ncbi.nlm.nih.gov/pubmed/29759485",
        "http://www.ncbi.nlm.nih.gov/pubmed/33621242"
      ]
    },
    {
      "id": "644281e557b1c7a31500005b",
      "type": "summary",
      "body": "What is the difference between Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1) and type 2 (FSHD2)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31243061",
          "text": "In FSHD2, pathogenic variants are found anywhere in SMCHD1 while in BAMS, pathogenic variants are restricted to the extended ATPase domain.",
          "offsetInBeginSection": 245,
          "offsetInEndSection": 384,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26356006",
          "text": "In the case of FSHD1, a contraction of the D4Z4 repeat array is disease causing whereas FSHD2 is most often caused by mutations in the structural maintenance of chromosomes hinge domain 1 (SMCHD1) gene.",
          "offsetInBeginSection": 470,
          "offsetInEndSection": 672,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25256356",
          "text": "It is caused by contractions of the D4Z4 repeat array on chromosome 4 to 1-10 units (FSHD1), or by mutations in the D4Z4-binding chromatin modifier SMCHD1 (FSHD2).",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 326,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24639337",
          "text": "Participants with testing suggestive of restrictive lung involvement (n\u2009=\u20096) were more severely affected (P\u2009=\u20090.005), had weaker hip flexion (P\u2009=\u20090.0007), and were more likely to use a wheelchair (P\u2009=\u20090.01).",
          "offsetInBeginSection": 640,
          "offsetInEndSection": 847,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30055030",
          "text": "FSHD type 1 (FSHD1) is associated with pathogenic D4Z4 repeat array contraction, while FSHD type 2 (FSHD2) is associated with SMCHD1 variants (a chromatin modifier gene that maps to the short arm of chromosome 18).",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 441,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34297364",
          "text": "ct FSHD types is essential: FSHD1 is an autosomal dominantly inherited repeat disorder, whereas FSHD2 is a digenic disorder. This has become even more",
          "offsetInBeginSection": 290,
          "offsetInEndSection": 440,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29436205",
          "text": "Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25037087",
          "text": "Approximately 95% of patients, termed FSHD1, have a deletion of a key number of repetitive elements on chromosome 4q35.",
          "offsetInBeginSection": 339,
          "offsetInEndSection": 458,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35093715",
          "text": "FSHD type 1 (FSHD1) is caused by multicopy contraction of D4Z4 repeats on chromosome 4q35.",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370034",
          "text": "Recently, in a subset of patients without D4Z4 repeat contractions, variants in the SMCHD1 gene have been identified that lead to hypomethylation of D4Z4 and thus DUX4 transcription, which causes FSHD type 2.",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 445,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24639337",
        "http://www.ncbi.nlm.nih.gov/pubmed/33381940",
        "http://www.ncbi.nlm.nih.gov/pubmed/31518905",
        "http://www.ncbi.nlm.nih.gov/pubmed/24882751",
        "http://www.ncbi.nlm.nih.gov/pubmed/36348371",
        "http://www.ncbi.nlm.nih.gov/pubmed/24075187",
        "http://www.ncbi.nlm.nih.gov/pubmed/23969240",
        "http://www.ncbi.nlm.nih.gov/pubmed/30055030",
        "http://www.ncbi.nlm.nih.gov/pubmed/29748383",
        "http://www.ncbi.nlm.nih.gov/pubmed/25037087"
      ]
    },
    {
      "id": "63f03ea0f36125a426000020",
      "type": "factoid",
      "body": "SER-109 is developed for prevention of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908752",
          "text": "CONCLUSIONS\nSER-109 successfully prevented CDI and had a favorable safety profile, supporting a novel microbiome-based intervention as a potential therapy for recurrent CDI.",
          "offsetInBeginSection": 1444,
          "offsetInEndSection": 1617,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158136",
          "text": "We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 464,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36140013",
          "text": " its rigorous manufacturing process, which mitigates the risk of pathogen transmission. Additionally, we discuss compositional and functional changes ",
          "offsetInBeginSection": 1423,
          "offsetInEndSection": 1573,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228",
          "text": "omposed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.\n\n\nMETHODS\nWe conducted a phase 3, double-blind, randomize",
          "offsetInBeginSection": 250,
          "offsetInEndSection": 400,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17091902",
          "text": "This article summarises the most recent guidelines on the prevention of common cardiovascular diseases: coronary artery disease, stroke, and peripheral artery disease.",
          "offsetInBeginSection": 585,
          "offsetInEndSection": 752,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36140013",
        "http://www.ncbi.nlm.nih.gov/pubmed/17091902",
        "http://www.ncbi.nlm.nih.gov/pubmed/26908752",
        "http://www.ncbi.nlm.nih.gov/pubmed/36158136",
        "http://www.ncbi.nlm.nih.gov/pubmed/35045228"
      ]
    },
    {
      "id": "6431f71057b1c7a315000019",
      "type": "yesno",
      "body": "In twin-twin transfusion syndrome, are the twins identical?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33345886",
          "text": "Among donors with twin-twin transfusion syndrome with double survivors after undergoing laser therapy (n=4), prelaser renal artery Doppler peak systolic velocity ratios (mean, 1.46; standard deviation, 0.37) were significantly higher than postlaser renal artery Doppler peak systolic velocity ratios (mean, 0.87; standard deviation=0.37; P=.02).",
          "offsetInBeginSection": 3522,
          "offsetInEndSection": 3867,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/848859",
          "text": "The 76 pairs were separated into three classes: 23 pairs in which there was clear evidence of a substantial birthweight differences (indicating the probable existence of the identical twin transfusion syndrome), 27 pairs in which the information on birthweight was ambiguous (?",
          "offsetInBeginSection": 691,
          "offsetInEndSection": 968,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12665487",
          "text": "nd show discordant intertwin vascular compliance in childhood despite identical genotype. We hypothesized that discordance is prevented by intrauterin",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11109260",
          "text": "This article examines twin-twin transfusion syndrome, a condition in which identical twins share a single placenta with abnormal anastomoses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29796818",
          "text": "In case of twin-to-twin transfusion syndrome, there were no significant differences in innate immune protein expressions between twins.",
          "offsetInBeginSection": 1144,
          "offsetInEndSection": 1279,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29796818",
          "text": "Whereas monozygotic (MZ) twins are considered to have identical genetic material, they still differ.",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/848859",
          "text": "ho do not suffer from placental circulation problems. Most likely, the identical twin transfusion syndrome produces anoxia and brain damage during ear",
          "offsetInBeginSection": 2603,
          "offsetInEndSection": 2753,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33345886",
          "text": " renin-angiotensin system result in a hypovolemic, oliguric donor twin and a hypervolemic, polyuric recipient twin. Renal artery Doppler assessments h",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9714432",
          "text": "Twin 1, the smaller of the pair, had Tetralogy of Fallot, a characteristic facial appearance, swallowing dysfunction, anal atresia, short stature, and mental retardation, whereas twin 2 had a characteristic facial appearance but no other signs of the 22q11 deletion syndrome.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 409,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15746688",
          "text": "CONCLUSION\nIn twin-to-twin transfusion syndrome, the recipient twin has progressive biventricular hypertrophy with predominant right ventricular systolic and biventricular diastolic dysfunction.",
          "offsetInBeginSection": 1388,
          "offsetInEndSection": 1582,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/11109260",
        "http://www.ncbi.nlm.nih.gov/pubmed/18033069",
        "http://www.ncbi.nlm.nih.gov/pubmed/848859",
        "http://www.ncbi.nlm.nih.gov/pubmed/9628441",
        "http://www.ncbi.nlm.nih.gov/pubmed/10335354",
        "http://www.ncbi.nlm.nih.gov/pubmed/9714432",
        "http://www.ncbi.nlm.nih.gov/pubmed/15746688",
        "http://www.ncbi.nlm.nih.gov/pubmed/12665487",
        "http://www.ncbi.nlm.nih.gov/pubmed/18354242",
        "http://www.ncbi.nlm.nih.gov/pubmed/32858578"
      ]
    },
    {
      "id": "6414c1ae690f196b51000003",
      "type": "summary",
      "body": "What is the definition of trichotillomania?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25878445",
          "text": "Trichotillomania is a disorder of an impulsive hair pulling that occurs in both adults and children alike.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34903086",
          "text": "OBJECTIVES\nTrichotillomania is characterized by repetitive pulling out of one's hair, leading to distress and/or functional impairment.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2175127",
          "text": "Advances an opinion about the validity of singling out the definition \"a pathological habitual action\" as an independent psychopathological sign of certain varieties of trichotillomania.",
          "offsetInBeginSection": 688,
          "offsetInEndSection": 874,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8340306",
          "text": "tillomania. These results suggest that when trichotillomania is a benign habit disorder, the treatment of a covarying habit such as thumb-sucking can ",
          "offsetInBeginSection": 536,
          "offsetInEndSection": 686,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31954616",
          "text": "The sample comprised 50 adults with trichotillomania (100% not taking psychotropic medication; mean [SD] age 34.3 [12.3] years; 92% female).",
          "offsetInBeginSection": 684,
          "offsetInEndSection": 824,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18950408",
          "text": "Trichotillomania in early childhood is considered a benign habit disorder in contrary to older children and adults where trichotillomania is associated with greater psychopathology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27086334",
          "text": "AIM\nTrichotillomania is a lack of control of one's hair pulling. It is estimated that about 1% of population develops trichotillomania. In up to 20% o",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034750",
          "text": "gument that trichotillomania can usefully be conceptualized as a stereotypic disorder. Speculatively, this argument may be especially valid in trichot",
          "offsetInBeginSection": 1891,
          "offsetInEndSection": 2041,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23960397",
          "text": "Trichotillomania is a complex psychiatric disorder and occurs along with a large number of comorbidity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31321109",
          "text": "PURPOSE\nTrichotillomania is a behavioral and mental disorder and is characterized by a recurring habit of pulling out one's hair.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30745687",
        "http://www.ncbi.nlm.nih.gov/pubmed/33124597",
        "http://www.ncbi.nlm.nih.gov/pubmed/35486996",
        "http://www.ncbi.nlm.nih.gov/pubmed/11122936",
        "http://www.ncbi.nlm.nih.gov/pubmed/7480576",
        "http://www.ncbi.nlm.nih.gov/pubmed/19479123",
        "http://www.ncbi.nlm.nih.gov/pubmed/8641889",
        "http://www.ncbi.nlm.nih.gov/pubmed/2175127",
        "http://www.ncbi.nlm.nih.gov/pubmed/35118122",
        "http://www.ncbi.nlm.nih.gov/pubmed/27086334"
      ]
    },
    {
      "id": "64179113690f196b5100002e",
      "type": "factoid",
      "body": "Where is the DMD gene located?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2597987",
          "text": "s were used to construct a physical map of the DMD region including the 2.3 Mb DMD gene. FIGE-analysis allows rapid screening of the complete region u",
          "offsetInBeginSection": 22,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36361862",
          "text": "urned out to affect the DMD gene with one of the breakpoints located in exon 54 (detected by genome sequencing). The X-inactivation test revealed skew",
          "offsetInBeginSection": 580,
          "offsetInEndSection": 730,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014122",
          "text": "The DMD gene, located on Xp21, is the largest human gene in the human genome (2.3 Mb).",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 415,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
          "text": "n coded by the Duchenne muscular dystrophy (DMD) gene located on the X-chromosome. Truncating mutations in the DMD gene cause loss of dystrophin and t",
          "offsetInBeginSection": 39,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18471087",
          "text": "r disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region. Up to 65% of the patients present dystrophin gene deletions. Mothe",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28740938",
          "text": "BACKGROUND\nDuchenne muscular dystrophy (DMD) is caused by a defective gene located on the X-chromosome, responsible for the production of the dystrophin protein.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19837995",
          "text": " muscle disorders, caused by mutations in the dystrophin gene located in Xp21. DMD occurs with the incidence 1:3500, BMD with the incidence of 1:18,50",
          "offsetInBeginSection": 100,
          "offsetInEndSection": 250,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20948175",
          "text": "ers for 12 years. After we discovered that dystrophin is located on the cell membrane in 1988, we studied the architecture of dystrophin and dystrophi",
          "offsetInBeginSection": 502,
          "offsetInEndSection": 652,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28867298",
          "text": "ne (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus. It spans 2.2Mb and accounts for approximately 0,1% of the enti",
          "offsetInBeginSection": 17,
          "offsetInEndSection": 167,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19078586",
          "text": "Duchenne muscular dystrophy (DMD), glycerol kinase deficiency (GKD), and adrenal hypoplasia congenita (AHC) can occur together as part of a contiguous gene syndrome located at chromosome Xp21, GKD can manifest with recurrent episodes of vomiting, acidemia, mental retardation, or stupor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9851976",
        "http://www.ncbi.nlm.nih.gov/pubmed/3826553",
        "http://www.ncbi.nlm.nih.gov/pubmed/10437291",
        "http://www.ncbi.nlm.nih.gov/pubmed/21134752",
        "http://www.ncbi.nlm.nih.gov/pubmed/31661024",
        "http://www.ncbi.nlm.nih.gov/pubmed/12145744",
        "http://www.ncbi.nlm.nih.gov/pubmed/23914114",
        "http://www.ncbi.nlm.nih.gov/pubmed/19078586",
        "http://www.ncbi.nlm.nih.gov/pubmed/28740938",
        "http://www.ncbi.nlm.nih.gov/pubmed/18935728"
      ]
    },
    {
      "id": "64040c6b201352f04a00000f",
      "type": "summary",
      "body": "What is the mechanism of action of Tolebrutinib?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34724345",
          "text": " adverse events were mild. Tolebrutinib was rapidly absorbed following oral administration with a rapid half-life of ~\u00a02\u00a0h. Peripheral BTK occupancy w",
          "offsetInBeginSection": 1121,
          "offsetInEndSection": 1271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31781552",
          "text": "at their main mechanism of action in vivo relies on paracrine signaling and extracellular vesicles. Mesenchymal stromal cell-derived extracellular ves",
          "offsetInBeginSection": 338,
          "offsetInEndSection": 488,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34724345",
          "text": "ptor and Fc-receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, resulting in durable inhibition w",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18642372",
          "text": "AIMS\nThe mechanism of action of injection therapy is virtually unknown. Urethral Pressure Reflectometry (UPR) is a novel technique for measuring press",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34418400",
          "text": "BACKGROUND\nTolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
          "text": "The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/31781552",
        "http://www.ncbi.nlm.nih.gov/pubmed/18642372",
        "http://www.ncbi.nlm.nih.gov/pubmed/34418400",
        "http://www.ncbi.nlm.nih.gov/pubmed/34724345"
      ]
    },
    {
      "id": "6415b7b8690f196b5100000c",
      "type": "yesno",
      "body": "Optogenetics refers to the study of gene expression optimization",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22245580",
          "text": "basis for optogenetics, a term that refers to the control of organismal physiology and behavior by light. We establish as novel optogenetic tools the ",
          "offsetInBeginSection": 156,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404352",
          "text": "Optogenetics offers a non-invasive, highly tunable, and reversible method of dynamically regulating gene expression.",
          "offsetInBeginSection": 440,
          "offsetInEndSection": 556,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34592347",
          "text": "ncreasingly popular in various areas of research, especially in the precise control of gene expression. While this technology is already well establis",
          "offsetInBeginSection": 85,
          "offsetInEndSection": 235,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27069384",
          "text": "Optogenetics refers to the ability to control cells that have been genetically modified to express light-sensitive ion channels.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255969",
          "text": "Optogenetics refers to the genetic modification of cells to express light-sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33119964",
          "text": "Optogenetics refers to the control of biological processes with light. The activation of cellular phenomena by defined wavelengths has several advanta",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32795553",
          "text": "ly understood as the manipulation of the activity of genetically modified cells (typically neurons) with light, i.e. optical actuators. (2) A second c",
          "offsetInBeginSection": 385,
          "offsetInEndSection": 535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27805047",
          "text": " precision. However, outside of neuroscience, the impact of optogenetics has been limited by a lack of user-friendly, flexible, accessible hardware. Here, we engineer the Light Plate Apparatus (LPA), a device that can deliver two independent 310 to 1550\u2009nm light signals to each well of a 24-well plate with intensity control over three orders of magnitude and millisecond resolution. Signals are programmed using an intuitive web tool named Iris. All components can be purchased for under $400 and the device can be assembled and calibrated by a non-expert in one day. We use the LPA to precisely control gene expression from blue, green, and red light responsive optogenetic tools in bacteria, yeast, and mammalian cells",
          "offsetInBeginSection": 124,
          "offsetInEndSection": 846,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29118219",
          "text": "Optogenetics is the use of genetically coded, light-gated ion channels or pumps (opsins) for millisecond resolution control of neural activity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26310015",
          "text": "However, unlike gene therapy, which is aimed at repairing damaged genes or replacing them with healthy ones, optogenetics is focused on protein genes delivery for further molecular control of the cell.",
          "offsetInBeginSection": 482,
          "offsetInEndSection": 683,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27805047",
        "http://www.ncbi.nlm.nih.gov/pubmed/26310015",
        "http://www.ncbi.nlm.nih.gov/pubmed/34592347",
        "http://www.ncbi.nlm.nih.gov/pubmed/29118219",
        "http://www.ncbi.nlm.nih.gov/pubmed/27069384",
        "http://www.ncbi.nlm.nih.gov/pubmed/33119964",
        "http://www.ncbi.nlm.nih.gov/pubmed/28255969",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404352",
        "http://www.ncbi.nlm.nih.gov/pubmed/32795553",
        "http://www.ncbi.nlm.nih.gov/pubmed/22245580"
      ]
    },
    {
      "id": "6415c9e9690f196b51000018",
      "type": "factoid",
      "body": "Which form of breast cancer has Keytruda been FDA approved for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978559",
          "text": "The FDA has approved abemaciclib for women with advanced or metastatic ER-positive, HER2-negative breast cancer whose disease has progressed on endocrine therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32846967",
          "text": "cally advanced TNBC. Several FDA-approved drugs that target programmed cell death protein-1 (Keytruda) and programmed death ligand-1 (Tecentriq), poly",
          "offsetInBeginSection": 724,
          "offsetInEndSection": 874,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823221",
          "text": "ion (FDA) in 2007 for the treatment of locally advanced breast cancer (LABC) or metastatic breast cancer (MBC). When added to the existing endocrine t",
          "offsetInBeginSection": 252,
          "offsetInEndSection": 402,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35860268",
          "text": " has been approved by the US Food and Drug Administration for non-small-cell lung cancer. Here, we report a rare case of an abdominal fibroinflammator",
          "offsetInBeginSection": 373,
          "offsetInEndSection": 523,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29273617",
          "text": "The drug was approved to treat patients with HER2-positive breast and metastatic stomach cancers.",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27672333",
          "text": "ribulin, the studies that have propelled eribulin to FDA approval for liposarcoma, and future directions of the drug. The benefits of eribulin in STS ",
          "offsetInBeginSection": 755,
          "offsetInEndSection": 905,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31775939",
          "text": "OBJECTIVE\nThis paper aims to describe the clinical and regulatory aspects of new drugs and indications that were approved for lung, breast, prostate, and colorectal cancer, from 2016 to 2018, in order to provide health technology assessment trends in oncology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35745835",
          "text": "PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved for FDA, successfully representing the combination therapy of immunotherapy and chemotherapy for the first time in 2020.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 230,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28356261",
          "text": "The FDA has approved ribociclib combined with aromatase inhibitor therapy for women with metastatic HR-positive, HER2-negative breast cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35736598",
          "text": "Pembrolizumab (Keytruda) is now approved as a single agent to treat advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient in those whose disease has progressed following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24715764",
        "http://www.ncbi.nlm.nih.gov/pubmed/30915922",
        "http://www.ncbi.nlm.nih.gov/pubmed/24855725",
        "http://www.ncbi.nlm.nih.gov/pubmed/32905036",
        "http://www.ncbi.nlm.nih.gov/pubmed/33983696",
        "http://www.ncbi.nlm.nih.gov/pubmed/32645193",
        "http://www.ncbi.nlm.nih.gov/pubmed/28923211",
        "http://www.ncbi.nlm.nih.gov/pubmed/27672333",
        "http://www.ncbi.nlm.nih.gov/pubmed/33188141",
        "http://www.ncbi.nlm.nih.gov/pubmed/35860268"
      ]
    },
    {
      "id": "64178f94690f196b51000027",
      "type": "summary",
      "body": "What is eteplirsen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18642372",
          "text": "AIMS\nThe mechanism of action of injection therapy is virtually unknown. Urethral Pressure Reflectometry (UPR) is a novel technique for measuring press",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18633828",
          "text": "The representations are therefore shared between self and other (shared representations of action, SRA).",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 196,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/18642372",
        "http://www.ncbi.nlm.nih.gov/pubmed/18633828",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312"
      ]
    },
    {
      "id": "63f03155f36125a426000019",
      "type": "yesno",
      "body": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088386",
          "text": "BACKGROUND\nThere are no effective treatments for diffuse intrinsic pontine gliomas (DIPGs); these tumors cannot be surgical resected, and diagnosis is based on magnetic resonance imaging.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790919",
          "text": "Although large numbers of specific targeted therapies have been tested, no significant progress has been made in treating these high-grade gliomas.",
          "offsetInBeginSection": 133,
          "offsetInEndSection": 280,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594041",
          "text": "Clinical trials evaluating intratumoral DNX-2401 in adults with recurrent glioblastoma have demonstrated that the virus has a favorable safety profile and can prolong survival.",
          "offsetInBeginSection": 509,
          "offsetInEndSection": 685,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31342064",
          "text": "BACKGROUND\nNo link has been demonstrated between diffuse intrinsic pontine glioma and developmental venous anomaly in pediatric patients.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 137,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432077",
          "text": "Methods A phase I, dose-escalation, biologic-end-point clinical trial of DNX-2401 was conducted in 37 patients with recurrent malignant glioma.",
          "offsetInBeginSection": 245,
          "offsetInEndSection": 388,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31813457",
          "text": "Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric tumor with no currently available treatment options.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432077",
          "text": "Conclusion Treatment with DNX-2401 resulted in dramatic responses with long-term survival in recurrent high-grade gliomas that are probably due to direct oncolytic effects of the virus followed by elicitation of an immune-mediated antiglioma response.",
          "offsetInBeginSection": 1667,
          "offsetInEndSection": 1918,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26903150",
          "text": "Diffuse intrinsic pontine gliomas (DIPGs) are invariably fatal tumors found in the pons of elementary school aged children.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26971411",
          "text": "In diffuse intrinsic pontine glioma compared to low-grade brainstem glioma, axial diffusivity was lower in the bilateral posterior limb of the internal capsule.",
          "offsetInBeginSection": 978,
          "offsetInEndSection": 1138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33080729",
          "text": "BACKGROUND\nThe standard treatment for diffuse intrinsic pontine glioma (DIPG) is radiotherapy, although conventional fractionated radiotherapy (CFRT) may not be in the best interest of the patient.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33080729",
        "http://www.ncbi.nlm.nih.gov/pubmed/23249962",
        "http://www.ncbi.nlm.nih.gov/pubmed/29432077",
        "http://www.ncbi.nlm.nih.gov/pubmed/25473916",
        "http://www.ncbi.nlm.nih.gov/pubmed/29594041",
        "http://www.ncbi.nlm.nih.gov/pubmed/23293772",
        "http://www.ncbi.nlm.nih.gov/pubmed/29088386",
        "http://www.ncbi.nlm.nih.gov/pubmed/26903150",
        "http://www.ncbi.nlm.nih.gov/pubmed/31813457",
        "http://www.ncbi.nlm.nih.gov/pubmed/26971411"
      ]
    }
  ]
}